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1.1 Nuclear medicine.

Nuclear medicine is a medical specialty that uses unsealed radioactive materials
(radiopharmaceuticals) for diagnosis and treatment of disease. A radiopharmaceutical is a
radionuclide linked to a “target seeking” molecule. Radiopharmaceuticals are administered
systemically to the patient and are aimed at specific tissues (bones, tumours…) in the body
into which they can adhere or incorporate. The radiopharmaceuticals used in nuclear
medicine for diagnostic purposes contain radionuclides that emit gamma rays, which can be
detected externally by so called ”scintigraphy”, providing information about an organ’s
function and structure in a non-invasive way.














Fig. 1.1. Scintigraphic camera.

In positron emission tomography (PET), the radiopharmaceutical is linked to a positron
emitter. A positron will anneal with an electron almost immediately after emission to produce
annihilation photons of 511 keV emitted over 180°. Images produced in PET are based on
the detection of these photons.
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1.2 Radionuclide therapy.

Although nuclear medicine is commonly used for diagnostic purposes, it also has important
therapeutic applications. In radionuclide therapy, large quantities of radiopharmaceuticals,
which selectively target the tissue under consideration, are administered to the patient in
order to treat disease. For therapeutical purposes, the radiopharmaceutical is usually a β-
emitter. The radionuclide mostly used for this kind of therapy is 131I (radioiodine).

131I has been used for radionuclide therapy since 1942. 131I emits both β-rays (maximum
energy 606 keV), which travel a maximum distance of 3 mm in tissue and thereby ensure
local treatment of the tissue under consideration and 364 keV γ-rays used for imaging of the
patient. Its physical half-life of 8 days enables long-term irradiation of the target tissue.
Supplemental advantages of 131I consist of: the low production cost, it’s easy availability and
the long-term expertise that has been gathered for this isotope.
There are also some drawbacks to the use of 131I. Perhaps the most important one is that
because 131I emits high-energy gamma rays (364 keV), the patient represents a radiation
hazard to his surroundings i.e. family members and hospital staff. To avoid irradiation of
these persons after administration of high activities of 131I, the patient has to be hospitalised
in a so called “isolation room”. This room is specially designed of lead walls to avoid
irradiation to bystanders and allows management of radioactive waste produced by the
patient by separate waste collection, storage and disposal after complete decay. In
conjunction with its long half-life of 8 days, this means that hospitalisation times can be up to
7 days and waste storage to decay takes at least 6 months.

The imaging by Gamma camera is not ideal for 131I due to the high energy (364 keV) of the
gamma rays. Gamma cameras are designed for imaging of radiopharmaceuticals labelled
with 99mTc, the most used isotope in diagnostic imaging, with a gamma ray energy of only
140 keV.
The third disadvantage of 131I is that its beta rays have a rather low energy max. 606 keV,
which allows a penetration depth in tissue of only 3 mm. Therefore, the isotope needs to be
distributed homogeneously throughout the whole tumour to be effective in oncological
applications.
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1.3 Radionuclide therapies using 131I-labelled radiopharmaceuticals.

In the following chapter, a brief overview is given of all pathologies included somewhere into
the scientific work of this thesis. In each case, the disease is briefly situated, followed by its
therapeutic option involving 131I-labelled radiopharmaceutical. Other treatment options are
not discussed, as they do not form part of this work.

1.3.1.  131I for hyperthyroidism and thyroid cancer.

Since its first use in 1942 (Hertz S.  et al. 1942), the most important systemic treatment using
ionising radiation is radioiodine (131I) treatment for hyperthyroidism and thyroid carcinoma. In
Belgium about 14.000 patients are treated every year (data from RIZIV Belgium).

1.3.1.1. Normal thyroid function.


Fig. 1.2. Anterior view of the thyroid (Eisenberg, 1991)

The thyroid is the organ responsible for the production of the hormones T3 (tri-
iododothyronine) and T4 (thyroxine). Microscopically, the thyroid is composed of spherical
follicles, each composed of a single layer of follicular cells surrounding a lumen filled with
colloid (mostly thyroglobulin).
A daily intake of I (under the form of I-) is provided for by regular diets, a minimum intake of
50 µg a day is needed to prevent iodine deficiency goitre (Utiger RD. 2002). In Belgium,
slight iodine deficiency exists.
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Although it has been known for decades that I- transport into the thyroid gland is mediated by
a specific Na+  dependent I- transporter located at the basolateral membrane of thyroid
follicular cells, the Na+/I- symporter (NIS) gene was cloned just in 1996 (Dai et al., 1996). NIS
is a transmembrane protein with 13 transmembrane domains, an extra cellular amino
terminus and an intracellular carboxyl terminus. The structure of NIS is visualised in figure
1.3. NIS co-transports two Na+  ions along with one I- ion, with the transmembrane Na+
gradient serving as the driving force for the I- uptake. The Na+  gradient providing the energy
for this transfer, is generated by the Na+/K+  adenosine triphosphatase (Na+/K+- ATP-ase).

Fig. 1.3. The NIS protein.

After active transport across the basolateral membrane, I- is translocated across the apical
membrane by pendrin to exocytotic vesicles fused with the apical cell membrane. In these
vesicles the I- is rapidly oxidised and covalently bound to a few of the tyrosyl residues along
the thyroglobulin backbone. The thyroid hormones T3 and T4 are synthesized by coupling of
two iodo-tyrosine residues and stored in the colloid. All of these steps are stimulated through
pituitary derived TSH (thyroid stimulating hormone), which interacts with the TSH receptor
located on the basolateral membrane of thyroidal cells. To liberate T4 and T3, thyroglobulin
is resorbed into the thyroid follicular cells in the form of colloid droplets. The droplets fuse
with lysosomes to form phago-lysosomes, in which the thyroglobulin is hydrolysed to T4 and
T3. The hormones are then secreted into the extra cellular fluid and enter the circulation.
In addition to its key role in thyroid physiology, NIS-mediated I- accumulation in the thyroid
gland is a crucial prerequisite for diagnostic scintigraphic imaging as well as for the highly
efficient radioiodine therapy of benign and malignant thyroid diseases.
Patient dosimetry and radiation protection issues for radionuclide therapy using 131I
Introduction. 1. 6

Fig. 1.4. Negative feedback regulation of thyroid hormone production (Eisenberg, 1991)

1.3.1.2. Thyroid pathologies treated with 131I.

On the average, up to 5 to 10 % of the population may suffer from thyroid pathologies during
their lifetime. (Johnston, 1995), but there are regional differences depending on factors such
as presence or absence of iodine deficiency. In this thesis, we will only focus on the
pathologies that can be treated with 131I: hyperthyroidism and thyroid carcinoma.

1.3.1.2.1. Hyperthyroidism.

Hyperthyroidism is a pathology where the cells of the thyroid have escaped the feedback
mechanism of thyroid production in the body resulting in an overproduction of thyroid
hormone. The cause of these problems can be threefold: Graves’ disease, toxic adenoma
and multinodular goitre.

Graves’ disease.
Graves’ disease is the most common cause of hyperthyroidism in children as well as adults.
In Europe the disease is found in about 10 to 50 people in 100.000 (Barker and Philips,
1984). The disease is an autoimmune pathology since spontaneous development of “thyroid
stimulating immunoglobulins” (TSAb) that mimic TSH action leads to the excessive
production and release of thyroid hormones, resulting in hyperthyroidism. The disease is
characterised by diffuse goitre, hyperthyroidism and ophtalmopathy.
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Fig. 1.5.  99mTc-pertechnetate scan of a patient with Graves’ disease.

Toxic adenoma and multinodular goitre.
Toxic adenoma and toxic mutinodular goitre are common causes of hyperthyroidism, second
only to Graves’ disease. 20 to 80 % of toxic adenomas and some nodules of multinodular
goitres have somatic mutations of the TSH receptor gene that confers autonomous
hyperactivity (Tonacchera et al., 1998).
A classical clinical presentation for toxic adenoma is a hyperthyroid patient with a palpable
nodule that corresponds to an area of increased radioiodine concentration on thyroid
scintigraphy. There should also be suppression of radioiodine uptake in surrounding and
contra lateral tissue.
Toxic multinodular goitre in comparison, typically presents with one or more focal areas of
increased radioiodine uptake, which may or may not correspond to palpable nodules; non-
functioning “cold” nodules are present in some patients (see figure).


Fig. 1.6.  99mTc-pertechneate scan of a patient with multinodular goitre
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1.3.1.2.2. Differentiated thyroid carcinoma.

In about 4 to 5 people in 100.000, a thyroid carcinoma will be diagnosed during life. The
disease can be treated well so the death rate due to this kind of carcinoma is only 0.5 % of
all cancer related deaths (Thompson et al., 1978). 85 to 90% of all thyroid carcinoma’s are
differentiated thyroid carcinomas: papillary and follicular carcinoma. Since only the
differentiated thyroid carcinomas can be treated with 131I, only these will be discussed further.
The thyroid carcinoma cells usually are less capable to incorporate I- and produce thyroid
hormones than normal thyroid cells. This at least partly due to a reduction in NIS expression
(Lazar et al., 1999) as well as a decrease in TSH receptor positive cells (Caillou et al., 1998).

1.3.1.3. Therapeutic modalities using 131I.

1.3.1.3.1. Hyperthyroidism.

The thyroid cannot differentiate between stable I- and 131I-, and will therefore incorporate the
131I- in the precursor for thyroid hormone. The short range (<3 mm) β-rays of the iodine will
therefore selectively irradiate the over-productive thyroid tissue, curing the hyperthyroid state
of the patient and reduce goitre.
131I (radioiodine) therapy has become the most widely used therapy for patients with Graves’
disease in the United States. It is the least expensive treatment option and is rarely
accompanied by acute side effects. A number of dosing regimens have been proposed,
ranging from those based on high precision dosimetry and ultrasound-guided volume
determination, to large, fixed doses of 131I intended to cause hypothyroidism soon after
treatment. Whatever the protocol, it is now clear that most Graves’ disease patients
ultimately become hypothyroid after 131I treatment. Possible complications include
exacerbation of ophtalmopathy, particularly in patients who smoke.
Patients suffering from a toxic adenoma or multinodular goitre on the other hand are usually
euthyroid after 131I treatment, because the radioiodine preferentially accumulates in the hyper
functioning nodules.
For the treatment of hyperthyroidism, typical administered activities are 185 - 1110 MBq. This
activity is excreted from the thyroid with a mean half-life of about 4-5 days before it is urinary
excreted.  The advantages of the therapy are: non-invasiveness, easy (oral) administration
and little side effects. The therapy result is known after about 3 months (Murray and Ell,
1994), and therapeutic efficiency is high: 57% to 100% (Delgrange et al., 1994).
Approximately 10-20% of patients fail the first administration of radioiodine and require a
second treatment. These patients typically have severe hyperthyroidism or large goitres.
Patient dosimetry and radiation protection issues for radionuclide therapy using 131I
Introduction. 1. 9
In spite of the high administered activities, no significant increase in the incidence of
secondary neoplasms has been reported in the literature (Clarke S.1991; Hall P.  et al. 1992;
Halnan K. E.1992).  So far, studies of children with Graves’ disease have not revealed an
increased risk of thyroid neoplasia, but as only 1000 children have been included and results
were not followed up long term, caution to treat younger patients remains (Moll and Patel,
1997). Other  disadvantages of the therapy are the radiation hazard the patient represents for
his family and the medical staff, the radioactive waste he produces and the fact that the
therapy results are only known after 3 months.

1.3.1.3.2. Thyroid carcinoma.

The unique property of thyroid follicular cells to trap and concentrate I- due to expression of
NIS allows effective therapy of differentiated thyroid carcinoma and their metastases by
administration of radioiodine, thereby improving the prognosis of thyroid cancer patients
significantly and making thyroid cancer one of the most manageable cancers. Therapy with
131I has been successfully used for over 40 years in the treatment strategy of differentiated
thyroid cancer. Recurrence rates are significantly higher in patients treated with surgery and
TSH suppression by T4 alone than in those who also receive radioiodine treatment. The
efficacy of radioiodine therapy is reflected in the low mortality of patients suffering from
metastatic thyroid cancer who are treated with 131I (3%) compared with those who are not
(12%) (Mazzaerri EL, 1996).
A standard activity of 3700 MBq to 7400 MBq is usually administered. These high
administered activities are necessary, because only a very small part of the 131I (about 2% of
the administered activity) is retained within the thyroid remnant tissue. The rest is eliminated
from the body within a few days after administration by urinary excretion.
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1.3.2.  131I-MIBG for neuroendocrine tumours.

1.3.2.1. Neuroblastoma.

Neuroblastoma, which is a tumour of the peripheral nervous system arising from the neural
crest, is the most common extra cranial solid tumour of childhood and has an incidence of
1/70000 children under the age of 15. (Young and Miller, 1975). Depending on local
extension of tumour and on presence of metastases, several stages can be defined in
neuroblastoma and an overview figure of all different stages is given below.

Fig 1.7. (Brodeur et al., 1988)
INSS (international neuroblastoma staging system) staging of neuroblastoma: Stage 1:
localised tumour confined to the area of origin. Stage 2a: unilateral tumour, no lymph node
involvement. Stage 2b: unilateral tumour with regional lymph node involvement. Stage 3:
tumour and/or lymph node metastases infiltrating across the midline. Stage 4: dissemination
of tumour to distant lymph nodes, bone, bone marrow, liver and/or other organs. Stage 4-S:
localised primary tumour as defined for stage 1 and 2 with dissemination limited to liver, skin
and/or bone marrow.

Analysis of prognostic factors at the time of diagnosis is essential for selecting appropriate
therapy. In general, risk groups can be defined by clinical stage of disease, age, N-Myc gene
amplification and DNA ploidy of the tumour, histopathology and serum markers at diagnosis.
Approximately 60% of children with neuroblastoma are at high risk for developing fatal
progressive disease (Reynolds et al., 1990). This group includes patients with stage 4,
disease who are diagnosed after one year of age, and patients whose tumours have N-Myc
amplification, regardless of stage of disease or age at diagnosis.
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1.3.2.1.1.  131I-MIBG therapy.

Neuroblastoma cells actively take up nor-adrenalin via an uptake-1 system. The 131I-marked
molecule meta-iodo benzyl guanidine (MIBG) has a similar molecular structure and is taken
up and stored in the cell in the same way as nor-adrenalin.





Fig 1.8. Molecular structures of nor-adrenalin and 131I-MIBG

Since its first scintigraphic use, in 1981 (Sisson et al., 1981), 131I-MIBG has played an
important role in the diagnosis and staging of neuroendocrine tumours. With a cumulative
sensitivity of 92% and specificity of 100% in 779 patients with neuroblastoma (Hoefnagel et
al, 1994), 131I MIBG scintigraphy has established itself as the most sensitive technique for
detection, staging and follow-up of this disease. Diagnostic images are nowadays usually
made with 123I-labeled MIBG. The purely γ-emitting radionuclide 123I possesses better
imaging qualities than 131I with a γ-ray energy of 159 keV as compared to the 364 keV of 131I.

















Fig 1.9. 131I-MIBG scintigraphy of a stage 4 neuroblastoma patient.
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Since 1984, 131I-MIBG has also been used therapeutically in neuroblastoma (Hoefnagel et
al., 1987; Hoefnagel, 1991). In 1991, the cumulative experience in 276 children with
neuroblastoma indicated an objective response rate (improvement in disease status,
reduction of pain, patient resumes normal life) of 35% (Hoefnagel, 1994; Troncone and Galli,
1991). Most of these patients had, progressive and intensely pre-treated stage 4 disease as
they were only treated with 131I-MIBG after chemotherapy had failed. In addition, 131I-MIBG
provided adequate palliation and improved quality of life for many children. Usually a fixed
dose of 3700 to 7400 MBq of 131I-MIBG is infused intravenously over a 2h to 4h period.


Fig 1.10. Neuroblastoma patient receiving 131I-MIBG therapy in an isolation room of the
Netherlands Cancer Institute.










Fig 1.11. Set-up of 131I-MIBG infusion system.
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1.3.2.2. Carcinoid tumours.

Carcinoid tumours are the most common occurring gut endocrine tumours. The incidence of
carcinoid tumours is estimated to be approximately 1.5 cases per 100000 of the general
population. Nonetheless, they account for 13-34% of all tumours of the small bowel and 17-
46% of all malignant tumours of the small bowel (Buchanan et al, 1986).  They are derived
from a totipotential stem cell in the gut wall, capable of differentiating into any one of a variety
of cells, which may be responsible for the clinical syndrome. Carcinoids usually appear in the
gut, but are also found in the pancreas, the rectum, the ovary, the lungs and elsewhere. The
tumours grow slowly and are often clinically silent for many years before becoming manifest,
usually when metastases have occurred. They frequently metastasise to the regional lymph
nodes, the liver and less common to bone. The age distribution of carcinoids is Gaussian in
nature and the peak incidence occurs in the sixth and seventh decade.

1.3.2.2.1. 131I-MIBG therapy.

Since carcinoids are neuroendocrine tumours, they also selectively take-up MIBG. The first
report of 131I-MIBG imaging of a carcinoid tumour was that of Fisher and co-workers in 1984
in which hepatic metastases, that were seen as photopenic areas on a 99mTc-phytate liver
scan, concentrated 131I-MIBG (Fisher et al. 1984).  Since this initial description, 131I-MIBG has
been used for successful imaging of carcinoid tumours. Reported results reveal that 70% of
carcinoids in 275 patients concentrate this tracer (Hoefnagel, 1994). The overall sensitivity is
calculated to be only 55%, because MIBG is taken up by a large variety of neuroendocrine
tumours.
For therapeutic use of 131I-MIBG to treat metastatic carcinoid disease, results were available
for 52 patients in 1991, revealing on the one hand an objective response of only 15% but on
the other hand palliation, which may be very meaningful and long lasting, in 65% (Hoefnagel,
1991). As for neuroblastoma, usually a fixed dose of 3700 to 7400 MBq of 131I-MIBG is
infused intravenously over a 2h to 4h period.

1.3.2.3. Medullary thyroid carcinoma and pheochromocytoma.

Both Medullary thyroid carcinoma and pheochromocytoma are neoplasms of endocrine
organs and are linked together by at least two major considerations. Firstly, the tumours
arise from the so called “amine precursor uptake and decarboxylation” (APUD) cells which
constitute the diffuse system of neuroendocrine cells distributed throughout the body
(Pearse, 1968; Pearse and Polack, 1974). The APUD acronym denotes the capacity of these
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cells to synthesize and/or secrete biogenic enzymes formed through activity of the enzyme L-
dopa decarboxylase. The second feature linking these particular neoplasms is that they can
occur in individual patients as a consequence of autosomally dominant genetically
transmitted disorders. Inherited genetic defects affect different groups of APUD cells and
lead to neoplastic development of related cell types in diverse anatomic regions (Baylin,
1990).

Medullary thyroid carcinoma (MTC) is an uncommon tumour representing 5-10% of all
thyroid cancers. It is a neoplasm of the calcitonin secreting C-cells, which are sparsely
distributed in the thyroid gland. The only known etiological factors for occurrence of this
neoplasm are the autosomal dominant genetic disorders MEN 2a, MEN 2b and non-MEN
syndromes which account for 20 % of patients with MTC. Otherwise, MTC arises as a
sporadic tumour, equally distributed among both sexes and different ethnical groups. The
peak onset for the sporadic form of MTC is around the age of 50-60, while the tumour
represents much earlier in life in the MEN syndromes (Alexander and Norton, 1991).

Pheochromocytoma describes a neoplasm of chromaffin cells found in the adrenal medulla
or elsewhere in the sympathetic paraganglionic axis. Pheochromocytomas occur infrequently
and are found in approximately 0.1-0.5% of hypertensive patients (Scott and Halter, 1984).
90% of Pheochromocytomas occur sporadic and 10% are associated with familial syndromes
MEN2a and MEN2b. Familial Pheochromocytomas typically follow a benign course, but
because of their potential for causing significant morbidity and mortality, they must be
diagnosed or removed. Only 10% of Pheochromocytomas are malignant and the overall 5-
year survival in this case is about 44%.

1.3.2.3.1.  131I-MIBG therapy.

30-40% of MTC cells concentrate MIBG although the mechanism of uptake is not understood
(Troncone et al., 1991). Treatment protocol consists of repeated high activity 131I-MIBG
infusions at 2-8 month intervals. The results of 22 patients treated with 131I-MIBG are
variable. 50-100% of patients derived some kind of relief from the treatment. Response was
indicated as symptom palliation, reduced calcitonin secretion or tumour regression. Complete
remission is rare, although partial response with disease stabilisation is reported in 30-80%
(Hoefnagel et al., 1991).

95% of Pheochromocytomas concentrate MIBG, which can therefore be used for targeted
radiotherapy. The 131I-MIBG retention within the cell is rather low so the treatment has to be
Patient dosimetry and radiation protection issues for radionuclide therapy using 131I
Introduction. 1. 15
repeated several times in order to have a manifest effect (Shapiro and Fig, 1989). The cause
for this insufficient uptake of MIBG by chromaffin neoplasms is not fully understood, but it
may be due to the fact that these neoplasms may have a less differentiated amine uptake
and storage phenotype compared to benign and normal chromaffin cells. In 1994, results
were available for 99 patients and are listed in the table below.

Centre Pts CR PR SD BR PD NE
Michigan 28 0 2 16 5 9 1
Brescia 6 0 2 3 2 1 0
Southampton 23 0 2 11 8 0 10
France (multicentre) 15 0 5 7  3 0
Kassel 14 0 2 8  4 0
Rome 5 1 1 2 2 1 0
Varese 4 0 0 3 1 1 0
Amsterdam 4 0 1 3 3 0 0
Total: 99 1 15 53 21 19 11

Table 1.1. Cumulated results of 131I-MIBG therapy for pheochromocytoma in 1994. Pts:
number of included patients, CR: complete remission, PR: partial remission, SD: stable
disease, BR: biochemical response, PD: progressive disease, NE: not evaluable.
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1.3.3.  131I-lipiodol for hepato cellular carcinoma (HCC).

1.3.3.1. Hepato cellular carcinoma.

HCC has one of the greatest geographical variations of any major cancer. While rare in the
US and Western Europe, liver cancer is one of the most common neoplasms in eastern Asia
and Sub-Saharan Africa. Due to the large population sizes in these areas, HCC ranges as
one of the most common cancers in the world. It is responsible for an estimated one million
deaths annually. (London, 1981). The survival time among patients with irresectable HCC is
extremely short and may be as low as 1-2 months. (Novell and Hilson, 1994).
Also the peak age incidence has geographical variability. In South Africa the peak incidence
occurs between the ages of 35 and 45 years. In Asia the peak occurs ten years later and in
the US the peak is ten years later yet (Kew et al., 1984 ). The male/female ratio among
cases of HCC is heavily biased towards males with ratios between 4/1 (low incidence area’s)
to 9/1 (high incidence area’s). The male preponderance can be explained by a number of
factors, including the male bias towards hepatitis B virus carriers, genetic susceptibility,
androgenic steroids, and higher body iron stores.
The relationship between chronic hepatitis B virus (HBV) and HCC has been established
over more than 30 years: those areas in the world that have high incidences of HCC also
have high infection rates of HBV. Epidemiological research in low and moderate incidence
areas has shown a relationship between alcohol consumption and HCC (as well as liver
cirrhosis).


Fig 1.12. T2-MRI scan of a patient with a 4 cm HCC nodule in the liver and the resected
nodule.
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1.3.3.1.1.   131I-lipiodol therapy

Of the approaches available for treating irresectable HCC, much interest is currently focused
on the improved results achieved with arterially delivered therapies using iodised oil as a
vehicle (Bhattacharya et al., 1994). Lipiodol consists of mono-, di- and tri-iodinated ethyl
esters of linoleic, oleic and stearic acids. It naturally contains up to 38% of iodine. In 1979,
Nakakuma et al. (Nakakuma et al., 1979) established the selective retention of iodised oil in
the foci of HCC, following its injection into the hepatic artery. It is now well established that
lipiodol is retained by HCC for periods ranging from several weeks to over a year, while it is
cleared from the normal liver parenchyma within 7 days (Ohishi et al., 1985; Okuyasu et al.,
1988).  Coupling lipiodol with chemotherapeutic agents (such as doxorubicin or cisplatinum)
allows in-situ chemotherapy (Takayasu et al., 1987).
Intra-arterial infusions of emulsions composed of lipiodol and anticancer agents in
combination with gel-foam embolisation (so called “chemo-embolisation” treatments) that
stops blood flow to the affected parts of the liver, increased therapeutic efficiency (survival
rates of 89% at 6 months and 69% at 1 year  (Ohishi et al., 1985), 48% after 6 months (Raoul
et al., 1994), but a drastic increase in side effects, due to necrosis of part of the liver, was
seen as well.
Internal radiation therapy can be achieved, when some of the iodide present in the lipiodol is
substituted by 131I using a nuclidic exchange reaction. The clinical results of patients treated
with 131I-lipiodol are at least as good as with the chemo-embolisation method; moreover the
patients experience less side effects (Raoul et al., 1994, Raoul et al., 1997) since liver
necrosis is prevented.
However, 131I-lipiodol treatments are not only used for palliation. The treatment can be
curative when the 131I-lipiodol is given neo-adjuvant before liver transplantation and/or after
resection of hepatocellular carcinoma (Lau et al., 1999). It is believed that the adjuvant
administration of 131I-lipiodol will clear up the micrometastases that form due to HCC cells
that are inevitably left in the body after tumour or liver resection.
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2.1. Introduction.

In Nuclear Medicine, target-finding molecules coupled to a radioisotope
(radiopharmaceuticals) are injected into the patient to enable physiological imaging
(diagnosis) or therapeutic effects (radionuclide therapy). For radionuclide therapy, high
activities (several GBq) of radiopharmaceuticals are administered to the patient in order to
have a significant therapeutic effect. Although the injected radiopharmaceuticals mainly
target the tissue under treatment, inevitably the rest of the body is also irradiated to some
extent. This is partly due to the circulation of the radiopharmaceutical in the body before it is
incorporated into the target tissue, or is excreted, and partly by the long-range γ-rays emitted
from the radiopharmaceutical inside the target tissue. Since radionuclide therapies are often
repeated several times for the same patient and can be considered as curative in the
treatment of some tumours, it is important to determine the radiation dose to the patient as
measure of the mutagenic effect of the therapies and the risk for development of fatal
cancers. Ideally, bone marrow dose data for a specific patient should be known prior to the
planned radionuclide therapy, so the amount of administered activity can be prescribed
accordingly.
In this work biological and physical dosimetry methods were used.

A second problem occurring from the long-range γ-rays emitted from the radiopharmaceutical
inside the patient is the radiation hazard they pose for their surroundings, especially their
relatives. Based on a revision of the epidemiological data on the incidence of cancer and
leukaemia in populations exposed to ionising radiation (UNSCEAR, 1994), EURATOM 96/29
(1996) has recommended reducing the limit for members of the public for exposure to
ionising radiation from 5 mSv/yr. to 1 mSv/yr. This recommendation has been included into
the Belgian legislation, issued on 31 July 2001. It is therefore necessary to determine what
safety measures have to be taken to ensure that the dose to the relatives does not exceed
this new dose limit.
In this work the patient dose and the dose to the relatives has been determined for different
radionuclide therapies using 131I-labelled radiopharmaceuticals.
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2.2. Determining the patient effective dose and the dose to specific organs
using physical dosimetry methods.

Physical dosimetry methods in nuclear medicine are based on the MIRD (Medical Internal
Radiation Dosimetry) formalism:

DT  = Σs Ãs  . S(T←S)
Where:DT  = Absorbed dose to target organ T
Ãs   = Cumulated activity in the considered source organ S
S = the organ specific S factor: Dose in the target organ per unit of cumulated activity present
in the source organ. ,

The cumulated activity values are determined by means of a set of biplanar scans taken at
various intervals after administration of the therapeutic activity.

2.2.1. Can the patient dose after radionuclide therapy be determined before
administration of the therapeutic activity?

Since a high total body dose to the patient can cause severe side effects such as long lasting
pancytopenia, ideally, dose data for a specific patient should be known prior to the planned
radionuclide therapy, so the amount of administered activity can be prescribed accordingly.
In the case of 131I-MIBG therapy, the dose limiting organ is the bone marrow. In practice, the
whole body absorbed dose is used as an adequate representation or index of bone marrow
toxicity. To predict the whole body dose prior to therapy, one must measure the retention of a
tracer dose of MIBG.
Pre-therapeutic MIBG scans can be performed using either 123I-MIBG or 131I-MIBG. Since the
123I-MIBG data reflect predominantly the blood clearance phase while the delayed timing of
the 131I-MIBG scans reflects predominantly the second slower component of clearance,
neither type of scan reflects both components. Therefore we decided to combine the” best of
both worlds” and use the information of the combination of 123I-MIBG pre-therapy scans and
131I-MIBG post therapy scans as the gold standard to determine the total body dose to the
patient after 131I-MIBG therapy. The aim of the present study was to evaluate the feasibility of
this combination and to determine how much information about the 131I-MIBG therapy can be
gathered from 123I-MIBG pre-therapy scans alone.
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2.2.2. What are the differences for the absorbed dose to the organs and the effective
dose to the patient between calculations by means of the MCNP Monte Carlo code
and the MIRDOSE program?

Although some bio distribution studies have been performed (Raoul et al., 1988; Madsen et
al., 1988; Nakajo et al., 1988), data on patient dosimetry for the 131I-lipiodol treatment are
scarce. Therefore, the aim of the present study was to determine the effective dose to
patients treated with 131I-lipiodol.
In order to use the MIRD formalism to calculate the absorbed dose to each organ and the
effective dose to the patient, the “cumulated activity” and the “S-factor” have to be
determined. In this work, the S factors have been determined in two different ways:
-  Derived from the MIRDOSE software program, based on phantoms, sex- and age
matched to the patient.
-  In a more patient specific way by calculating S factors using the Monte Carlo code
MCNP program. The anatomy of the specific organs can be derived from CT or MRI
images of the patient and is inserted into a sex and age matched phantom of the
patient in the Bodybuilder software program. Using the 131I emission spectrum, the S-
factors can then be derived for all source and target organs.
The results of the patient specific Monte Carlo calculations were compared to the output of
the MIRDOSE-3  program.


2.3. Determining the mutagenic effects directly after therapy using cytogenetic
dosimetry methods.

In a healthy population, the mutagenic potential of a certain treatment or drug can be
determined by cytogenetic biodosimetry as the in vitro cytokinesis-blocked micronucleus
assay (Ramalho et al., 1995; Thierens et al., 1995; Thierens et al., 1999). In nuclear
medicine therapy however, biological dosimetry by means of the micronucleus assay has
only been carried out for 131I-therapy for thyroid carcinoma (Wuttke et al., 1996) and 89Sr
therapy for palliation of painful bone metastases (Watanabe et al., 1998). For
hyperthyroidism as compared to thyroid carcinoma, a lower activity is administered to the
patient, but the patient is exposed to the radiation for a longer time due to the higher
percentage of 131I uptake and half-life in the thyroid. For patients treated with 131I-MIBG and
131I-lipiodol, high administered activities are given and the therapy is usually repeated, but no
biological dosimetry data are available.
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2.3.1. How do the results of a biological dosimetry method such as the in vitro
micronucleus assay compare to a physical dosimetry method based on bi-planar
scans?

In this work we report the results of studies on biological dosimetry using the in vitro
micronucleus assay for patients treated with 131I and 131I-MIBG.
For 131I treated hyperthyroidism patients, results were compared to thyroid carcinoma
patients. From, the increase in micronuclei, the ETBD was calculated and correlated to the
administered activity and the activity retained in the thyroid. For patients treated with 131I-
MIBG, the comparison was made between the ETBD determined by the micronucleus assay
and the results of a purely physical dosimetry method based on the MIRD formalism.
The obtained results can be interpreted within the framework of cancer mortality assessment
for radionuclide therapies.

2.3.2. What is the effect of multiple radionuclide therapies on the micronucleus yield?

In this study, 6 patients treated with multiple 131I-MIBG therapies (4 patients had 2
subsequent therapies while one patient had as many as 5 subsequent therapies) and 1
patient treated with 3 subsequent 131I-lipiodol therapies were followed over time. For each
therapy, the micronucleus yield was determined in a blood sample taken before the therapy
and 1 week after administration of the activity. The obtained micronucleus yield in each blood
sample was plotted versus time and from these results the mean lymphocyte half-life was
calculated.

2.3.3. What is the residual damage after radionuclide therapy one year after treatment?

Stable chromosome aberrations have a very long half-life and are therefore better indicators
of the mutagenic potential at long term. Therefore, we investigated the incidence of
translocations induced by 131I therapy in hyperthyroidism patients one year after the
administration of the radiolabeled compound. Tricolour FISH with chromosome 2, 4 and 8
whole chromosome probes was used for the scoring of the translocations. From the genomic
translocation frequencies, whole body doses were calculated based on the in vitro dose
response.
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2.3.4. Can 131I treatment be considered as an in vivo conditioning dose leading to an in
vivo adaptive response?

No statistically significant increase in leukemia or solid tumors has been reported in the
literature (Clarke, 1991; Hall et al., 1992; Huysmans et al., 1996) after 131I-therapy for thyroid
disease, in spite of the therapy’s frequent use since 1942. The risk for late detrimental effects
after 131I therapy is estimated to be less than 1% over lifetime (Hall et al., 1992; Huysmans et
al., 1996; M’Kacher et al., 1996; Watanabe et al., 1998). Exposure to low levels of ionizing
radiation (conditioning dose) can stimulate the DNA repair system, resulting in less genetic
damage after subsequent high levels of ionizing radiation (challenge dose). This
phenomenon has been called adaptive response because it is similar to the induced repair
described in E. Coli (Samson and Cairns, 1977). The existence of an in vivo  adaptive
response in humans is a possible explanation for the fact that the incidence of cancer in
some populations exposed occupationally is lower than expected as suggested by the results
of some epidemiological studies recently reviewed by Pollycove (1995) and Van Wijngaerden
and Pauwels (1995).
Therefore the aim of this study was to assess whether or not an adaptive response in vivo
could be observed in peripheral blood lymphocytes of patients treated with 131I for thyroid
disease.

2.3.5. Are there specific problems for biodosimetry of cancer patients?

In a healthy population, the mutagenic potential of a certain treatment or drug can be
determined by cytogenetic techniques, such as the in vitro cytokinesis-blocked micronucleus
assay (Ramalho et al., 1987; Thierens et al., 1995; Thierens et al., 1999). For patients
treated with 131I-MIBG and 131I-lipiodol, the effect of the malignant disease status and
previous treatments on the feasibility of cytogenetic biodosimetry were investigated. For 131I-
MIBG treated patients, the in vitro dose response relationship was compared to the response
of a control population (Thierens et al., 2001).
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2.4. Determining the radiation burden to relatives of patients treated with 131I.

Based on a revision of the epidemiological data on the incidence of cancer and leukaemia in
populations exposed to ionising radiation (UNSCEAR, 1994), EURATOM-29 (1996) has
recommended to reduce the limit for members of the public for exposure to ionising radiation
from 5 mSv/y to 1 mSv/y. Due to the high activities administered to patients treated with 131I
and the high energy (364 keV) γ-radiation emitted from the patient, it may be difficult for the
relatives of these patients to comply with this new dose limit. In Belgium about 14000
patients are treated with radioactive iodine every year (RIZIV, 2003).
The practical consequences of the EURATOM-29 (1996) regulations, should be investigated
by studies measuring the real-life radiation burden of family members of patients treated with
131I for thyroid disease (O’Doherty et al., 1993). However, because of logistic or practical
problems, most studies published so far, are based on dose rate measurements of 131I-
treated patients upon leaving the hospital and extrapolations of time spent at varying
distances to the patient (Mountford PJ, 1987; Culver and Dworkin, 1992; O’Doherty et al.,
1993; Wasserman and Klopper, 1993; Mountford and O’Doherty, 1994; Weber and
Castronovo, 1996; Demir et al., 1996; Zanzonico et al., 1997; Guanasekera et al., 1997). The
major drawback in these studies is the use of occupancy models for calculation of the doses,
which may be inaccurate (Greaves et al., 1996). A number of studies measuring the “real life”
radiation burden to family members using film badges, TLD dosimeters or digital dosimeters
have been carried out (Harbert and Wells, 1974; Barrington et al., 1993; Thomson et al.,
1993a; Thomson et al., 1993b; Barrington et al., 1995; Monsieurs et al., 1996; Mathieu et al.,
1996; Barrington et al., 1997. Mathieu et al., 1997). But most of these studies report results
on small groups of patients and each individual study uses a separate set of guidelines.

2.4.1 What is the radiation burden of relatives of patients treated with 131I for thyroid
diseases when implementing different sets of guidelines?

We report the results of a multicentre study, carried out in 8 centres of Flanders (Belgium),
where a total of 65 131I-treated patients and 94 of their relatives were monitored up to 14 days
after the patient returned home, using wrist TLD measurements. Each participating centre
advised its own routine guidelines to their patients. The real-life radiation burden of the
patient’s relatives, measured under different sets of guidelines, is compared to the
EURATOM-29 (1996) dose limit. Conclusions are drawn regarding the guidelines for patients
treated with 131I.
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3.1. Cytogenetic dosimetry methods.

3.1.1. Introduction.

When ionising radiation passes through matter, it ejects electrons from this matter leaving
positively charged ions. In cytogenetics, the matter under consideration is the DNA of the cell
nucleus. The induced damage to the DNA can either be repaired, resulting in an apparently
normal DNA strand, be misrepaired to form a DNA exchange or remain unrepaired, resulting in
a break in the DNA strand.

The DNA damage will increase with increasing dose (since more molecules can be hit). Also
the LET (linear energy transfer) of the radiation will determine the biological effect of the
radiation. The higher the LET, the more interactions will arise with the DNA strands for the
same distance travelled and the more damage will be inflicted upon the DNA.
The aberrations scored in the lymphocytes are interpreted in terms of absorbed dose by
reference to a dose response calibration curve. This curve is produced by in vitro  exposure of
blood to well known doses of ionising radiation.
The dose response relationship for low LET radiation (as studied in this work) has a linear
quadratic shape (fig. 3.1):
Number of aberrations = αD2 + βD + γ
Where D = dose.

For low LET radiation, low doses do not create many aberrations, as mostly single strand DNA
breaks will be inflicted that can be repaired quite easily. The higher the radiation dose becomes
however, the higher the chance of double strand breaks (resulting form multiple single strand
DNA breaks) that are more difficult to repair and therefore lead to aberrations.
For high LET radiation, the number of interactions with matter over a short distance is so high
that even for a low dose, double strand breaks will be inflicted upon the DNA. Therefore the
dose to aberrations relationship has a linear shape (fig. 3.1):

Number of aberrations = αD + γ
Where D = dose

Patient dosimetry and radiation protection issues for radionuclide therapy using 131I.
Materials and Methods. 3. 3

Fig 3.1. Dose response curve

In cytogenetics, the aberrations are scored in peripheral blood T-lymphocytes. The dose value
obtained by referring a measured yield of aberrations to a calibration curve represents an
averaged absorbed dose to the lymphocytes. This approximates to an averaged whole body
dose because lymphocytes are widely distributed over the body (both in the peripheral blood
and in the organs) and migrate. Thus, with the lymphocyte test system, the observed
chromosome aberrations are induced in lymphocytes in the peripheral blood itself and in
lymphocytes distributed in different organs throughout the body (Bogen, 1993). Most of the
peripheral T lymphocytes are in the “resting” stage of the cell cycle (G0) while chromosomal
aberrations can be observed in DNA at metaphase, thus during cell division. It is therefore
necessary to stimulate the lymphocytes to divide. The lymphocytes can be initiated to undergo
in vitro  mitosis by the introduction of phytohaemagglutinin (PHA), a protein derived from the
bean plant Phaseolus vulgaris (Nowell, 1960).
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3.1.2. In vitro  micronucleus assay on peripheral blood lymphocytes.

3.1.2.1. Short description of the method.

Micronuclei (fig. 3.2) are small, round cytoplasmic bodies containing chromatin. They originate
when radiation or chemicals disrupt the DNA and chromosome fragments fail to incorporate in
the nucleus during subsequent cellular division. 

Fig. 3.2. Binucleated cell containing micronuclei

To understand how micronuclei are formed, one has to know how normal cell division takes
place. The process is visualised in figure 3.3.
First the cell will double the existing amount of DNA, so all DNA is copied (1). The chromatin
condenses into the well known shape of chromosomes (2), the nuclear membrane dissolves
and the copies are arranged in the midplane of the cell. A “spindle” is formed linking the
centromere of each chromosome to one of the cell poles (3) and the chromosomes are drawn
to the poles of the cell (4). Around both groups of chromosomes a nuclear membrane is formed
so we essentially have a “binucleated” cell at this stage (5). The chromosomes start to de-
condense and finally the cytoplasm of the cells divides to form two new cells (6).
When radiation has led to DNA breakage, the chromosome fragment will not be included into
the spindle formation and is left behind. In the binuclear state of cell division, these fragments
can be seen as small nuclei or “micronuclei” as can be seen in figure 3.4.
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Fig 3.3. Normal cell division











Fig 3.4. Cell division after DNA damage due to ionising radiation with formation of a
micronucleus

In order to block the cell cycle in the binuclear state to allow scoring of the micronuclei,
Cytochalasin B is added to the culture medium as described by Fenech and Morley (1985).
The dose dependent induction of micronuclei in lymphocytes has been well characterised after
exposure to various kinds of radiation (Fenech and Morley, 1985; Prosser et al., 1988;
Gantenberg et al., 1991; Huber et al., 1992; Thierens et al., 1992; Huber et al, 1994; Vral et al.,
1994; Wuttke et al., 1994). A good agreement between in vitro  and in vivo induced
micronucleus frequencies was obtained after total-body irradiation and partial body irradiation
(Thierens et al., 1995), indicating that micronuclei in lymphocytes are a reliable non-invasive
tool to estimate radiation damage for purposes of biological dosimetry.
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3.1.2.1. General study protocol.

Details of the exact study protocol can be found in the papers of chapter 4.  In general, for each
patient two blood samples were taken. The first was taken immediately before administration of
the therapeutic activity, the second 7 days post-administration. These time points were taken
since they corresponded with scheduled check-ups for the patient and the normal blood
sampling routine.

For patients treated with 131I and 131I-MIBG, the first blood sample was divided in three fractions
to determine an individual in vitro dose-response curve. Since the scoring of the micronucleus
yield was done manually and requires at least 1000 binucleated cells to be scored per blood
sample in order to gain statistical significance, only three dose points could be taken. In this way
results could be reached within a reasonable time frame for all patients.











Fig. 3.5. Study protocol for biodosimetry based on the in vitro micronucleus assay.

For patients treated with 131I-lipiodol the first blood sample was not irradiated in vitro  due to the
expected cell culture problems related to the hypersplenism. For this patient the dose-response
relationship determined by Thierens et al. (1999) was used:

YMN = (23.3±6.6) + (81.1±0.3)D + (19.5±0.5)D2
Where: YMN = micronucleus yield after therapy
D = Dose (Gy)
Therapy:
Blood sample 1
Day 7
0 Gy 0,5 Gy 1 Gy 60Co
Cytokinesis-blocked micronucleus assay
Sampling
In-vitro irradiation


 


Patient dosimetry and radiation protection issues for radionuclide therapy using 131I.
Materials and Methods. 3. 7
Using the individual or general dose response curve, the equivalent total body dose (ETBD)
was derived from the increase in micronucleus yield between the blood sample before and after
therapy. The ETBD is the dose of ionising radiation, which, if received homogeneously by the
whole body would produce the same increase in micronucleus yield as observed after
radionuclide therapy.

3.1.2.3. Adaptive response

The in vitro micronucleus assay can also be used for another purpose: the search for the in vivo
existence of an “adaptive response”. Exposure to low levels of ionizing radiation (“conditioning
dose”) can stimulate the DNA repair system in certain individuals, resulting in less genetic
damage after subsequent high levels of ionizing radiation (“challenge dose”). This phenomenon
has been called adaptive response because it is similar to the induced repair described in E.
Coli (Samson and Cairns, 1977). An “adaptive response” differs from “natural selection” in that
it is not related to the selection of cells that are already better suited to withstand the genetic
damage inflicted by a mutagen, but that it involves active biochemical changes inside the cell
after the “conditioning dose” of the mutagen has been distributed. These biochemical changes
do not consist of a mere up-regulation of proteins involved in DNA repair, but in de novo
synthesis of DNA repair proteins as was determined by Weichselbaum et al. (Weicheselbaum
et al., 1991).

To investigate the existence of an in vivo  adaptive response, only a slight change in the
micronucleus protocol was necessary. In this case, also the second blood sample (after
therapy) was divided into three fractions and irradiated in vitro with the same protocol as the
blood sample before therapy, as is visualized in figure 3.6.
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Fig. 3.6. Study protocol for adaptive response

The increase in micronucleus yield after in vitro  irradiation of the blood samples taken before
and after 131I therapy was compared. An adaptive response exists when the increase in
micronucleus yield in vitro  is significantly less in the blood sample taken after therapy than the
increase in the blood sample taken before therapy.

3.1.3. Scoring translocations in peripheral blood lymphocytes.

3.1.3.1. Short description of the method.

There are several chromosome aberrations that can be formed after DNA damage by ionising
radiation. Chromosome aberrations that allow for all DNA to be passed through to the next
generation of cells are called “stable”. When acentric fragments are formed, these aberrations
are called “unstable”, since they can not be incorporated into the daughter cells that will
consequently miss pieces of genetic information and are therefore not viable.

The most common unstable chromosome aberrations are dicentrics (fig. 3.7). Dicentrics are
formed when two centromere containing DNA fragments are linked. Another unstable
chromosome aberration is a ring chromosome (fig. 3.8), formed when two parts of the same
chromosome containing a centromere are linked. In both cases the other chromosome
fragments recombine into an acentric fragment.
 Therapy:

Blood sample 1

0 Gy  0,5 Gy  1 Gy
Cytokinesis - blocked micronucleus assay

Blood sample 2
Day 7
0 Gy 0,5 Gy 1 Gy 60Co
   
Sampling
In-vitro irradiation
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Fig. 3.7. Dicentrics formation


Fig. 3.8. Ring chromosome formation

The only stable aberrations are translocations (fig. 3.9). Translocations are formed when a
centric and an acentric chromosome fragment combine, forming a “longer” and a “shorter”
chromosome. The daughter cell still contains all information (although some genetic information
is now moved to another place).




Fig. 3.9. Translocation formation

In order to study long term DNA genotoxic effects, the micronucleus assay is not appropriate
since micronuclei are essentially unstable chromosome aberrations and will slowly disappear
with time after irradiation. On the other hand, a lot of data indicate that translocations are an
efficient tool to study the long term DNA genotoxic effects after irradiation (Lucas et al.,1996;
Snigiryova et al., 1997; Lindholm et al., 1998). Therefore, translocations were studied in order to
investigate long term effects of radio-iodine treatment on thyrotoxicosis patients.
Translocations are scored by staining different chromosomes with different fluorescent DNA
probes (harlequin staining). A translocation is then visualised as a monocentric chromosome
with more than one colour (fig 3.10). The technique used is called FISH, short for “fluorescent in
situ hybridisation”.
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Fig 3.10. FISH
3.1.3.2. General study protocol

Blood samples were taken immediately before therapy and at about one year after therapy,
when the patient reported to the endocrinologist for his scheduled check-up. Blood cultures and
FISH analysis were performed by V. Lambert of the “Laboratoire ORME” of the University of
Liege (Belgium). Harlequin staining with whole chromosome probes for chromosomes 2, 4 and
8 was used. The frequencies of translocations for the painted chromosomes were extrapolated
for a frequency for the whole genome using the formula of Lucas et al. (1999):
Fp = 2.05 (fp2.(1-fp2) + (fp4.(1-fp4) + fp8.(1-fp8)) – fp2.fp4 – fp2.fp8 – fp4-fp8).FG
Fp = frequency of translacations for the 3 chromosomes
fpx = length of each individual chromosome relative to the whole genome.

The equivalent total body dose was determined from the observed FG using a previously
determined in vitro  calibration curve (Thierens et al., 1999):
FG = (0.050±0.013)D2 + (0.031±0.004)D + (0.02±0.007)
Where: D = dose (Gy)

A detailed description of the method used can be found in chapter 4.
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3.2. Physical dosimetry methods.

3.2.1. Patient dosimetry based on bi-planar total body scans and the MIRD formalism.

3.2.1.1. Short description of the method.

In physical dosimetry using the Medical Internal Radiation Dose (MIRD) principle, the body is
considered as a collection of organs and tissues that homogeneously contain a radionuclide
(“source organs”) and other organs (“target organs”) that do not contain any activity themselves,
but are irradiated by radiation emitted from inside source organs. So irradiation from source
organs can deliver dose to target organs. Target and source organs can be the same. Some
examples of source and target organs depending on the radiopharmaceutical are given in the
figure below (fig. 3.11).


Fig. 3.11. Examples of source and target organs depending on the administered
radiopharmaceutical

The “total body dose” is determined by considering the whole body as source and target organ.
When the “effective dose” to the total body needs to be calculated, the body is divided into
different source and target organs and the effective total body dose is than calculated as a
weighted sum of the absorbed doses for all organs inside the body. These weighting factors
take into account the radiosensitivity of the organs with respect to late effects.
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3.2.1.1.1. Cumulated activity.

In order to calculate the dose in a target organ, one first has to know the cumulated activity
inside the source organ. The cumulated activity is the time integrated activity inside the source
organ from the time it entered the source organ until the activity can be neglected. The amount
of activity in any organ depends on the time after administration. Activity is usually taken up
from the blood and decreases partly by physical decay inside the organ (physical half-life) and
partly by biological excretion from the organ (biological half-life). In practice, ROIs (regions of
interest) are drawn around the relevant structures visualized on the scan, and the amount of
activity inside each ROI is calculated. The evolution of the activity in the organ can be visualized
when several sequential scintigrams are taken from the patient.















Fig. 3.12. Determination of cumulated activity
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Attenuation correction.

When simply comparing the number of counts on the gamma camera from a known activity in a
ROI to the number of counts from inside an organ, the activity inside the organ measured in this
way is usually too low. Simply put: the more tissue along the route of the radiation, the more
radiation is lost along the way. This process is called attenuation. Nowadays, attenuation
correction is usually done by measuring an “attenuation map” of the patient, by putting a moving
point- or line source or a steady flood source under the patient and measuring the percentage of
radiation penetrating through the patient’s body. The map constructed in this way is then
applied to correct the activity measurement of the actual patient scan. In order to do so, either
the gamma camera has to be capable of measuring two different radionuclide energies at the
same time (dual isotope scanning) or it is necessary to make two subsequent scans of the
patient. The first scan (transmission scan) is of the patient with the flood source placed
underneath, the second scan (emission scan) is taken in the exact same position with he
radiopharmaceutical of interest injected into the patient. In this way, the imaging time is of
course much longer.
Since the camera used n our studies (GE Elscint) can not measure two different energies at the
same time, dual isotope scanning was not possible for our patients. We also could not to take a
transmission scan of the patients, since most of our patients were children. It was hard enough
to keep them from moving for the duration of one scan, let alone two.
We therefore had to resort to a simpler method, using a homogeneous correction factor for the
whole body, based on the patient equivalent thickness of perspex. Attenuation correction curves
giving correction factors for the measured activities of 123I and 131I were determined
experimentally in Perspex phantoms with increasing thickness with a syringe containing a
known activity of 123I (respectively 131I) in the middle, on the GE Helix camera. In figure 3.13 the
correction factor versus the Perspex equivalent patient thickness relative to the standard
phantom of 6 cm thickness is shown.
The purpose of correlating everything to the 6 cm Perspex phantom is that the measured
activity in the scans can be corrected for using the same correction factor since the attenuation
of the patient remains the same for all subsequent scans.
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Fig. 3.13. Attenuation correction curves for 123I and 131I in respect to the 6 cm Perspex phantom

The activity inside the organ at each point in time is plotted, and the best fitting curve is drawn
through the data. When the uptake of activity in the organ is instantaneous, the curve can
usually be represented by a sum of two exponentials: a “bi-exponential” best fitting curve. The
cumulated activity is calculated by time integrating this curve.

3.2.1.1.2. S factors and dose calculation.

The next step is to determine what the dose in the target organ will be per unit of cumulated
activity emitted from the source organ. The result is given as Gy/MBq.s, the so called “S-factor”.
The kind of radiation and its energy will determine how far the radiation will penetrate into the
tissue e.g. for 131I, the β-rays can only penetrate 3 mm of tissue and will therefore not contribute
significantly to the dose to most organs other than the source organ, while the 364 keV γ-rays
will irradiate all other organs and therefore contribute to their dose. The emission spectrum of
each radionuclide can be found in ICRP tables (ICRP report 38).
The distance between organs depends upon the age and gender of the patient. The MIRD
Committee has developed several age and gender specific phantoms determined as “standard”
humans. For all phantoms the S-factors have been determined by Monte Carlo simulations and
are tabulated for common radionuclides used in nuclear medicine.
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The dose to each organ can be determined by simply multiplying the cumulated activity of the
source organ with the specific S factor between source and target organ, and is then summed
over all source organs. The dose to the total body is the sum of all absorbed organ doses. The
MIRD formalism can therefore be described as follows:

Dorg n = Σm Ãorg m Sorg n←org m
Where: Ãorg m = cumulated activity in the considered source organ m
Sorg n←org m = The specific S factor for radiation from organ m to organ n,

In this work, the doses have been obtained using two different methods:

The MIRDOSE-3 software package.
MIRDOSE-3 (Stabin MG., 1996)  is a commercially available software program and holds a
number of gender and age specific phantoms (with standard organs) and a number of listed S-
factors for different radionuclides. Calculations are therefore always for the phantom that comes
closest to the anatomy of the patient, but are never patient specific.
It is possible to calculate selfdose to the tumour using the “nodule module”. The tumour is then
modelled as a sphere of specific diameter (several available in the program) and the S factor
can be inserted (after calculation) or taken from the program depending on discrete intervals of
the diameter of the nodule chosen. It is not possible to calculate dose from this nodule to other
organs or dose to the nodule from other organs.

MCNP-4B calculations on a modified Bodybuilder phantom.
This method could only be used for the patients treated with 131I-lipiodol since CT or MRI scans
were not always available for the 131I-MIBG treated patients.
The Bodybuilder (J. Briessmeister, 1997) software program lists a variety of gender and age
specific phantoms including organs that can be adapted in size and shape. For each patient, in
the best fitting phantom volume and location of the liver and of the tumour within the liver were
modelled according to patient’s CT or MRI scans.
Using the MCNP-4B (Monte Carlo n Particle version 4B) (J. Briessmeister, 1997) software,
organ specific S factors (“absorbed dose” in Gy/MBq.s) were derived for each organ. Estimated
relative errors of the calculated S factors were less than 1%. The organ doses were then
calculated using the MIRD formula.
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To calculate the effective dose, all organ contributions were summed according to their
weighting factors as determined in the ICRP publication number 60 (ICRP, 1990). By this
method it is possible to use patient specific S factors for the liver and tumour, and to calculate
dose to the tumour from all other organs (mainly the liver) and dose from the tumour to all other
organs (mainly the liver).

3.2.1.2. General study protocol:

A detailed description of each protocol can be found in chapter 4.

3.2.1.2.1. Total body scans.
In our studies, the cumulated activity was always derived from a set of 180° bi-planar total body
scans on a GE Helix camera. In each scan, along with the patient a syringe, containing a known
activity of the radionuclide administered to the patient, in a 6 cm Perspex phantom was scanned
to allow calculation of the activity.

On the Helix XPERT system (GE) or the HERMES software system (Nuclear Diagnostics,
Sweden), conformal regions of interest (ROIs) were drawn by eye around the organs of interest
and the syringe, along with suitable background regions. The activity in each ROI was
determined by comparing to the known activity in the syringe taking into account the attenuation
correction described above. Every scan was evaluated three times and the mean activity
calculated from these evaluations was used. In all cases the SD/mean was less than 5%. Using
this methodology, the mean error in calculated activity in phantom studies was 18 % (SD: 4%)

Since we did not have CT or MRI scans for the 131I-MIBG treated patients, attenuation
correction had to be carried out for the whole body as a whole.
Since the first 123I-MIBG scan was taken immediately after administration of the 123I-MIBG, the
total activity in the body is known. However, due to attenuation in the patient’s body, the activity
measured from the scan is lower than the administered activity and should be corrected for
using the following correction factor:
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F123-I = A actual / A measured
Where: A actual = the decay corrected administered activity.
A measured = the activity determined by comparing to the activity in the syringe.

From this correction factor, the patient equivalent Perspex thickness can be found figure 3.13.
For the 131I-MIBG post-therapy scans, the 131I attenuation correction factor corresponding to the
patient equivalent Perspex thickness determined above, can also be found in figure 3.13.
The total body activity, corrected for attenuation was plotted versus time. Best fitting curves to
the data sets were applied in 3 different ways:
1) For the post-therapy 131I-MIBG scans, a single exponential best fit was drawn through
the 3 obtained data points.
2) For the pre-therapy 123I-MIBG scans, the 123I-MIBG data were first corrected for the
difference in half-life and administered activity between 123I-MIBG and 131I-MIBG,
following the detailed description in chapter 4. A single exponential best fit was then
drawn through the obtained corrected data points.
3) By combining the corrected pre-therapy 123I-MIBG data points (0h–24h) and 131I-MIBG
data points (2-10 days) a bi-exponential best fit was drawn through the resulting 6 data
points using SPSS.

For patients treated with 131I-lipiodol, the thickness of the patient’s trunk, as determined by his
CT or MRI scan, was converted into the equivalent thickness of Perspex. The activity inside
liver and tumour were than corrected for, using the obtained attenuation correction factor of
figure 3.13.
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3.2.2. Dosimetry of relatives based on TLD dosimetry.

3.2.2.1. Short description of the method:

In our study, thermoluminescent dosemeter (TLD) measurements were used to measure the
radiation burden to relatives of patients treated with 131I. The study was carried out in 8 centers
of Flanders. Each participating center advised its own routine guidelines to their patients. The
real-life radiation burden of the patient’s relatives, measured under these different sets of
guidelines, is compared to the EURATOM-29 (1996) doselimit.
In order to facilitate comparison between results of centers using different sets of guidelines,
the guidelines of the 8 participating centers were divided in 3 categories according to the
difference of the duration each centre advised the patient to sleep separately. 

The principle of a thermoluminescent (TLD) crystal is based upon delayed fluorescence.
Within a crystal, electrons can exist in only two energy states: low energy (valence band), which
is a stable state, and high energy (conduction band), which is an unstable state. Between both
energy levels there is a band of “forbidden” energy levels, which means that the electrons can
not exist in these energy states.
By the introduction of small impurities into the crystal, so called “trapping” energy levels will be
introduced into the “forbidden” band in which the electron energy can exist in a semi stable way.


Fig 3.14. Principle of a TLD crystal

When the electrons from the valence band interact with ionising radiation, they will absorb
energy and rise to the conduction band levels. Since this is an unstable state, the electrons will
quickly try to dissipate energy and fall back to the stable valence band levels or to the semi
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stable trapping levels. The semi stable state means that when a small amount of energy is
introduced to the irradiated crystal (eg. by heating the crystal), the electrons in the trapping
energy levels will absorb this energy and are able to fall back completely to the stable valence
band energy level, thereby dissipating the excess energy in the form of visible light. The more
radiation hits the crystal, the more electrons populate the trapping levels, and therefore while
heating the crystal in a glow plate, the more light flashes can be detected.
When TLD crystals (usually LiF with Tl impurities) are irradiated and afterwards heated in a
standardised way in an instrument containing a photo electric cell (the “reader”), the light
intensity seen at different temperatures can be converted into the dose received by the crystal.
The level of accuracy of the dose determination can be up to 2.5 %.

3.2.2.2. General study protocol:

The dose received by the patient’s relatives was measured by thermoluminescent dosemeters
(TLD 100).
Relatives were given two TLD’s to be worn sequentially during one week each on the wrist. This
was done in order to enhance co-operation and because sequential data were preferred. In
addition, some TLD dosemeters were located on the patient’s bedside table in order to measure
the dose their partner would receive during the night if they had been sleeping together.
To validate guidelines, the data on doses received by the in-living relatives were split-up for
discussion according to the patient’s diagnosis (thyroid carcinoma or thyrotoxicosis), the
treatment regimen (hospitalised or ambulatory) and the relative’s relationship to the patient
(partner, child or parent).
A detailed description of the method used can be found in chapter 4.
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4.1. Determining the patient effective dose and the dose to specific organs
using physical dosimetry methods.

4.1.1. Patient dosimetry for neuroendocrine tumours based on 123I-MIBG pre-therapy
scans and 131I-MIBG post therapy scans. European Journal of Nuclear Medicine, 2002,
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Abstract. Pre-therapeutic metaiodobenzylguanidine (MIBG)
scans can be performed using labelling with either iodine-
123 or iodine-131. 123I-MIBG scans provide better image
quality and count statistics, while 131I-MIBG allows reg-
istration of tracer kinetics over a longer period. The aim
of this study was to determine how much information
about the 131I-MIBG therapy total body dose according to
the MIRD formalism can be gathered from 123I-MIBG
pre-therapy scans. Thirty-eight 131I-MIBG therapies ad-
ministered to a total of 15 patients suffering from neuro-
blastoma (n=6), carcinoid tumours (n=5), phaeochromo-
cytoma (n=3) and medullary thyroid carcinoma (n=1)
were included. The mean administered activity was
5.3 GBq (SD 2.4 GBq). Three biplanar 123I-MIBG total
body scans were taken only once before a series of thera-
pies while three biplanar 131I-MIBG scans were taken af-
ter each therapy. Attenuation correction was performed
taking into account the difference in attenuation between
123I and 131I. Using the MIRD formalism, the total body
dose to the patient was calculated on the basis of: (1) a
single exponential fit drawn through the data from the
123I-MIBG pre-therapy scans, (2) a bi-exponential fit
through the combined data of 123I-MIBG pre-therapy 
and 131I-MIBG post-therapy scans. The mean total body
dose calculated in our study was significantly higher 
for patients suffering from neuroblastoma (mean±SD
0.37±0.21 mGy/MBq) than for patients suffering from
phaeochromocytoma (0.08±0.02 mGy/MBq), carcinoid
tumours (0.07±0.01 mGy/MBq) and medullary thyroid
carcinoma (0.09 mGy/MBq). The correlation coefficient
between the dose calculated on the basis of the 123I-
MIBG pre-therapy scans and the subsequent 131I-MIBG
therapy was 0.93 when a correction factor of 1.26 was
taken into account. When considering all following thera-
pies, the correlation was 0.85 and the correction factor,
1.20. Our results show that it is feasible to use data from
pre-therapy 123I-MIBG scans to calculate the total body
dose of the subsequent 131I-MIBG therapy.
Keywords: 131I-MIBG – 123I-MIBG – Dosimetry – 
131I-MIBG therapy
Eur J Nucl Med (2002) 29:1581–1587
DOI 10.1007/s00259-002-0973-4
Introduction
Since 1984, iodine-131 metaiodobenzylguanidine (131I-
MIBG) has been used therapeutically in neuroblastoma
[1, 2]. The cumulative experience in 276 children with
neuroblastoma, published in 1991, indicated an objective
response rate of 35% [3, 4]. Also in that year, results in
52 patients with metastatic carcinoid disease revealed an
objective response rate of only 15% but on the other
hand showed that palliation was obtained in 65% and
was sometimes very significant and long lasting [1]. In
1997, Loh et al. [5] reviewed 116 phaeochromocytoma
patients treated with 131I-MIBG. Their results showed an
overall response rate of 30% in the three mixed patient
groups, and toxicity was found to be much lower than af-
ter chemotherapy.
As 131I-MIBG therapy is not exclusively used for pal-
liation but can also have a curative effect and as the ther-
apy is usually repeated, the radiation dose to the patient
should be determined. We have previously reported the
results of a study on neuroblastoma patients in which the
total body dose determined by the MIRD formalism
based on data from post-therapy total body scans was
compared with the total body dose determined from bio-
logical dosimetry based on the micronucleus assay [6].
The two approaches yielded comparable results. Howev-
er, this kind of dosimetry can only be performed after the
therapy has been given to the patient.
Ideally, bone marrow dose data for a specific patient
should be available prior to 131I-MIBG therapy, so that
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the amount of administered activity can be prescribed ac-
cordingly. In practice, the whole body absorbed dose is
used as an adequate representation or index of bone mar-
row toxicity. To predict the whole body dose prior to
therapy, one must measure retention of a tracer dose of
MIBG.
Pre-therapeutic MIBG scans can be performed using
either 123I-MIBG or 131I-MIBG. 131I-MIBG allows the
measurement of the bi-exponential pattern of whole
body clearance because of its long half-life (8.02 days).
On the other hand, 123I-MIBG is more suitable for tu-
mour dosimetry because 123I possesses better image
quantification properties than 131I owing to its gamma
ray energy of 159 keV (131I has a gamma ray energy of
364 keV). An ideal scenario for a pre-treatment investi-
gation would include both 123I-MIBG and 131I-MIBG da-
ta, but it would be cumbersome (and more expensive) to
undertake such complex evaluations before each therapy.
Since the 123I-MIBG data reflect predominantly the
blood clearance phase while the delayed timing of 131I-
MIBG scans means that they reflect predominantly the
second slower component of clearance, neither type of
scan reflects both components. Therefore we decided to
combine the “best of both worlds” and use the informa-
tion obtained by the combination of 123I-MIBG pre-ther-
apy scans and 131I-MIBG post-therapy scans as the gold
standard for determination of the total body dose to the
patient after 131I-MIBG therapy. The aim of this study
was to evaluate the feasibility of this combination and to
determine how much information on 131I-MIBG therapy
can be gathered from 123I-MIBG pre-therapy scans
alone.
Materials and methods
Patients
This prospective study included 38 131I-MIBG therapies given to a
total of 15 patients treated for neuroblastoma (six patients), phaeo-
chromocytoma (three patients), carcinoid tumours (five patients)
and medullary thyroid carcinoma (one patient). The patients includ-
ed seven children with a mean age of 7.5 years (range 2–13 years)
and eight adults with a mean age of 54 years (range 28–68 years).
Patients were treated three times on average, but one patient
had as many as six therapies. The mean interval between the pre-
therapy scan and the subsequent first therapy was 2 weeks (range
1–7 weeks). The overall mean interval between the pre-therapy
scan and any given therapy was 11 weeks (range 1–59 weeks).
The overall mean (±SD) administered activity for therapy was
5.3±2.4 GBq. The highest mean activities (7.8±1.2 GBq) were
given to patients treated for carcinoid tumours while the mean ad-
ministered activities were somewhat lower (6.9±1.6 GBq) for pa-
tients treated for phaeochromocytoma and much lower
(3.4±1.5 GBq) for patients treated for neuroblastoma. The patient
suffering from medullary thyroid carcinoma received an activity
of 7.4 GBq.
All patients gave their informed consent prior to their inclusion
in the study.
Total body scans
123I-MIBG pre-therapy scans. 123I-MIBG scans were obtained only
once before a series of therapies. The mean administered activity
was 138 MBq (SD 59 MBq).
Biplanar total body scans of the patient were taken shortly af-
ter, 5 h after and 24 h after 123I-MIBG administration with an Elsc-
int Helix camera using medium-energy collimators. Scan speed
was 10 cm/min. A 5-ml syringe, containing a known activity of
123I in a 6-cm-diameter Perspex phantom, was scanned along with
the patient.
131I-MIBG post-therapy scans. After each 131I-MIBG therapy, bi-
planar total body scans were taken at days 3, 6 and 10 with an El-
scint Helix camera using high-energy collimators. The scan speed
for each of these scans was, respectively, 30 cm/min, 20 cm/min
and 10 cm/min to avoid overflow. A 5-ml syringe, containing a
known activity of 131I in a 6-cm-diameter Perspex phantom, was
scanned along with the patient.
Determining the measured activity. On the Helix XPERT system,
for the first scan of the series of three, irregular regions of interest
(ROIs) were drawn over the total body, the syringe containing a
known activity of either 123I or 131I and the background. These
ROIs were then copied (and moved when necessary) for each se-
quential scan and mirrored to the posterior image. The geometric
mean of the counts per pixel was calculated in each ROI. In the
EXCEL software, the total net counts within each ROI were con-
verted to the activity within the ROI on the basis of the known ac-
tivity in the syringe.
Attenuation correction for the measured activity. Attenuation cor-
rection curves giving correction factors for the measured activities
of 123I and 131I were determined experimentally in Perspex phan-
toms of increasing thickness with a syringe containing a known
activity of 123I (or 131I) in the middle, on the Elscint Helix camera.
A best fit was drawn through the 123I and the 131I data and is
shown in Fig. 1 as the correction factor versus the Perspex equiva-
lent patient thickness relative to the standard phantom of 6 cm
thickness. The purpose of correlating everything to the 6-cm Per-
spex phantom is that the measured activity in the scans can be cor-
rected for using the same correction factor since the attenuation of
the patient remains the same for all subsequent scans.
From these curves, a general attenuation correction can easily
be carried out by the following procedure:
● Step 1: Since the first 123I-MIBG scan was taken before the pa-
tient had urinated after administration of the 123I-MIBG, the to-
tal activity in the body equals the administered 123I-MIBG ac-
tivity. However, due to attenuation in the patient’s body, the
measured activity is lower than the administered activity and
should be corrected for by using the following correction fac-
tor:
where Aactual = the decay-corrected administered activity, and
Ameasured = the activity determined by comparison with the ac-
tivity in the syringe.
Since the attenuation of the patient remains the same for all subse-
quent 123I-MIBG scans, the measured activity in these scans can
be corrected for using the same correction factor.
● Step 2: To determine the correction factor for the 131I-MIBG
post-therapy scans, first the thickness of the Perspex phantom
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corresponding to the attenuation of 123I in the patient’s body
can be found in Fig. 1. The 131I attenuation correction factor
corresponding to the determined Perspex thickness can then be
derived from the 131I attenuation curve of Fig. 1.
The attenuation correction curves given in Fig. 1 correspond to the
data measured on our Elscint Helix camera system.
Determining the cumulative activity. The attenuation-corrected to-
tal body activity was plotted versus time. Best fitting curves to the
data sets were applied in three different ways:
1. For the post-therapy 131I-MIBG scans, a single exponential
best fit was drawn through the three obtained data points.
2. For the pre-therapy 123I-MIBG scans, the 123I-MIBG data were
first corrected for the difference in half-life and administered
activity between 123I-MIBG and 131I-MIBG. For the 123I-MIBG
data points:
where y123 is the activity of 123I in the body at time t, A123 is
the administered activity of 123I-MIBG, λph123 is the physical
decay constant of 123I and R(t) is the retention function of the
MIBG in the body. Accordingly, the fit was changed into:
where y131 is the activity of 131I in the body at time t, A131 is
the administered activity of 131I-MIBG, λph131 is the physical
decay constant of 131I and R(t) is the retention function of the
MIBG in the body.
The following adjustments were needed:
1. Activity correction coefficient (ACC): ACC = A131/A123
2. Half-life correction coefficient (HLCC): 
HLCC = exp ((λph123 – λph131) · t)
By multiplying the ACC and the HLCC with the true activity
function of the 123I-MIBG (y123), the corrected fit through 123I-
MIBG data points was obtained:
where:
A single exponential best fit was then drawn through the ob-
tained corrected data points.
3. By combining the corrected pre-therapy 123I-MIBG data
points (0–24 h) and 131I-MIBG data points (2–10 days), a bi-
exponential best fit was drawn through the resulting six data
points using SPSS.
Calculating the total body dose. By time integrating over the re-
sulting curve, the cumulative activity was calculated. Dividing by
the administered activity, the residence time was obtained and
combined with the (gender- and age-matched, total body → total
body) S factors as determined by the MIRDOSE3 software [7], re-
sulting in the total body dose for the patient (mGy/MBq):
where Ã is the cumulative activity in the total body of the patient
and S(TB→TB) is the age- and gender-matched S (total body to total
body) factor.
Statistics
Mean values, standard deviations, single-exponential best fits and
their correlation coefficients were calculated by means of Excel.
The bi-exponential best fits, as well as their correlation coeffi-
cients, and the Mann-Whitney tests were calculated using the
SPSS software. Wilcoxon tests were performed using Medcalc.
Results
An overview of the results is given in Table 1, which in-
cludes patient number and age, diagnosis, gender, the in-
terval between the pre-therapy 123I-MIBG scans and the
131I-MIBG therapy, administered activity, dose calculat-
ed on the basis of a single exponential fit through the
123I-MIBG data, dose calculated on the basis of a single
exponential fit through the 131I-MIBG data and dose cal-
culated on the basis of a bi-exponential fit through the
combination of 131I-MIBG and 123I-MIBG data. Means
and standard deviations are shown for the patient popula-
tion as a whole as well as for all patient groups.
The mean (±SD) total body dose calculated on the ba-
sis of a single exponential fit through the data of the 123I-
MIBG pre-therapy scans was 0.69±0.38 Gy. The mean
total body dose calculated on the basis of a single expo-
nential fit through the data of the 131I-MIBG post-thera-
py scans was 1.02±0.64 Gy. The mean total body dose
calculated on the basis of a bi-exponential fit through the
combination of data from the pre-therapy scans and the
post-therapy scans was 0.84±0.51 Gy.
In the vast majority of cases (35 therapies out of 38),
the calculated total body dose was lowest based on the
single exponential fit through the data from the 123I-
MIBG pre-therapy scans and highest based on the single
exponential fit through the data from the 131I-MIBG
post-therapy scans. As expected, the bi-exponential fit
through the combined data yielded an intermediate total
body dose.
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Fig. 1. Attenuation correction factors for 123I and 131I according to
the Perspex equivalent thickness (cm) of the patient relative to the
standard phantom of 6 cm thickness
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Table 1. Overview of results
Patienta Diagnosis Age (yrs) Gender Interval Therapeutic Gy prec Gy postd Gy bie
(weeks)b activity 
administered 
(MBq)
1 CA 46 F 7 10,952 0.60 1.02 0.73
2A PHAEO 75 F 2 7,400 0.98 0.71 0.88
2B PHAEO 75 F 13 11,110 1.47 1.22 0.81
2C PHAEO 75 F 6,253 0.83 0.75 0.77
3A NB 7 M 1 5,550 0.75 1.30 0.75
3B NB 7 M 13 3,700 0.50 0.88 0.60
3C NB 7 M 24 3,700 0.50 1.02 0.63
4A NB 9 M 2 3,700 0.59 0.92 0.65
4B NB 9 M 7 3,700 0.59 0.95 0.71
4C NB 9 M 22 3,226 0.52 1.03 0.98
5A PHAEO 12 M 1 5,550 0.33 0.64 0.41
5B PHAEO 12 M 6 5,550 0.33 0.54 0.42
5C PHAEO 12 M 14 7,400 0.44 0.83 0.63
5D PHAEO 13 M 20 7,400 0.33 0.56 0.48
5E PHAEO 13 M 40 5,550 0.44 0.81 0.52
5F PHAEO 13 M 59 5,550 0.33 0.54 0.38
6 NB 2 F 2 7,400 1.66 3.67 2.57
7A CA 45 M 2 7,400 0.37 0.57 0.45
7B CA 45 M 12 7,400 0.37 0.55 0.47
7C CA 45 M 24 7,400 0.37 0.59 0.48
8A NB 6 M 1 3,700 1.12 1.29 1.16
8B NB 6 M 10 1,850 0.56 0.57 0.56
8C NB 6 M 13 1,850 0.56 0.67 0.63
8D NB 6 M 18 1,536 0.46 0.57 0.60
8E NB 7 M 23 1,850 0.56 0.78 0.74
9A NB 5 M 12 3,700 1.67 2.25 2.15
9B NB 5 M 4 2,775 1.25 1.75 1.62
9C NB 5 M 4 1,850 0.83 1.51 1.60
9D NB 5 M 10 1,850 0.83 1.58 1.65
10 CA 54 F 3 7,400 0.36 0.74 0.52
11 MTC 54 F 2 7,400 0.78 0.62 0.64
12 CA 56 F 2 7,400 0.64 0.76 0.71
13A NB 5 F 8 3,700 0.95 1.23 1.06
13B NB 5 F 1 3,700 0.95 1.57 1.46
13C NB 5 F 8 5,550 1.43 2.33 1.45
14A CA 68 M 2 6,745 0.30 0.49 0.37
14B CA 68 M 16 7,511 0.34 0.53 0.39
15 PHAEO 28 M 7 6,973 0.34 0.42 0.34
Mean 25 11 5,348 0.69 1.02 0.84
SD 25 12 2,436 0.38 0.64 0.51
Mean NB 6 3,415 0.86 1.36 1.14
SD NB 2 1,484 0.39 0.73 0.57
Mean PHAEO 33 6,873 0.58 0.70 0.56
SD PHAEO 28 1,615 0.37 0.21 0.19
Mean CA 55 7,774 0.42 0.66 0.52
SD CA 12 1,221 0.12 0.16 0.13
NB, Neuroblastoma; CA, carcinoid tumour; PHAEO, phaeo-
chromocytoma; MTC, medullary thyroid carcinoma; M, male; F,
female; SD, standard deviation
a The number indicates the patient while the letter indicates the
therapy number for that patient
b Interval: Interval in weeks between the pre-therapy uptake scan
and the therapy
c Gy pre: The total body dose in Gy calculated on the basis of a single
exponential fit through the pre-therapy 123I-MIBG scanning data only
d Gy post: The total body dose in Gy calculated on the basis of a
single exponential fit through the post-therapy 131I-MIBG scan-
ning data only
e Gy bi: The total body dose in Gy calculated on the basis of a bi-
exponential fit through the pre- and post-therapy scanning data to-
gether
For all methods of calculating the total body dose, the
mean total body dose was highest for patients suffering
from neuroblastoma, being 0.86±0.39 Gy, 1.36±0.73 Gy
and 1.14±0.57 Gy for the pre-therapy, post-therapy and bi-
exponential dose, respectively. The mean total body dose
was significantly (P<0.01) lower for patients suffering
from phaeochromocytoma (0.58±0.37 Gy, 0.70±0.21 Gy
and 0.56±0.19 Gy, respectively) and for those suffering
from carcinoid tumours (0.42±0.12 Gy, 0.66±0.16 Gy and
0.52±0.13 Gy, respectively).
Based on the bi-exponential fit through the data, the
dose per MBq administered activity was also highest 
for patients suffering from neuroblastoma (0.37±
0.21 mGy/MBq) than for patients suffering from phaeo-
chromocytoma (0.08±0.02 mGy/MBq) and carcinoid tu-
mours (0.07±0.01 mGy/MBq).
The correlation between the total body dose calculat-
ed on the basis of the 123I-MIBG pre-therapy scans and
the bi-exponential fit through the combined data of the
123I-MIBG pre-therapy scans and the first scans follow-
ing 131I-MIBG therapy was R=0.93, P<0.0001 (Fig. 2),
while the linear best fit was:
Bi-exponential dose (Gy) = 1.26 (σ=0.069) × 123I-MIBG
pre-therapy dose (Gy)
The correlation coefficient was still high when all fol-
lowing therapies were taken into account: R=0.85,
P<0.0001 (Fig. 3), while the linear best fit was:
Bi-exponential dose (Gy) = 1.20 ((σ=0.056) × 123I-MIBG
pre-therapy dose
Discussion
Although previously published studies [8, 9] have com-
pared pre- and post-therapy dosimetry in patients treated
with 131I-MIBG, our study is the first in which a series of
total body scintigrams in the same patients have been
compared before (123I-MIBG) and after (131I-MIBG)
therapy under the same circumstances, thereby combin-
ing “the best of both worlds”. Geiger-Müller total body
retention measurements (as used by Fielding et al. [8])
allow rapid evaluation of the activity remaining in the
body and are less cumbersome for the patient. However,
since it is difficult to attain the same geometry for each
measurement, a lot of data are required and absolutely no
information is obtained about the distribution of the 
131I-MIBG in the body. Planar images of the main tu-
mour region (as used by Fielding et al. [8] and Tristam et
al. [9]) probably render better count statistics for defined
areas, while a total body dose is necessary as an indica-
tion of the dose to the bone marrow.
Since the Elscint Helix camera is not equipped for du-
al-isotope scanning, acquisition of separate transmission
and emission scans to correct for attenuation was consid-
ered too cumbersome. Furthermore, we wanted our
method to have the widest possible applicability.
Taking into account a factor of 1.20, our results show
a good correlation (R=0.84) between the dose calculated
on the basis of the 123I-MIBG pre-therapy scans and that
calculated on the basis of the 131I-MIBG post-therapy
scans. When the dose calculated on the basis of 123I-MIBG
pre-therapy scans was compared with the dose calculated
on the basis of a bi-exponential fit combining pre-thera-
py scans and the first scan following post-therapy data
points, the correlation was R=0.93 (shown in Fig. 2) and
the correction factor, 1.26.
There has been much discussion in the literature as to
whether or not the kinetics of a tracer activity of 
123I-MIBG and a therapeutic activity of 131I-MIBG are
the same. Wafelman et al. [10] stated that clearance of
therapeutic 131I-MIBG is faster because of increased cell
damage during therapy. Smets et al. [11] suggested that
diagnostic studies probably overestimate the loading ca-
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Fig. 2. Correlation between the total body dose calculated on the
basis of the pre-therapy 123I-MIBG scans only and on the basis of
a bi-exponential fit through the combination of 123I-MIBG pre-
therapy scans and the 131I-MIBG scans of the first therapy follow-
ing the pre-therapy scans
Fig. 3. Correlation between the total body dose calculated on the
basis of the pre-therapy 123I-MIBG scans only and on the basis of
a bi-exponential fit through the combination of 123I-MIBG pre-
therapy scans and the 131I-MIBG scans of all following therapies
pacity of phaeochromocytoma and certainly underesti-
mate that of neuroblastoma owing to differences in in-
tracellular MIBG concentration. Fielding et al. [8] con-
cluded that the only difference between therapeutic and
tracer doses of MIBG is the higher amount of carrier
present in the therapeutic doses, which may affect the
kinetics of the radiopharmaceutical. These consider-
ations tend to suggest that dose calculation based on 123I
pre-therapy uptake values may represent an overestima-
tion of the dose actually received during 131I-MIBG
therapy.
In fact, our results show the exact opposite: the dose
calculated on the basis of the 123I-MIBG scans leads to a
systematic underestimation in comparison with the dose
calculated on the basis of a combination of 123I-MIBG
scans and 131I-MIBG scans (32 therapies out of 38). This
observation is attributable to the short half-life (13.2 h)
of 123I. The single exponential curve fitted through the
123I-MIBG pre-therapy data to a large extent represents
the fast clearance of 123I-MIBG from the blood. On the
other hand, the post-therapy 131I-MIBG scans only start
at 48 h after administration of the therapeutic activity, so
the longer retention of the 131I-MIBG in the body is pri-
marily visualised. The bi-exponential fit through the
combined data from pre- and post-therapy scans (six data
points) takes into account both components and yields an
intermediate total body dose that may be considered the
most accurate.
The difference in half-life between 123I (13.2 h) and
131I (8.02 days) is an argument raised against using 123I-
MIBG scans as a predictor of 131I-MIBG therapy [9].
However, our results (R=0.93) show that it is acceptable
to benefit from the better count statistics and the better
image resolution of 123I in order to calculate the total
body dose, taking into account a factor of 1.26. There-
fore, in keeping with Shapiro and Gross [12], who also
performed 123I scintigraphic studies, we assumed similar
biokinetics, independent of the activity of MIBG.
In the present study, patients were also followed over
time. The mean number of therapies in our study was
three, while one patient had as many as six consecutive
therapies. The correlation between pre-therapy total
body dose and the total body dose based on a bi-expo-
nential fit through a combination of the data was some-
what lower (R=0.85) when all subsequent therapies were
considered (correction factor =1.20). This observation is
in keeping with the results of Tristam et al. [9], stating
that the pattern of 131I-clearance remains constant for a
given patient over time if tumour burden and/or tumour
function do not change. Therefore, a new set of pre-ther-
apy scans would only be necessary after a dramatic in-
crease in tumour load. We would therefore suggest that
the overall correction factor of 1.20 be taken into ac-
count when calculating the dose for 131I-MIBG therapy
based on 123I-MIBG pre-therapy scans.
For all methods of calculating the total body dose, the
mean total body dose was highest for patients suffering
from neuroblastoma (mean±SD 0.37±0.21 mGy/MBq)
while it was significantly (P<0.01) lower for patients suf-
fering from phaeochromocytoma (0.08±0.02 mGy/MBq)
and carcinoid tumors (0.07±0.01 mGy/MBq). A similar
observation has been made previously [6], and the find-
ings can be explained by the mean age of the patients: 8
years for neuroblastoma patients as compared with 33
years for patients suffering from phaeochromocytoma
and 53 years for patients with carcinoid tumours. The
mean calculated total body dose for neuroblastoma pa-
tients (0.37 mGy/MBq) in our study is very similar to the
results obtained by Fielding et al. [8] and Lashford et al.
[13] (0.33 mGy/MBq), but is double the result obtained
by Tristam et al. [9] (0.16 mGy/MBq) and even triple that
reported by Ertl et al [14]. (0.11 mGy/MBq). However,
most of the patients included in the latter two studies
were adults, resulting in a lower total body dose.
In our study, for neuroblastoma patients, a mean value
of 6.4 h (range 0.2–23.7 h) was found for the mean total
body half-life for the fast excretion component and
47.6 h (range 16.8–106.0 h) for the longer retention com-
ponent. These results concur with the results obtained by
Fielding et al. [8] (mean 6.8 h and 35–95 h) and Tristam
et al. [9] (9 h and 25 h). For patients suffering from
phaeochromocytoma, the mean half-lives were 16.1 h
(range 0.7–41.8 h) and 35.9 h (range 21.5–78.1 h), re-
spectively. These results also concur with the results ob-
tained by Tristam et al. [9] (13 h and 30 h, respectively).
For patients suffering from carcinoid tumours, the mean
half-lives for the fast and slow components obtained in
the study were 16.4 h (range 10.7–20.6 h) and 102.3 h
(36.0–192.0 h), respectively. The half-lives for both the
fast and the slow component for neuroblastoma patients
were significantly different than those for the other pa-
tient groups (P=0.018 and P=0.001 for the phaeo-
chromocytoma and carcinoid tumour patients, respec-
tively). There were no significant differences in half-
lives for either component between patients suffering
from phaeochromocytoma and those with carcinoid tu-
mours (P=0.414).
In conclusion: The 131I-MIBG therapy dose can be
predicted from a single set of 123I-MIBG dosimetric
scans for all following 131I-MIBG therapies, taking into
account a correction factor of 1.20 (R=0.85). 123I-MIBG
pre-therapy scans do not need to be repeated before each
therapy, except when the biodistribution of 131I-MIBG 
is expected to change rapidly. Combination of the 
123I-MIBG pre-therapy data and 131I-MIBG post-therapy
data to obtain a bi-exponential fit is feasible.
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Abstract. Patient dosimetry data for intra-arterial iodine-
131 lipiodol therapy for hepatocellular carcinoma (HCC)
are scarce. The aim of this study was to determine the
absorbed dose (D) to the tumour and healthy tissues, as
well as the effective dose (E), by different methods for
17 therapies in 15 patients who received a mean activity
of 1.9 GBq (SD 0.2) 131I-lipiodol. Eight patients received
thyroid blocking by potassium iodide (KI). Patient do-
simetry was performed based on bi-planar total body
scans using the Monte Carlo simulation program MCNP-
4B and the MIRDOSE-3 standard software program. CT
images of each patient were used to determine liver and
tumour volume and position. The total body dose to the
patient was also determined by biological dosimetry with
the in vitro micronucleus (MN) assay. From the increase
in micronucleus yield after therapy, the equivalent total
body dose (ETBD) was calculated. Results for D and E
were comparable between MCNP and MIRDOSE (liver:
mean 7.8 Gy, SD 1.8, lungs: 6.8 Gy, SD 2.9, E: 2.01 Gy,
SD 0.58). MIRDOSE gave a systematic overestimation
for the tumour dose, especially for tumours <3 cm
(15%). The MCNP method is more accurate since the
dose contributions from tumour to organs and vice versa
can be accounted for. The absorbed dose to the thyroid
was significantly lower for patients who received KI
(7.2 Gy, SD 2.2) than for the other patients (13.8 Gy, SD
5.0). MN yields could be obtained for only 12 of the 17
therapies due to hypersplenism. A mean ETBD of
1.66 Gy (SD 0.73) was obtained, but the MN results
showed no correlation between the ETBD and the total
body dose values of the physical dosimetry. Also, in all
except one of the patients, no further reduction in the
number of thrombocytes was observed after therapy,
probably due to the existing hypersplenism. It is con-
cluded that in view of the high E values, patient dosime-
try is necessary for patients receiving 131I-lipiodol thera-
py. Except in the case of the smaller tumours, compara-
ble results were obtained with MCNP and MIRDOSE.
Due to hypersplenism, biological dosimetry results based
on the MN assay are not reliable.
Keywords: 131I-lipiodol therapy – Dosimetry – Monte
Carlo simulations – MIRD – Micronucleus assay
Eur J Nucl Med Mol Imaging (2003) 30:554–561
DOI 10.1007/s00259-002-1108-7
Introduction
Primary hepatocellular carcinoma (HCC) is one of the
most common malignant tumours in the world. It is re-
sponsible for an estimated one million deaths annually.
The tumour often presents late, which, with the underly-
ing cirrhosis, makes surgery difficult or impossible in
many patients. The median survival of patients with un-
resectable HCC may be as low as 1–2 months [1].
Of the approaches available for the treatment of unre-
sectable HCC, arterially delivered therapies using iodised
oil as a vehicle are attracting much attention owing to the
improved results that have been achieved. Lipiodol con-
sists of mono-, di- and tri-iodinated ethyl esters of linoleic,
oleic and stearic acids. It naturally contains up to 38% io-
dine. In 1979, Nakakuma et al. [2] established the selec-
tive retention of iodised oil in the foci of HCC following
its injection into the hepatic artery. It is now well estab-
lished that lipiodol is retained by HCC for periods ranging
from several weeks to over a year, while it is cleared from
the normal liver parenchyma within 7 days [3]. Coupling
lipiodol with chemotherapeutic agents (such as doxorubi-
cin or cisplatin) allows in situ chemotherapy. Intra-arterial
infusions of emulsions composed of lipiodol and antican-
cer agents are frequently associated with embolisation,
thereby increasing therapeutic efficiency (survival rates of
89% at 6 months and 69% at 1 year have been reported
[3]), but increasing side-effects as well.
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Internal radiation therapy is possible when some of
the iodide present in the lipiodol is substituted by iodine-
131 using a nuclidic exchange reaction. The results in
patients treated with 131I-lipiodol are at least as good as
those achieved with the chemo-embolisation method,
and patients experience fewer side-effects [4]. Further-
more, 131I-lipiodol treatments are not only used for palli-
ation. The treatment can be curative when the 131I-lipiod-
ol is given neo-adjuvantly before liver transplantation
and/or after resection of HCC [5]. Therefore dosimetry is
important not only in studying the direct effects on the
organs but also in evaluating the occurrence of late ef-
fects after irradiation.
Although some biodistribution studies have been per-
formed [6, 7, 8], data on patient dosimetry for the 131I-
lipiodol treatment are scarce [8]. Therefore, the aim of
this study was to determine patient dose using bi-planar
total body scans and Monte Carlo techniques. The results
of these calculations were compared with the output of
the MIRDOSE-3 program. The total body absorbed dose
was also determined by a completely independent bio-
logical dosimetry method: the cytokinesis-blocked mi-
cronucleus assay.
Materials and methods
Patient population. This study comprises a total of 17 131I-lipiodol
therapies carried out on 15 adult patients (six women and nine
men) with a mean age of 61 years (SD 11). Patients received a
mean activity of 1,883 MBq (SD 200) of 131I-lipiodol adminis-
tered intra-arterially into the liver artery by catheterisation. Six-
teen of the patients received a single therapy: only patient 1 re-
ceived three consecutive therapies, over a period of 8 months. The
mean administered activity for this patient was 1,820 MBq (SD
240).
Patients were divided into two groups: the first group consisted
of eight patients (eight therapies) who did not receive any thyroid
blocking before therapy and the second group consisted of eight
patients (nine therapies) who received thyroid blocking in the
form of stable potassium iodide capsules at a dose of 100 mg per
day starting 2 days before therapy and continuing until 2 weeks af-
ter therapy. Patient 1 did not receive thyroid blocking during the
first therapy, while his thyroid was blocked for both subsequent
therapies. The administration of the potassium iodide was verified
during hospitalisation in isolation from day 1 until day 6 after
therapy.
131I-lipiodol uptake based on total body scans. In all except two
patients, a set of two total body 180° biplanar scans were taken af-
ter therapy. For patients 8 and 10, only one scan could be taken
because they returned home immediately after their 7-day stay in
isolation. All scans were acquired using a GE Helix double-head
gamma camera fitted with high-energy parallel-hole collimators.
The first scan was performed on day 7 and the second on day 14
after administration. The medical condition of the patients did not
allow the acquisition of more scans.
A syringe containing a known activity of 131I in a PMMA sy-
ringe phantom (diameter 6 cm) was placed at the patient’s feet.
The thickness of the trunk as determined by CT or MRI was con-
verted into the equivalent thickness of Perspex. The factor of dif-
ference was then calculated between the patient-equivalent thick-
ness of Perspex and the 6-cm Perspex phantom that housed the sy-
ringe containing a standard activity. 131I attenuation correction fac-
tors between the patient-equivalent thickness of Perspex were
measured in phantom experiments. The activity inside liver and
tumour were then corrected for attenuation using this factor.
On the HERMES software system (Nuclear Diagnostics, 
Sweden), conformal regions of interest (ROIs) were drawn by eye
around the syringe, the total body, the liver, the tumour, the lungs
and the thyroid. Suitable background regions were selected as fol-
lows: the normal liver for the tumour, the upper leg for the organs,
and along but outside the body for the syringe and the total body.
ROIs were mirrored to the posterior image and copied (and
moved) to the subsequent scan. For each ROI the geometric mean
of the total counts was calculated after subtraction of background
counts. The activity in each ROI was determined by comparison
with the known activity in the syringe, taking into account the at-
tenuation correction described above. Each scan was evaluated
three times and the mean activity calculated from these evalua-
tions was used. In all cases the SD/mean was less than 5%. Using
this methodology, the overall uncertainty for calculated activity in
phantom studies was less than 13%.
The activity in each ROI was then plotted versus time, and a
mono-exponential function, assuming instantaneous uptake of the
activity, was fitted through the dataset. The exponential function
was integrated to infinity in order to calculate the cumulated 
activity.
Calculation of the absorbed dose per MBq h based on Monte 
Carlo simulations. A gender- and age-specific phantom layout of
the body was made using the Bodybuilder (Oak Ridge Associated
Universities) software. The following organs were assumed to
contain 131I homogeneously: tumour, liver (excluding the tumour),
lungs and thyroid. The volume and location of the liver and of the
tumour within the liver were modelled according to the patient’s
CT or MRI scans. Organs were modelled using their true composi-
tion as described in the ICRU report 44 [9]. Using the MCNP-4B
(Monte Carlo n Particle version 4B) software, organ-specific S
factors (“absorbed dose” per MBq) were derived for each organ.
Estimated relative errors of the calculated S factors were less than
1%. Since direct image fusion was not possible between CT or
MRI images and biplanar total body scans, only tumours with a
diameter of more than 2 cm were taken into account. Tumour vol-
ume was measured on CT or MRI scan. Activity in the tumour
was determined from biplanar scans. The absorbed dose to each
organ was then calculated using the MIRD principle:
(1)
where: org = organ, Dorg n = absorbed dose to target organ n, 
org m = source organ other than or same as target organ, Ã = cu-
mulated activity in the considered source organ, and S = the organ-
specific S factor, calculated by means of MCNP.
Finally, to calculate the effective dose, all organ contributions
were summed according to their weighting factors as determined
in the ICRP publication number 60 [10].
Calculation of the absorbed dose based on MIRDOSE-3. The cu-
mulated activity in each organ (MBq h) was divided by the admin-
istered activity (MBq) in order to calculate the residence time. The
residence times were inserted into the MIRDOSE3 (oak Ridge as-
sociated Universities) software program and the absorbed doses
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were then calculated. The “self dose” to the tumour was deter-
mined by using the “nodule module” by linear interpolation for
the correct tumour diameter between the given S values for dis-
crete sphere diameters. To calculate the effective dose, two dose
calculations were performed in MIRDOSE: a first where the tu-
mour activity was added to the liver activity for the calculation of
the absorbed dose to all organs except the liver, and a second
where the activity of the tumour was subtracted from the liver to
give the absorbed dose to the normal liver. The effective dose was
then manually calculated using the appropriate weighting factors
for all organs.
Micronucleus assay. The first heparinised 5-ml blood sample was
taken immediately before administration of the 131I-lipiodol thera-
peutic activity. This blood sample served as the non-irradiated
control. A second heparinised blood sample of 5 ml was taken 
7 days post administration.
Whole blood cultures were incubated following the protocol
described by Vral et al. [11]. Micronuclei were scored based on
the criteria summarised by Fenech [12].
The equivalent total body dose (ETBD) is the absorbed dose of
ionising radiation, which, if received homogeneously by the whole
body, would produce the same yield of micronuclei as observed in
the patients. The ETBD was derived from the increase in micronu-
cleus yield in the blood sample of each patient 1 week after ad-
ministration of the activity, using the dose-response relationship of
Thierens et al. [13]. This value was then corrected for the 131I re-
maining in the body after the first week by multiplying with a fac-
tor of 1.71. This factor was experimentally calculated by dividing
the absorbed total body dose derived from Monte Carlo calcula-
tions to infinity by the absorbed total body dose derived from
Monte Carlo calculations for the first week only.
Thrombocyte counts. Blood samples were taken for every patient
before administration of the radiopharmaceutical and at least once
after therapy in order to allow follow-up of the thrombocyte count
after therapy.
Statistics. Statistical analysis was performed by means of SPSS.
Differences for the mean were investigated by means of non-para-
metric two-tailed Mann Whitney U tests. Correlations were inves-
tigated by means of the Pearson correlation test.
Results
An overview of the results obtained is given in Tables 1
and 2.
Based on the data from the total body scans, the mean
decay-corrected percentage of 131I uptake in the total
body at 7 days after administration was 72.8% (SD
13.6). At the same time the uptake in the normal liver,
the tumour and the lungs was, respectively, 26.1% (SD
8.3%), 17.2% (SD 7.5%) and 11.7% (SD 5.4%). The up-
take in the thyroid was significantly (P=0.027) lower in
the patient group who received thyroid blocking (mean
0.36%,SD 0.18%) than in patients who did not receive
thyroid blocking (mean 0.57%,SD 0.18%). For patient 1,
the percentage uptake in the thyroid was halved in the
second and third treatments, in which thyroid blocking
was administered.
The percentage uptake in the total body at the time of
the second scan (14 days after therapy) had decreased to
53.1% (SD 13.8%). The percentage uptake for the nor-
mal liver, the tumour and the lungs at the time of the sec-
ond scan was 14.4% (SD 4.3%), 14.5% (SD 6.4%) and
7.4% (SD 4.1%), respectively. The uptake in the thyroid
at the time of the second scan was also significantly low-
er (P=0.018) in the patient group who received thyroid
blocking (mean 0.27%, SD 0.13%) than in the patients
who did not receive thyroid blocking (mean 0.50%, SD
0.17%). Mean tumour to total liver activity ratio was
40% (SD 15%) at the time of the first scan and reached
49% (SD 11%) at the time of the second scan.
The effective half-life, calculated from the single ex-
ponential fit through the data, was 5.2 days (SD 0.8) for
the total body and 4.3 (SD 0.9), 5.8 (SD 0.9), 4.5 (SD
1.0) and 6.0 days (SD 1.3) for the normal liver, the tu-
mour, the lungs and the thyroid, respectively. There
was no significant (P=0.82) difference between the
half-life in the thyroid of patients who received thyroid
blocking and that in the thyroid of those who did not
receive it: mean 5.8 (SD 1.4) and 6.2 (SD 1.0) days, re-
spectively.
Based on an exponential fit through the data and the S
factors determined by the MCNP software, the following
absorbed doses were obtained: normal liver 7.8 Gy (SD
1.8, range 4.0–11.8), tumour 129.5 Gy (SD 58.2, range
68–246) and lungs 6.8 Gy (SD 2.9, range 2.2–11.3). The
absorbed dose to the thyroid was significantly (P=0.005)
lower for the patients receiving thyroid blocking by po-
tassium iodide (mean 7.2 Gy, SD 2.2, range 3.4–10.7)
than for those who did not receive thyroid blocking
(mean 13.8 Gy, SD 5.0, range 8.0–21.9). For the total
body dose, a mean value of 0.95 Gy(SD 0.18, range
0.58–1.18) was obtained. The mean effective dose for
the patient calculated from the weighted contributions of
the organs was 2.01 Sv (SD 0.58, range 0.83–2.70).
The absorbed dose based on the bi-planar scans calcu-
lated according to the MIRDOSE program for the total
body was 0.97 Gy (SD 0.23, range 0.65–1.27). The mean
absorbed dose was 6.70 Gy (SD 1.88, range 3.05–11.08)
for the normal liver, 144.4 Gy (SD 68.5, range 69–288)
for the tumour and 6.5 Gy (SD 3.4, range 0.8–11.6) for
the lungs. The absorbed dose to the thyroid was signifi-
cantly (P=0.005) lower for the patients receiving thyroid
blocking by potassium iodide (mean 8.0 Gy, SD 2.4,
range 3.8–11.9) than for those who did not receive thy-
roid blocking (mean 15.5 Gy, SD 5.7, range 8.9–24.6).
The mean total body dose was 0.93 Gy (SD 0.18, range
0.56–1.16). The mean effective dose for the patient cal-
culated from the weighted contributions of the organs
was 2.05 Sv (SD 0.59, range 0.93–2.94).
Figure 1A provides an overview of the mean ab-
sorbed dose to all source organs according to Monte 
Carlo simulations and the MIRDOSE-3.1 program. In
Fig. 1B, the mean absorbed doses to all other organs are
given.
557
European Journal of Nuclear Medicine and Molecular Imaging Vol. 30, No. 4, April 2003
Ta
bl
e 
1.
R
es
ul
ts 
re
ga
rd
in
g 
da
ta
 fr
om
 th
e 
sc
an
s a
nd
 th
e 
ce
ll 
cu
ltu
re
s
Pt
K
I
Y
G
G
Bq
%
1 
%
2 
T 
TB
%
1 
%
2 
T 
Li
%
1 
%
2 
T 
Tu
%
1 
%
2 
%
1 
%
2 
T 
Lu
%
1 
%
2 
T 
Th
M
N
 
M
N
 
TB
TB
Li
Li
Tu
Tu
T/
L
T/
L
Lu
Lu
Th
Th
pr
e
ps
t
1a
N
44
F
2.
04
73
.4
61
.8
5.
8
19
.9
15
.6
5.
8
32
.4
26
.6
6.
6
62
63
12
.4
10
.0
5.
9
0.
8
0.
7
6.
4
29
78
1b
Y
44
F
1.
86
82
.6
65
.0
6.
0
23
.5
12
.0
4.
1
13
.8
12
.0
5.
8
37
50
20
.1
12
.9
4.
9
0.
4
0.
4
7.
8
82
11
3
1c
Y
44
F
1.
56
88
.8
61
.6
5.
8
38
.5
19
.8
3.
9
15
.0
15
.6
6.
3
28
44
19
.8
10
.7
4.
0
0.
4
0.
3
6.
9
62
17
4
2
N
70
F
2.
02
71
.2
63
.5
5.
7
26
.8
19
.1
5.
2
12
.6
9.
4
5.
9
32
33
10
.2
7.
4
5.
3
0.
9
0.
7
5.
9
42
–
3
N
66
F
2.
01
53
.2
34
.1
4.
3
18
.0
8.
8
3.
7
15
.9
9.
1
5.
4
47
51
6.
2
2.
9
3.
6
0.
3
0.
2
4.
3
47
19
1
4
N
75
F
1.
99
62
.1
52
.4
5.
3
30
.5
18
.0
4.
3
9.
1
16
.6
7.
0
23
48
5.
8
4.
0
4.
9
0.
5
0.
5
7.
6
43
10
4
5
Y
70
M
1.
54
52
.3
32
.0
4.
1
23
.1
11
.5
3.
7
15
.4
8.
0
5.
3
40
41
4.
1
2.
3
4.
1
0.
2
0.
1
6.
3
25
81
6
N
72
F
1.
79
91
.1
72
.7
6.
3
20
.8
14
.8
5.
2
23
.4
19
.6
6.
3
53
57
16
.5
14
.0
6.
3
0.
5
0.
7
7.
6
15
69
7
N
71
M
1.
99
80
.8
70
.5
6.
0
20
.1
15
.7
5.
9
27
.8
24
.6
7.
2
58
61
18
.8
13
.1
5.
3
0.
6
0.
4
5.
4
18
98
8
Y
58
M
1.
79
90
.8
–
–
38
.0
–
–
21
.4
–
–
36
–
13
.6
–
–
0.
6
–
–
20
24
9
Y
48
M
1.
54
84
.3
51
.3
4.
8
30
.2
17
.4
3.
1
26
.8
23
.1
5.
8
47
57
14
.3
9.
1
3.
5
0.
7
0.
5
3.
9
13
69
10
Y
56
M
1.
93
66
.1
–
–
34
.0
–
–
8.
5
–
–
20
–
9.
0
–
–
0.
3
–
–
24
–
11
Y
56
M
2.
13
80
.4
58
.8
5.
6
18
.7
8.
3
3.
7
12
.0
7.
7
4.
9
39
48
15
.3
6.
0
3.
4
0.
3
0.
2
4.
7
93
12
5
12
N
68
M
2.
01
73
.9
52
.3
5.
2
41
.0
19
.2
3.
6
6.
7
10
.3
6.
2
14
35
8.
3
4.
9
5.
3
0.
4
0.
3
5.
9
18
–
13
N
62
M
1.
67
71
.2
49
.8
5.
4
25
.8
16
.4
4.
8
19
.5
12
.4
4.
7
43
43
10
.0
7.
1
5.
4
0.
5
0.
4
6.
4
21
–
14
Y
62
M
2.
04
46
.5
27
.9
3.
7
10
.7
5.
9
3.
7
22
.7
13
.7
4.
1
68
70
2.
8
1.
3
3.
2
0.
2
0.
2
6.
7
52
12
5
15
Y
66
F
2.
13
68
.5
42
.9
4.
7
24
.7
12
.9
3.
9
10
.1
8.
2
5.
8
29
39
12
.1
5.
6
3.
5
0.
3
0.
2
4.
4
44
–
M
ea
n
61
1.
88
72
.8
53
.1
5.
2
26
.1
14
.4
4.
3
17
.2
14
.5
5.
8
40
49
11
.7
7.
4
4.
5
0.
5
0.
4
6.
0
34
96
SD
11
0.
20
13
.6
13
.8
0.
8
8.
3
4.
3
0.
9
7.
5
6.
4
0.
9
15
11
5.
4
4.
1
1.
0
0.
2
0.
2
1.
3
20
42
Pt
, P
at
ie
nt
 n
um
be
r (
pa
tie
nt 
1 h
ad
 th
ree
 th
era
pie
s: 
a, 
b a
nd
 c)
; K
I, 
blo
ck
ing
 of
 th
yro
id 
by
po
ta
ss
iu
m
 io
di
de
: Y
,
 
ye
s;
 N
, n
o;
 Y
,
 
pa
tie
nt
 a
ge
 (i
n y
ea
rs)
; G
, p
ati
en
t g
en
de
r (
M
, m
an
; F
,
w
o
m
an
); 
GB
q, 
ad
mi
nis
ter
ed
 ac
tiv
ity
 (G
Bq
); 
%,
 p
erc
en
tag
e u
pta
ke
 (%
1: 
at 
7 
da
ys
 af
ter
th
er
ap
y;
 %
2:
 a
t 1
4 
da
ys
 a
fte
r 
th
er
ap
y);
 T
,
 
ha
lf-
lif
e 
of
 th
e 
13
1 I
 in
 e
ac
h 
or
ga
n 
(T
B,
 to
tal
bo
dy
; L
i, 
no
rm
al
 li
ve
r; 
Tu
, 
tu
m
ou
r;
 T
/L
, t
um
ou
r 
to
 li
ve
r 
ra
tio
; L
u,
 lu
ng
s; 
Th
, t
hy
ro
id
);
M
N
, m
ic
ro
nu
cl
eu
s y
ie
ld
 in
 1
,0
00
 b
in
uc
le
at
ed
 c
el
ls 
(M
N 
pre
: b
efo
re 
the
rap
y; 
M
N 
ps
t: a
f-
te
r 
th
er
ap
y);
 SD
, s
tan
da
rd 
de
via
tio
n
558
European Journal of Nuclear Medicine and Molecular Imaging Vol. 30, No. 4, April 2003
The mean equivalent total body dose at 1 week after
therapy based on the cytokinesis-blocked micronucleus
assay could be determined for 12 of the 17 therapies and
was 0.94 Gy (SD 0.52). When the results were corrected
for the 131I remaining in the body after the first week
post therapy, an ETBD value of 1.66 Gy (SD 0.73 Gy)
was obtained.
Information about the thrombocyte count was avail-
able for 10 of 15 patients. The evolution in thrombocyte
count versus time post administration is depicted in
Fig. 2.
Table 2. Calculated doses
Pt R Tu (cm) D Tu MCNP D Tu MIRD D Li D Lu D Th TB MC TB MIRD E MC E MIRD ETBD 
1a 2.5 112 125 7.8 7.8 21.3 1.09 1.05 2.70 1.93 1.27
1b 2.4 108 121 7.0 11.3 10.7 1.10 1.07 2.58 2.73 0.83
1c 2.4 98 113 9.1 9.5 7.6 0.97 0.95 2.13 2.33 2.87
2 – – – 10.0 6.4 21.9 1.09 1.08 2.61 2.94 –
3 2.1 246 288 6.6 4.2 8.5 0.77 0.75 1.45 1.54 3.12
4 – – – 8.4 3.9 14.1 0.87 0.85 1.76 1.93 1.49
5 3.3 72 82 6.7 2.2 3.4 0.58 0.56 0.83 0.93 1.20
6 4.0 166 176 6.9 9.4 8.0 1.12 1.09 2.25 2.32 1.50
7 5.2 134 139 7.2 10.3 14.9 1.13 1.09 2.69 2.76 2.34
8 – – – – – – – – – – –
9 – – – 7.3 7.1 9.1 0.87 0.84 1.84 1.93 1.29
10 – – – – – – – – – – –
11 3.8 99 107 6.6 9.5 7.1 1.18 1.16 2.26 2.34 0.91
12 – – – 11.8 5.5 10.9 1.03 1.01 1.89 2.17 –
13 3.1 101 115 8.2 5.3 10.9 0.81 0.79 1.71 1.88 –
14 7.6 68 69 4.0 2.2 5.8 0.67 0.64 1.00 0.94 1.50
15 2.6 221 252 8.8 7.9 6.8 0.98 0.96 1.94 2.13 –
Mean 3.6 129.5 144.4 7.8 6.8 5.8 0.95 0.93 2.01 2.05 1.66
SD 1.6 58.2 68.5 1.8 2.9 6.8 0.18 0.18 0.58 0.59 0.73
Pt, Patient number (patient 1 had three therapies: a, b and c); 
R TU, diameter of the tumour (cm) as determined by CT; D, ab-
sorbed dose in the organ (Gy) calculated by MCNP (Tu, tumour;
Li, liver; Lu, lungs; Th, thyroid); D Tu MIRD, absorbed dose in
the tumour (Gy) calculated by MIRD; TB, total body dose (Gy) 
(MC: calculated by MCNP; MIRD: calculated by MIRDOSE); E,
effective dose (Sv) (MC: calculated by MCNP; MIRD: calculated
by MIRDOSE); ETBD, equivalent total body dose (Gy) obtained
by the in vitro micronucleus assay; 
SD, standard deviation
Fig. 1. A Comparison of the absorbed dose to all source organs
according to Monte Carlo simulations and the MIRDOSE pro-
gram. Thyroid KI: patients receiving thyroid blocking by potassi-
um iodide (KI). Thyroid no KI: patients not receiving thyroid
blocking by potassium iodide (KI). Open squares: MCNP; filled
squares: MIRD. B Comparison of the absorbed doses to all non-
source organs according to Monte Carlo simulations and the 
MIRDOSE program. Open squares: MCNP; filled squares:
MIRD. ULI, Upper large intestine; LLI, lower large intestine
Fig. 2. Evolution of the thrombocyte count in ten patients post ad-
ministration of 131I-lipidol therapy
Discussion
The 131I-lipiodol uptake percentages for the liver and the
lungs obtained in this study support the results reported
by several authors [6, 7, 8], indicating that, aside from
the tumour, 131I-lipiodol is taken up mainly in these or-
gans.
The average 131I effective half-lives of 5.2 days (SD
0.8) for the total body, 4.3 days (SD 0.9) for the liver and
4.5 days (SD 1.0) for the lungs compare very well with
the results obtained by Raoul et al. [6]. The long reten-
tion of 131I in the body justifies the patient’s relatively
long (6–7 days) stay in the isolation ward. Nakajo et al.
[8] calculated a somewhat lower half-life in the total
body (varying between 3.7 and 4.8 days) and the normal
liver (3.7 days, SD 0.6). These lower half-lives were
likely due to the fact that, in their study, scans were only
taken up to 8 days post injection of the 131I-lipiodol.
As can be seen in Fig. 1, the mean absorbed dose for
the most relevant organs was comparable between the
MCNP calculations and MIRDOSE. Our result for the
normal liver is comparable to the absorbed liver dose
calculated by Raoul et al. [14] (5.5 Gy, SD 8.7), although
their absorbed dose to the lungs was lower, with a maxi-
mum of 2.9 Gy (SD 2.2). Direct effects after therapy
were never observed even though some of our patients
were treated with 131I-lipiodol up to 5 times.
None of the early authors [6, 7, 8], described any sig-
nificant 131I uptake in the thyroid. In fact, the guidelines
of the European Association of Nuclear Medicine [15]
do not recommend any special precautions. Thyroid up-
take has only recently been described systematically for
31 patients by Toubeau et al. [16]. The reason for this io-
dine uptake in the thyroid remains unclear since non-ion-
ic contrast media injected during the procedure contain
free inorganic iodide and the amount of stable iodide in-
jected should saturate the thyroid iodine uptake mecha-
nism.
In our study, we calculated a significantly lower mean
absorbed dose to the thyroid of 7.2 Gy for patients who
received thyroid blocking compared with the other pa-
tients (13.8 Gy). Also for patient 1, the dose to the thy-
roid of 21.3 Gy for the first therapy (without thyroid
blocking) was double the values found for the two subse-
quent therapies (10.7 Gy and 7.6 Gy respectively), in
which thyroid blocking was administered. Since our pa-
tient group is relatively small for the comparison of two
treatment schedules, a larger (68 therapies) randomised
prospective study [17] was undertaken. The results of
that study confirmed the halving of the absorbed dose to
the thyroid when thyroid blocking was administered.
Toubeau et al. [16] calculated a lower mean absorbed
dose of 6.9 Gy (range 1.5–13.0 Gy) for patients who did
not receive thyroid blocking, but their scans were taken
at later times than ours: up to 35 days after therapy.
Since thyroid blocking is well tolerated and 131I-lipiodol
treatment is usually repeated so that the thyroid will be
irradiated several times, we now systematically give KI
to all patients.
In our study, only tumours with a diameter of more
than 2 cm on CT or MRI images were considered be-
cause direct image fusion between CT or MRI scans and
biplanar total body scans was not possible. For these tu-
mours, a mean of 40% (first week), rising to 49% (sec-
ond week), of all the activity present in the liver was
contained within the tumour. The increase was due to the
fact that 131I-lipiodol was retained for longer in the tu-
mour (mean 5.8 days, SD 0.93) than in the liver (mean
4.3 days, SD 0.93). The mean half-life in the tumour was
comparable to the results of Nakajo et al. [8], obtained in
five patients.
The mean absorbed dose to the tumour calculated
with the MCNP software was 129.5 Gy (SD 58.2, range
68–246 Gy). Madsen et al. [7], calculated a mean ab-
sorbed dose of 65 mGy/MBq, corresponding to 121 Gy
for the mean activity administered in our study. When
the dose to the tumour was calculated by means of 
MIRDOSE, a mean tumour dose of 144 Gy (SD 68.5,
range 69–288) was obtained. The MIRDOSE results
were systematically higher than the MCNP values. The
difference was due to the linear interpolation that is nec-
essary between the tabulated discrete sphere sizes (and
corresponding S factors) tabulated in the “nodule mod-
ule” of MIRDOSE. The difference is particularly large
(mean 15%) for smaller tumours (<3 cm). For the larger
tumours (>3 cm) included in this study, the differences in
the calculated tumour S values are within the 5% margin.
The MCNP value is more accurate since the liver and
tumour are patient specifically introduced into the Body-
builder program and from there on calculated by MCNP
for the actual tumour diameter. By including the tumour
in the geometry, additional S factors (e.g. Sliver←tumour,
Stumour←liver, Slungs←tumour) could be calculated, which is
impossible with MIRDOSE. Additionally, in our MCNP
calculations, the contribution of the electron dose depos-
ited outside the tumour was included. This is not the case
in the MIRD formalism. Due to the medium energy of
the β rays, the contribution of the additional S values to
the dose is not important. Such would not be the case,
however, were high-energy beta emitters (such as rheni-
um-188) to be considered. Even though the Monte Carlo
simulations are more time consuming, for tumour dosim-
etry in metabolic radiotherapy, the MCNP method
should be used instead of the MIRDOSE-3.0 program.
In our study the ratio of the absorbed dose to the tu-
mour to the absorbed dose to the liver was 18.24 (SD
7.90) calculated by MCNP and 24.24 (SD 11.07) calcu-
lated according to MIRDOSE. According to Raoul et al.
[6], on average activity within metastases is 2.4 times the
level achieved in normal tissue and in HCC it is 4.3
times that in surrounding normal tissue. The ratio be-
tween tumorous and non-tumorous hepatic areas can
even exceed 5.3 [4]. However, their method of determin-
ing ratios was to compare ROIs with the same surface
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around the tumour and around the normal hepatic tissue,
while our ratio was between the absorbed dose to the tu-
mour and absorbed dose to the normal liver.
Overall, a good correlation (R=0.93) was obtained be-
tween the effective dose calculated by Monte Carlo sim-
ulation techniques (mean 2.0 Sv) and the effective dose
calculated by MIRDOSE (mean 2.1 Sv). For 15 out of 17
therapies, the effective dose calculated by MCNP was
somewhat lower than the effective dose calculated by
MIRDOSE. This was due to the activity present in the
tumour that was modelled as such in the MCNP pro-
gram, while we performed two dose calculations in
MIRDOSE: a first where the tumour activity was added
to the liver activity for the calculation of the dose to all
organs except the liver, and a second without the activity
of the tumour included to give the dose to the normal liv-
er. The effective dose was then manually calculated us-
ing the appropriate weighting factors for all organs. The
MCNP result was therefore more accurate.
To estimate the risk that patients would develop lethal
secondary neoplasms induced by the irradiation received
during the 131I-lipiodol therapy, a risk factor of 2% per
Sievert [10] had to be taken into account, considering the
mean age of this patient group. On this basis, the risk
was estimated as 5% following the MCNP calculations.
We realise that an exponential fit drawn through only
two (organs) or three (total body) data points may have
introduced uncertainty into our results. Performance of
more than one scan between 7 and 14 days after therapy
was not possible owing to the medical condition of the
patients. None of the other biodistribution studies [6, 7,
8] have included scans obtained later than 8 days after
therapy, and while Toubeau et al. [16] performed a sec-
ond scan at 35 days after therapy, they only reported re-
sults for the thyroid.
Only 12 of the 17 therapies could be evaluated by the
in vitro micronucleus assay owing to the low number of
peripheral blood lymphocytes and a reduction in their
proliferation capacity. The problem is a consequence of
the hypersplenism occurring in many of these patients.
Akimaru et al. [18] reported that splenic enlargement
was found in 20% of their HCC patients, resulting in hy-
persplenism in many of them. The enlarged spleen to-
gether with reduced liver function (as a result of HCC)
causes impaired detoxification of the body and a short-
ened half-life of all blood cells in the patient, resulting in
pancytopenia [19].
When the mean ETBD of 0.95 Gy after 7 days was
corrected for the remaining 131I in the body (mean factor
of 1.71, calculated by dividing the absorbed total body
dose derived from Monte Carlo calculations to infinity
by the absorbed total body dose derived from Monte
Carlo calculations for the first week only), a mean ETBD
of 1.66 Gy (SD 0.73) was obtained. Unlike in patients
treated with 131I-metaiodobenzylguanidine, in whom 
a good correlation has been found to exist between bio-
logical and physical dosimetry techniques (R=0.83) 
[Monsieurs M et al., unpublished work], there was no
correlation between the ETBD and the total body dose
calculated either by MCNP or by MIRDOSE for the pa-
tients treated with 131I-lipiodol. The lymphocytes in
HCC patients clearly no longer show the normal in vivo
behaviour of lymphocytes and therefore results obtained
by biological dosimetry have to be treated with caution.
The generally low number of blood cells for 131I-lipi-
odol patients was reflected by the low number of throm-
bocytes present in all except one of the patients before
therapy (Fig. 2). With effective doses calculated between
1.6 and 2.5 Gy, normally a 50% decrease in thrombo-
cytes would be expected within 30 days after therapy
[20]. In fact only the patient (patient 1) with the normal
thrombocyte count before therapy showed the expected
halving of the initial thrombocyte count, while the others
showed only a non-significant reduction in their throm-
bocyte count after therapy. This result was probably also
due to the existing hypersplenism.
Conclusion
The high value of the patient’s effective dose obtained in
this study points to the need for dosimetry after radionu-
clide treatments. MCNP calculations taking into account
the patient’s specific data for tumour and liver are prefer-
able to MIRDOSE calculations for assessment of the ab-
sorbed dose to the tumour. Biological dosimetry by
means of the in vitro micronucleus assay is not advisable
in these patients since the lymphocytes no longer show
the normal in vivo behaviour due to the existing hyper-
splenism.
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Summary
Aim The aim of the study was to determine the equivalent total body dose (ETBD) using the cytokinesis-
blocked micronucleus assay in 22 131I-meta-iodobenzylguanidine (131I-MIBG) therapies (18 neuroblastoma,
mean 5097 MBq, SD 1591; and four carcinoid tumours, mean 7681 MBq, SD 487). The results are correlated
with the total body radiation dose according to the Medical Internal Radiation Dosimetry (MIRD)
formalism.
Methods For each patient, blood samples were taken immediately before and 1 week after 131I-MIBG
therapy. The first blood sample was irradiated in vitro with 60Co g-rays to determine the dose–response
curve. Micronuclei were scored in 1000 binucleated cells. By using the dose–response curve the ETBD was
derived from the increase in micronuclei after 131I-MIBG therapy (second blood sample). Based on three
consecutive biplanar scans taken at 3, 6 and 9 days post-administration respectively, the total body dose
following the MIRD formalism was calculated.
Results The micronucleus assay was evaluable in only 14 out of 22 131I-MIBG therapies due to cell division
inhibition caused by previous chemotherapy treatments and lymphocyte dilution due to blood transfusions
given shortly after 131I-MIBG therapy. For these 14 therapies, the mean micronucleus yield after 131I-MIBG
therapy was significantly increased (P50.01) with a mean of 92 (SD 77) for neuroblastoma patients and with
a mean of 35 (SD 8) for carcinoid patients. The increase observed in the present study is greater than
previously observed after 131I therapy and 89Sr therapy but much lower than after external beam
radiotherapy. For all patients treated with multiple therapies, the initial increase in micronucleus yield had
at least partially recovered by the time of the next therapy. This might be explained by an increased turnover
of lymphocytes. A mean ETBD of 0.95 Gy (SD 0.55) for neuroblastoma patients and a mean of 0.46 Gy (SD
0.09) for carcinoid patients was calculated. A reasonable correlation (R = 0.87) between the ETBD and the
MIRD dose was obtained. The slope value of 0.75 can be explained by the low dose rate effect.
Conclusions The observation in the present study of important inter-individual variability in the total
body dose, with the possibility of high dose values, suggests the necessity of individual dosimetry when
administering 131I-MIBG therapy, especially considering that generally more than one therapy is given to
each patient. (# 2001 Lippincott Williams & Wilkins)
Keywords: patient dosimetry, 131I-MIBG therapy, neuroblastoma, carcinoid tumours.
Introduction
Since its first scintigraphic use, in 1981 [1], 131I-meta-
iodobenzylguanidine (131I-MIBG) has played an impor-
tant role in the diagnosis and staging of neuro-endocrine
tumours. With a cumulative sensitivity of 92% and
specificity of 100% in 779 patients with neuroblastoma
[2], 131I-MIBG scintigraphy has established itself as the
most sensitive technique for detection, staging and
follow-up of this disease. Moreover, reported results
reveal that 70% of carcinoids in 275 patients concentrate
this tracer [2].
Since 1984, 131I-MIBG has also been used therapeuti-
cally in neuroblastoma [3, 4]. In 1991, the cumulative
0143–3636/01 # 2001 Lippincott Williams & Wilkins
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experience in 276 children with neuroblastoma indicated
an objective response rate of 35% [2, 5]. Most of these
patients had progressive and intensely pretreated stage
IV disease as they were only treated with 131I-MIBG after
chemotherapy had failed. In addition, 131I-MIBG pro-
vided adequate palliation and improved the quality of
life for many children. In 1991, results were available for
52 patients with metastatic carcinoid disease, revealing
on the one hand an objective response of only 15% but on
the other hand palliation, which may be very meaningful
and long lasting, in 65% [2]. For both therapies, usually a
fixed dose of 3700–7400 MBq of 131I-MIBG is infused
intravenously over a 2–4 h period.
In general, 131I-MIBG therapy is well tolerated.
Haematological side effects are usually limited to
thrombocytopenia. However, the effect is much more
pronounced when the 131I-MIBG therapy is given after
pretreatment with chemotherapy. When bone marrow
invasion is present, 131I-MIBG therapy can lead to severe
bone marrow depression [3, 5,–8].
As 131I-MIBG therapy is not exclusively used for
palliation but can also have a curative effect, and as the
therapy is usually repeated, the radiation dose to the
patient should be determined. Although some dose
estimation studies have been performed, [3, 7, 9, 10],
cytological evaluation of radiation induced cytogenetic
damage to lymphocytes in vivo after therapy with 131I-
MIBG has not yet been performed.
For other common radionuclide therapies, such as 131I
therapy for thyroid disease and 89Sr therapy for pain
palliation of bone metastases, examination of the radia-
tion dose to lymphocytes has been performed using the
cytokinesis blocked micronucleus assay [11–17]. The
same procedure has also been used before to study the
radiation damage to lymphocytes after radiotherapy [18]
and after fractionated partial body radiotherapy [19].
The purpose of the study was primarily an evaluation
of the degree of cytological radiation induced damage to
lymphocytes in vivo after 131I-MIBG therapy for neuro-
blastoma and carcinoid tumours using the cytokinesis-
blocked micronucleus assay. Within this topic the effect
of multiple 131I-MIBG therapies to the lymphocytes was
also investigated. Secondly, the genetic damage to the
lymphocytes was correlated with the total body dose
calculated according to the Medical Internal Radiation
Dosimetry (MIRD) formalism.
Patients and methods
Patient population
This study comprises a total of 22 131I-MIBG therapies
carried out on 12 patients (eight females and four males).
A group of 10 patients with a mean age of 8 years (range
2–32 years) received a total of 18 therapies with a mean
activity of 4522 MBq (SD 1107 MBq) for neuroblastoma
stage III or IV. The remaining two patients, aged 45 and
50 years, each received two therapies, with a mean of
7681 MBq (SD 487) 131I-MIBG for carcinoid tumours with
multiple liver metastases.
Blood sample collection and irradiation
The first heparinized 5 ml blood sample was taken
immediately before administration of the 131I-MIBG
therapeutic dose. This blood sample was divided into
three fractions. One fraction served as a non-irradiated
control. The other two fractions were irradiated in vitro at
378C with a dose of 0.5 Gy and 1.0 Gy 60Co g-rays. A
second heparinized blood sample of 5 ml was taken 7
days post-administration.
Micronucleus assay
Whole blood cultures were incubated at 378C for 70 h in a
5% CO2 atmosphere. The culture medium consisted of
RPMI 1640 with 2 mm L-glutamine and Hepes buffer
(Gibco) supplemented with 15% fetal calf serum and
antibiotics. Phytohaemaglutinin (PHAP, Difco) at a
concentration of 40 mg×ml71 was used to stimulate cell
division. According to the method of Fenech and Morley
[20], cytochalasin B (6 mg×ml71 in DMSO, Sigma) was
added 42 h after culture initiation in order to block
cytokinesis. After an incubation period of 70 h, the cells
were harvested, treated with a hypotonic solution of
0.075 M KCl, and fixed with a mixture of methanol–
glacial acetic acid 8:1 following the protocol described by
Vral et al. [21]. Slides were stained with Romanowsky–
Giemsa and micronuclei were scored in 1000 binucleated
cytokinesis-blocked cells under the light microscope with
a magnification of 4006, based on the criteria summar-
ized by Fenech [22].
Equivalent total body dose
The equivalent total body dose (ETBD) is the dose of
ionizing radiation, which, if received homogeneously by
the whole body, would produce the same yield of
micronuclei, as the dose actually absorbed in the different
organs and tissues.
For each patient group, the mean micronucleus yield,
obtained after in vitro irradiation, was plotted against the
60Co dose and a linear-quadratic dose–response curve
was derived by a least squares fit to the data. The linear-
quadratic nature of the dose–response relationship for
induction of micronuclei has been studied previously
[23]. Based on this in vitro dose response, the ETBD was
368 Monsieurs et al.
Nuclear Medicine Communications (2001) 22
derived from the increase in micronucleus yield in the
blood sample of each patient 1 week after administration
of the activity.
131I-MIBG uptake and dose calculation according to the MIRD
formalism
For each patient a set of three total-body 1808 biplanar
scans was made after therapy. All scans were made on an
Elscint Helix double-head gamma camera fitted with high-
energy parallel hole collimators. The first scan was made at
day 3, the second scan at day 7 and the third scan at day 10
post-administration. A syringe containing a known activ-
ity of 131I in a polymethylmethacrylate (PMMA) syringe
phantom (diameter 6 cm) was placed at the patient’s feet.
By drawing regions of interest (ROIs) around the syringe,
the total body and suitable background regions, the
activity in each ROI could be determined by using the
geometric mean of the total counts in the anterior and
posterior scans after correction for the difference in
thickness between phantom and patient.
The activity at the time of administration in each ROI
was then plotted against time, and a bi-exponential
function was fitted through the dataset. To allow a
comparison between the ETBD derived from the cytokin-
esis blocked micronucleus assay and the total body dose
calculated with the MIRD formalism, the cumulated
activity until 168 h after administration was calculated by
integrating the bi-exponential fit. The dose to the total
body was then calculated using the standard MIRD
formalism using weight adapted S (total body / total
body) values. These S values were obtained by a fit
through the values of the different phantoms of various
ages considered in the MIRDDOSE-31 program (Oak-
ridge associated Universities, 1994).
Statistical analysis
Statistical analysis was performed by means of Med-
calc1. Data sets were first tested for normal distribution
by means of a chi-squared test. Differences for the mean
were evaluated by means of paired two-tailed Wilcoxon
tests, where applicable. Correlations were investigated by
means of the Spearman rank or Pearson correlation test.
Error bars in the figures represent the standard devia-
tions based on the Poisson distribution.
Results
An overview of the results obtained in the present study
is given in Table 1. Because 131I-MIBG therapy for
neuroblastoma is given as a second line treatment, many
of our patients had received chemotherapy treatment
shortly before the 131I-MIBG therapies. The effect of the
chemotherapy is to render the lymphocytes less suitable
for evaluation of cytotoxic damage by means of the
cytokinesis blocked micronucleus assay because it in-
hibits cell division. Since the technique is based upon a
baseline blood sample before therapy (divided into three
fractions) and a blood sample at 7 days post-therapy, all
blood samples, including the irradiated fractions, have to
be evaluable (1000 binucleated lymphocytes have to be
counted). As can be seen from Table 1, this was not the
case in three of our patients (numbers 10, 11 and 12), so
these data had to be excluded from the micronucleus
yield and ETBD calculations in the article.
Even when we were able to count 1000 lymphocytes,
we additionally found that a subset of patients had
received transfusions (containing non-irradiated lympho-
cytes) before the second blood sample was taken. Thus,
the micronucleus data of these patients (numbers 7, 8, 9
and 10) were useless for the determination of the ETBD.
The ETBD results of the present study are therefore based
on the first six patients (14 therapies) only.
As can be seen in Fig. 1, the micronucleus yield in all
remaining patients was significantly (P50.01) increased
after 131I-MIBG therapy. The mean increase was 92
micronuclei (SD 77) for neuroblastoma patients while it
was significantly less (P50.001) with a mean of 35
micronuclei (SD 8) for carcinoid patients. The mean
increase in micronucleus yield after in vitro irradiation
with 0.5 Gy and 1 Gy 60Co in this study was 40
micronuclei (SD 26) and 97 micronuclei (SD 30),
respectively, for neuroblastoma patients, and 29 micro-
nuclei (SD 11) and 66 micronuclei (SD 13), respectively,
for carcinoid patients.
Five patients received multiple subsequent 131I-MIBG
therapies. The micronucleus yields before and after each
therapy are plotted against time in Fig. 2.
As can be seen in Fig. 2, the increase in micronucleus
yield 7 days after administration of the therapeutic
activity has at least partially recovered by the time of
the subsequent therapy. For all patients, the micronucleus
yield rises again after the administration of the subse-
quent therapeutic amount of 131I-MIBG. The mean
lymphocyte half-life that can be calculated from these
results was 3.9 months (range 1.7–6.7 months).
From the increase in micronucleus yield after 131I-
MIBG therapy the ETBD for each treatment was
determined using the in vitro dose–response curve.
Within the different patient subgroups the highest ETBD
was found for patients suffering from neuroblastoma
(mean ETBD 0.96 Gy, SD 0.58), while it was significantly
less (P50.01) for the patients suffering from carcinoid
tumour (mean 0.46 Gy, SD 0.09). An ETBD value of more
than 2 Gy (2.39 Gy) was obtained only for patient 1. As
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Table 1. Overview of the demographic data and results
Age Gender Activity MN ETBD Cum. act.§ MIRD Time}
Patient* Diagnosis (years){ (M/F) { (MBq) 0 Gy 0.5 Gy 1 Gy incr (Gy) (GBq×h) (Gy) (mo)
1 NB 5 M 5550 47 136 172 309 2.39 278 2.26 several
2a NB 10 F 5550 78 134 140 112 1.18 214 1.23 8
2b NB 10 F 5550 163 179 247 63 0.76 161 0.92
2c NB 10 F 5550 116 141 232 58 0.71 198 1.13
2d NB 11 F 5550 109 172 260 100 1.08 215 1.23
2e NB 11 F 5550 115 192 213 148 1.44 178 1.02
3a NB 2 F 3700 46 70 171 35 0.46 134 0.75 84
3b NB 2 F 3700 68 104 164 41 0.53 145 0.81
4a NB 7 M 5550 31 38 74 56 0.69 157 1.15 2
4b NB 8 M 3700 46 70 171 35 0.46 127 0.93
5a CA 45 F 7400 52 68 109 25 0.35 270 0.45 –
5b CA 45 F 8525 31 77 109 29 0.39 344 0.57
6a CA 50 M 7400 24 48 74 43 0.55 355 0.79 –
6b CA 50 M 7400 50 80 129 43 0.55 420 0.94
7a NB 2 F 3700 16 62 126 111 1.18 95 1.89 6
7b NB 2 F 5550 62 98 129 70 0.80 139 1.84
8 NB 8 F 3700 27 69 127 5 0.07 100 0.52 72
9 NB 32 F 3700 186 244 346 85 0.96 333 1.59 24
10a NB 6 M 3700 69 – 210 -19 – 158 2.10 2
10b NB 6 M 1850 104 157 – -35 – 681 0.90
11 NB 7 F 5550 78 101 – – – 94 1.29 5
12 NB 5 M 3700 – – – 35 – 216 2.59 1
* Numerical values (1–8) were used to identify patients, while a letter (a–e) was added to indicate different therapies for the same patient.
{ Patient’s age at the time of the therapy.
{ Activity administered activity to the patient.
§ Cumulated activity in the body until 168 h after administration of the activity.
} Time between last chemotherapy treatment and first treatment with 131I-meta-iodobenzylguanidine (131I-MIBG).
M, male; F, female; NB, neuroblastoma; CA, carcinoid tumour.
MN, micronucleus yield per 1000 binucleated cells; 0 Gy, before therapy; 0.5 Gy, after in vitro irradiation with 0.5 Gy 60Co g-rays; 1 Gy, after in vitro
irradiation with 1 Gy 60Co g-rays; incr., increase in micronucleus yield 168 h after 131I-MIBG therapy.
ETBD, equivalent total body dose.
MIRD, total body dose as calculated by the Medical Internal Radiation Dosimetry (MIRD) formalism.
Fig. 1. Individual increase in micronucleus yield per 1000
binucleated cells 1 week after 131I-meta-iodobenzylguanidine
(131I-MIBG) therapy. Error bars represent the standard devia-
tions based on the Poisson distribution. (&), micronucleus yield
before therapy; (&), micronucleus yield after therapy.
Fig. 2. Time plot of the micronucleus yield during multiple
subsequent 131I-MIBG therapies in five patients.
can be seen from the total body scan presented in Fig. 3,
this patient showed both extensive metastases and bone
marrow invasion.
The mean cumulative activity to the total body
calculated from the biplanar scans was 201 GBq×h (SD
131) for neuroblastoma patients while it was significantly
(P50.001) higher with a mean of 231 GBq×h (SD 59) for
carcinoid patients.
The mean total body dose as calculated by the MIRD
formalism was 1.34 Gy (SD 0.66) for neuroblastoma
patients while for carcinoid patients it was significantly
(P50.001) lower with a mean of 0.46 Gy (SD 0.09).
As expected, no correlation was found between the
ETBD and the administered activity. However, a reason-
able correlation (R = 0.87) was obtained between the
ETBD and the total body dose calculated by the MIRD
formalism as shown in Fig. 4. The slope of the linear
regression fit was 0.75.
Discussion
Since 131I-MIBG therapy is a second line treatment for
neuroblastoma in Belgium, all of the included neuro-
blastoma patients received chemotherapy at a certain
time before 131I-MIBG therapy. Previous chemotherapy
can jeopardize the evaluability of the cytokinesis-blocked
micronucleus assay. These problems are purely technical,
because chemotherapy inhibits cell division when cells
are stimulated by the phytohaemaglutinin that is added
to the culture medium. For patients 10, 11 and 12, we
were not able to induce 1000 cells in each fraction to
divide, and therefore their data had to be excluded from
calculation of the ETBD. As can be seen in Table 1, the
time between the last chemotherapy treatment and the
first 131I-MIBG treatment tended to be shorter (1–5
months) in these patients. The effect is individually
dependent because patients 1 and 4 also had a rather
short (2 to ‘several’ months) period of time between
chemotherapy and 131I-MIBG therapy. Nevertheless, we
were able to count 1000 lymphocytes in every blood
sample.
Since every patient serves as his own personal control
(blood sample before therapy), possible ‘cross talk’
between radiomimetic effects from chemotherapy and
131I-MIBG radiation did not present a problem in our
study.
Additionally, a subset of patients (patients 7, 8, 9 and
10) received ‘whole blood’ transfusions. The effect of
blood transfusions is not easy to calculate. The infusion of
fresh lymphocytes dilutes the resident long-term irra-
diated lymphocytes. The lymphocytes for the blood
transfusion are simply exposed to the 131I irradiation for
a shorter period of time and, even more importantly, they
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Fig. 4. Correlation between the equivalent total body dose
(ETBD) and the dose according to the Medical Internal
Radiation Dosimetry (MIRD) formalism. The curve is the result
of a least squares analysis.
Fig. 3. Total body scan of patients 2, 10 and 12 showing
extensive metastases and bone marrow invasion.
are exposed to a lower resident activity of 131I-MIBG
because a large part of the unbound 131I-MIBG had
already been excreted from the body. The effects of blood
transfusion are obvious in patient 10 (Table 1). In this
patient the number of micronuclei after treatment is
actually significantly lower than before therapy in spite of
the considerable total body dose calculated according to
the MIRD formalism. To a lesser extent also patient 8
seems obviously affected because an unusually small
increase in micronuclei is found after 131I-MIBG therapy.
Although the effect is not directly observable for patients
7 and 9, the same mechanisms must be at work. We
therefore decided to exclude also the data from these two
patients from calculation of the ETBD to be sure of using
only perfectly ‘clean’ data. Therefore, the ETBD results of
the present study had to be based on the first six patients
(14 therapies) only.
The mean increase in micronucleus yield for neuro-
blastoma patients (mean 92 micronuclei, SD 77) found in
the present study is significantly higher (P50.001) than
for carcinoid patients (mean 35 micronuclei, SD 8). When
comparing the increase in micronucleus yield with other
radionuclide treatments, the increase in micronucleus
yield for neuroblastoma patients is higher than for
patients treated with 131I therapy for thyroid disease
(mean 32, SD 30 [17]; mean 21, SD 3 [15]; mean 9 [24]) or
with 89Sr for palliation of painful bone metastases (mean
22, SD 6 [16]). On the other hand, the increase in
micronucleus yield for carcinoid patients is within the
same order of magnitude as for the other radionuclide
therapies described above. However, the mean increase
in micronuclei found in the present study is significantly
lower than after external beam radiotherapy for carcino-
ma of the cervix (mean 298, SD 76) or Hodgkin’s disease
(mean 640, SD 381) using the same methodology [18].
For most patients the initial micronucleus yield is
already higher than expected for normal individuals of
this age group [23]. This is probably due to the fact that
most patients had previously received chemotherapy,
because 131I-MIBG therapy is a second line treatment for
neuroblastoma in Belgium.
For the first time the residual damage after multiple
subsequent 131I-MIBG therapies was investigated in the
present study. In all patients an initial large increase in
micronucleus yield after administration of the 131I-MIBG
therapy had at least partially recovered by the time of the
subsequent 131I-MIBG therapy. A similar effect was
reported by Watanabe et al. [16] by taking sequential
blood samples up to 2 months after 89Sr therapy for
painful bone metastases. Also Fenech et al. [19] reported
an initial increase followed by slow decline (50% after 12
months, but with large inter-individual fluctuations) in
micronucleus yield for patients treated with external
partial body radiotherapy. On the other hand, in a case
report with a long-term follow-up, Livingston et al. [11]
reported only fluctuations in the micronucleus yield of a
patient after 131I therapy for thyroid carcinoma but could
not find a significant change in micronucleus yield up to
8 months after therapy.
The mean half-life of lymphocytes found in the present
study (as derived from the reduction in micronucleus
yield between subsequent 131I-MIBG therapies in the
same patient) was 3.9 months (range 1.7–6.7 months).
This result corresponds to the increased turnover of
lymphocytes (micronucleus yields returning to pre-
treatment values within 4–6 months) found in children
treated repeatedly for thyroid carcinoma, as reported by
Streffer et al. [25]. From the analysis of the Goian˜a
accident, Ramalho et al. [26] concluded that the disap-
pearance of unstable chromosome aberrations (such as
micronuclei) is dose dependent. The mean lymphocyte
half-life in their study was 5.3 months in people receiving
up to 1 Gy while it was significantly less (3.7 months) in
people receiving more than 1 Gy, a result very similar to
the 3.9 months calculated in the present study.
The ETBD for neuroblastoma patients (mean 0.96 Gy,
SD 0.58) was significantly higher than for carcinoid patients
(mean 0.46 Gy, SD 0.09), although the administered
activities were significantly higher in the latter patient
group (4995 and 7681 MBq respectively). This is not
surprising taking into account the difference in body mass
between the pediatric neuroblastoma patients and the
adult carcinoid patients. Also the location of the activity
within the body was very different for both patient groups:
in the liver for carcinoid patients while for neuroblastoma
patients the activity was localized in multiple sites more
widely distributed throughout the body.
The mean ETBD of 0.96 Gy (SD 58) for neuroblastoma
patients found in present study is significantly higher
(P = 0.0001) than after 131I therapy for thyroid disease
mean 0.4 Gy [17] (a result correlating well with a similar
study carried out by Watanabe et al. [15], who found a
mean of 0.33 Gy) or after 89Sr therapy (mean 0.5 Gy [16]).
On the other hand, the mean ETBD of 0.46 Gy (SD 0.09)
for carcinoid patients is within the same order of
magnitude as for the other radionuclide therapies
described above. Excluding patient 1 with a very high
ETBD of 2.39 Gy, the ETBD values found in the present
study are much lower than after external beam radio-
therapeutic treatment for cervix carcinoma (mean
5.69 Gy, SD 1.40) or Hodgkin’s disease (mean 6.26 Gy,
SD 1.28) [18].
For the patient group as a whole, a mean MIRD dose
of 1.22 Gy (SD 0.57) was calculated. The MIRD dose was
significantly (P50.001) higher for neuroblastoma pa-
tients (mean 1.34 Gy, SD 0.56 Gy) than for carcinoid
patients (mean 0.46 Gy, SD 0.09). Within the neuroblas-
toma patient group, three patients (patients 1, 10 and 12)
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received a total body dose of more than 2 Gy (2.26 Gy,
2.10 Gy and 2.59 Gy, respectively). As can be seen in Fig.
3 these patients presented with both extensive metastases
and bone marrow invasion. According to the MIRD
calculations, in our study seven additional therapies
resulted in a total body radiation burden of more than
1 Gy. The observation in the present study of important
inter-individual variability in the total body dose both
according to the MIRD calculations and the ETBD, with
the possibility of high dose values, suggests the necessity
of individual dosimetry when administering 131I-MIBG
therapy, especially considering that generally more than
one therapy is given to each patient.
As observed in previous studies on patients treated
with 131I for thyroid disease [17], no correlation was
found between the administered activity and the ETBD,
nor with the MIRD dose calculations. On the other hand,
a reasonable correlation was found between the ETBD
derived from biological dosimetry (where evaluable) and
the total body dose according to the MIRD formalism
based on biplanar scans (R = 0.87). The linear regression
analysis depicted in Fig. 4, yields a slope value of 0.75.
This value less than 1, reflects the low dose rate effect of
the 131I irradiation in the body, allowing partial repair of
the cellular damage, resulting in less genetic damage and
an apparently lower radiation dose.
The fact that patient 1 seems to be such an isolated case
in Fig. 4, is due to the blood transfusions and/or
cytotoxic effects of previous chemotherapy treatments
which has caused us to omit the data of patients 7A, 7B,
10A and 12, who also received high total body doses
(1.89 Gy, 1.84 Gy, 2.10 Gy and 2.59 Gy, respectively)
according to the MIRD calculations. When patient 1 is
omitted from this figure, the correlation coefficient drops
to 0.56 instead of 0.87. However, the slope value of the
best fitting curve through the remaining data cloud (0.68
instead of 0.75) still supports the low dose rate effect and
the ETBD is still generally lower than the MIRD value.
Since the recent developments within the neuroblas-
toma task group in Europe point to a combination of
chemotherapy given at the same time as 131I-MIBG
therapy, we have decided not to continue this type of
cytogenetic study on patients treated with 131I-MIBG for
neuroblastoma.
Conclusion
The observation in the present study of important inter-
individual variability in the total body dose, with the
possibility of high dose values, suggests the necessity of
individual dosimetry when applying 131I-MIBG therapy,
especially considering that, generally, more than one
therapy is given to each patient.
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Adaptive Response in Patients Treated with 131I
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The aim of this study was to investigate whether an adaptive
response (defined as the induction of radiation tolerance after a
small dose of radiation) could be observed in peripheral blood
lymphocytes of patients treated with 131I for thyroid disease.
Methods: For each patient, blood samples were taken immedi-
ately before and 1 wk after 131I administration. Each blood sample
was divided into 3 fractions and the fractions were subsequently
irradiated in vitro with 0, 0.5, and 1.0 Gy 60Co g-rays. After blood
culture for 70 h, cells were harvested and stained with Ro-
manowsky-Giemsa and micronuclei were counted in 1000 bi-
nucleated cells. The increase in micronuclei by the in vitro
irradiation of the blood samples taken before and after therapy
was compared. In this setup, an adaptive response is repre-
sented by a significant decrease of the in vitro induced micro-
nucleus yield after therapy compared with that before therapy.
The iodine therapy can be considered as an in vivo adaptation
dose, after which the subsequent in vitro irradiation acts as a
challenge dose. To investigate the reproducibility of the method,
2 subsequent blood samples of healthy volunteers were taken 7
d apart. Irradiation and cell culture were performed as described.
Results: In 8 of 20 patients, a significant (P 5 0.0002) decrease
was found in the in vitro induced micronucleus yield in the blood
sample taken 1 wk after 131I administration compared with that of
the blood sample taken before therapy. No significant (P . 0.1)
differences were observed between these 8 patients and the
other patients when the number of micronuclei induced in vivo by
the iodine treatment and the resulting equivalent total body dose
were compared. None of the control subjects showed a signifi-
cant change in micronucleus yield after in vitro irradiation
between both blood samples taken 1 wk apart. Conclusion: The
iodine treatment can act as an in vivo adaptation dose and can
induce an adaptive response that is observed by a decrease of
the cytogenetic damage in peripheral blood lymphocytes after in
vitro irradiation as a challenge dose. A large interindividual
difference was observed.
Key Words: adaptive response; 131I therapy; thyrotoxicosis;
thyroid carcinoma
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Ever since its first therapeutic application in 1942 by
Hertz and Roberts (1), 131I has played a major role in the
treatment of thyrotoxic patients and patients suffering from
differentiated thyroid carcinoma. The risk for late detrimen-
tal effects after 131I therapy was studied by several investiga-
tors (2–5) and was estimated to be ,1% over a lifetime.
Indeed, to our knowledge, no statistically significant in-
crease in leukemia or solid tumors has been reported (2,3,6).
An additional explanation for the lack of epidemiologic
evidence for late detrimental effects could be found in the
existence of an in vivo adaptive response. This theory states
that exposure to low levels of ionizing radiation (adaptation
dose) can stimulate the DNA repair system in certain
individuals, resulting in less genetic damage after subse-
quent high levels of ionizing radiation (challenge dose). This
phenomenon has been termed ‘‘adaptive response’’ because
it is similar to the induced repair described in Escherichia
coli (7).
Much in vitro data confirm the existence of an adaptive
response. Most of these studies consist of in vitro work on
human cell cultures (8). In vitro pretreatment of lympho-
cytes with tritiated thymidine or with low doses of ionizing
radiation makes these cells less susceptible to cytogenetic
damage by subsequent high doses of ionizing radiation
(8–16). Some evidence of an in vivo adaptive response
exists for animals, usually mice (17–19).
The existence of an in vivo adaptive response in humans
could explain why the incidence of cancer in some occupa-
tionally exposed populations is lower than expected, as
suggested by the results of some epidemiologic studies
recently reviewed by Pollycove (20) and Van Wijngaerden
and Pauwels (21). However, only Barquinero et al. (22)
presented experimental evidence for its existence in periph-
eral blood lymphocytes of occupationally exposed individu-
als. To our knowledge, no studies indicating the existence of
an in vivo adaptive response after medical use of radiation
have been published. Therefore, the aim of this study was to
assess whether an adaptive response in vivo could be
observed in peripheral blood lymphocytes of patients treated
with 131I for thyroid disease.
MATERIALS AND METHODS
Patients
This study included 20 patients (5 men, 15 women; mean age, 57
y; range, 25–76 y) treated with 131I for thyroid disease. Seventeen
of the patients were suffering from thyrotoxicosis and received a
mean activity of 642 MBq (range, 259–1110 MBq). The 3 other
patients were suffering from differentiated thyroid carcinoma and
Received Dec. 10, 1998; revision accepted May 4, 1999.
For correspondence or reprints contact: Myriam Monsieurs, MS, Division of
Nuclear Medicine, University Hospital of Gent, De Pintelaan 185, 9000 Gent,
Belgium.
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received 3700 MBq. As a control population, 7 healthy volunteers
(1 man, 6 women; mean age, 39 y; range, 27–57 y) were also
included.
All patients and volunteers gave their informed consent.
Blood Sample Collection and Irradiation
The first blood sample (heparinized) was taken immediately
before administration of the 131I therapeutic activity. This blood
sample was divided into 3 fractions. One fraction served as a
nonirradiated control. The 2 other fractions were irradiated in vitro
at 37°C with doses of 0.5 and 1.0 Gy 60Co g-rays at a dose rate of
1.5 Gy/min. The second blood sample (heparinized) was taken 7 d
after 131I administration. This blood sample was also divided into 3
fractions and subsequently irradiated following the same protocol
as that used for the first blood sample.
Micronucleus Assay
Whole blood cultures were incubated at 37°C for 70 h in a 5%
CO2 atmosphere. Culture medium consisted of RPMI medium with
2 mmol/L L-glutamine and N-[2-hydroxyethyl]piperazine-N8-[2-
ethane sulfonic acid] buffer (GIBCO Laboratories, Grand Island,
NY) supplemented with 15% fetal calf serum and antibiotics.
Phytohemagglutinin (Difco, Detroit, MI) was used at a concentra-
tion of 40 µg/mL to stimulate cell division. According to the
method of Fenech and Morley (23), cytochalasin B (3.5 µg/mL in
dimethyl sulfoxide; Sigma Chemical Company, St. Louis, MO)
was added 42 h after culture initiation to block cytokinesis. After an
incubation period of 70 h, the cells were harvested, treated with a
hypotonic solution of 0.075 mol/L KCl, and fixed with an 8:1
mixture of methanol:glacial acetic acid following the protocol of
Vral et al. (24). Slides were stained with Romanowsky-Giemsa,
and micronuclei were counted under a light microscope (magnifica-
tion 3400) based on criteria summarized by Fenech (25).
Equivalent Total Body Dose Calculated from
Cytokinesis-Blocked Micronucleus Assay
The equivalent total body dose (ETBD) is the 60Co dose that
would produce the same yield of micronuclei as the in vivo 131I
dose actually received. The micronucleus yield, obtained after in
vitro irradiation, was plotted against the 60Co dose and an
individual linear-quadratic dose–response curve was derived by a
least-squares fit to the data. On the basis of this individual in vitro
dose–response, the ETBD after 131I therapy was calculated from the
number of micronuclei in the blood sample of the patient 1 wk after
administration of the activity. For thyrotoxicosis patients, the
ETBD was corrected for the dose (because of activity retained in
the body after the second blood sample was taken) using the
effective half-life determined from the pretherapy uptake curve.
Adaptive Response
To assess the existence of an adaptive response, the increase in
micronucleus yield after in vitro irradiation of the blood samples
taken before and after 131I therapy was compared. An adaptive
response exists when the increase in micronucleus yield in vitro is
significantly less in the blood sample taken after therapy than the
increase in the blood sample taken before therapy.
MIRD Total Body Dose
For all thyrotoxicosis patients, the pretherapy uptake curve
yielded both the maximal percentage uptake and the effective
half-life of the 131I in the thyroid. Using this information, the total
body dose for each patient, following the MIRD protocol, was
calculated by applying the MIRDOSE 3 code (Oak Ridge Associ-
ated Universities, Oak Ridge, TN) with the thyroid as the only
source organ.
Statistical Analysis
Differences between the increase in micronuclei after in vitro
irradiation were compared before and after therapy using 95%
confidence limits and the Poisson distribution. Differences from the
mean were assessed by 2-tailed unpaired Wilcoxon tests using
Medcalc (Medcalc Software, Mariakerke, Belgium).
RESULTS
An overview of the results is given in Table 1.
The increase in micronuclei after in vitro irradiation (1.0
Gy 60Co g-rays) of the blood sample taken before and 1 wk
after 131I administration is shown in Figure 1. For the control
subjects, the same variable determined for 2 subsequent
weeks is presented. No significant differences (P . 0.1)
were found between the increase in micronucleus yield after
irradiation of the first and the second blood samples for the
control subjects (Fig. 1). For the patient group as a whole, a
significant decrease (P 5 0.470) in micronucleus yield after
in vitro irradiation with 1.0 Gy 60Co g-rays was observed
after therapy compared with the yield before therapy.
However, this decrease was attributed solely to highly
significant reduction (P 5 0.0002) in the indicated patient
subgroup, whereas no significant difference was observed in
the other patients (P . 0.1). The results of the 0.5 Gy in vitro
irradiation are comparable with the results of the 1.0-Gy
samples, but the margin of error is larger. None of the
patients showed a significant increase in micronucleus yield
after irradiation in the second blood sample compared with
the yield in the first blood sample.
The mean dose–response curves after in vitro irradiation
with 60Co g-rays before and after 131I therapy are shown in
Figure 2. For the control subjects (Fig. 2A), the dose–
response curves for the first and the second blood samples
were not significantly different. The dose–response curves
for the blood samples taken before and after therapy
(Fig. 2B) also were not significantly different for the patient
subgroup that did not show a significant difference in the in
vitro induced micronucleus yield before and after therapy.
For the other patients (Fig. 2C), the mean micronucleus
increase after in vitro irradiation of the blood sample taken
after therapy decreased significantly (P 5 0.0002) compared
with the blood sample taken before therapy. For in vitro
irradiation with 0.5 Gy, mean values of 52 and 26 micronu-
clei were found before and after therapy, respectively,
whereas mean values of 150 and 78 micronuclei before and
after therapy, respectively, were found after in vitro irradia-
tion with 1.0 Gy. When the dose–response curves from
Figures 2B and C were compared with the dose–response
curves of the control population (Fig. 2A), the curves in
Figure 2B were similar whereas the curve before therapy
(Fig. 2C) was higher and became normalized after therapy.
For 17 of 20 patients (81%), a statistically significant
(P 5 0.0164) increase in micronuclei was observed after
therapy. The mean increase in micronuclei after 131I therapy
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observed in this study was 23 micronuclei (range, 0–121
micronuclei). There were no significant differences in the
mean increase in micronuclei after 131I therapy between
thyrotoxicosis patients (mean, 23 micronuclei; range, 0–121
micronuclei) and thyroid carcinoma patients (mean, 29
micronuclei; range, 16–34 micronuclei). By fitting the
micronucleus yield 1 wk after therapy to the dose–response
curve after in vitro irradiation before therapy, the ETBD of
each patient could be determined. The mean ETBD observed
in this study was 0.37 Gy (range, 0.00–0.96 Gy). On the
basis of these results, no significant difference in ETBD
values could be observed between thyrotoxicosis patients
and thyroid carcinoma patients. For the thyrotoxicosis
patients, the MIRD total body dose was determined from the
pretherapy uptake curve. These data are included in Table 1.
A mean total body dose of 0.30 Gy (range, 0.14–0.55 Gy)
was obtained, whereas the micronucleus assay yielded a
comparable mean ETBD of 0.37 Gy (range, 0.00–0.96 Gy)
for the thyrotoxicosis patient group.
The mean increase in micronucleus yield associated with
131I therapy seemed to be higher in the patient group that
showed a significant difference in the micronucleus increase
after in vitro irradiation before and after therapy (mean, 39
micronuclei; range, 6–121 micronuclei) than in the patient
group that did not show this difference (mean, 12 micronu-
clei; range, 0–35 micronuclei). Also, the mean ETBD tended
to be higher in the first patient subgroup: 0.45 Gy (range,
0.13–0.96 Gy) and 0.34 Gy (range, 0.00–0.70 Gy), respec-
tively, using the micronucleus yields and 0.31 Gy (range,
0.19–0.54 Gy) and 0.28 Gy (range, 0.14–0.55 Gy), respec-
tively, using the pretherapy uptake curve for thyrotoxicosis
patients. However, the differences did not reach statistical
significance (P . 0.1). The mean administered activities in
both subgroups, 1115 MBq (range, 555–3700 MBq) and
1092 MBq (range, 259–3700 MBq), respectively, also were
not significantly different (P . 0.1).
DISCUSSION
The results of this study show that exposure to low doses
of ionizing radiation during medical treatment (adaptation
dose) makes human peripheral blood lymphocytes less
TABLE 1
Overview of Results Obtained in Study
Subject
no. Diagnosis Sex
Age
(y)
Adm.
activity
(MBq)
MIRD
(Gy)
ETBD
(Gy)
Incr. MN
therapy
(Gy)
Incr. MN
before
0.5 Gy
Incr. MN
before
1.0 Gy
Incr. MN
after
0.5 Gy
Incr. MN
after
1.0 Gy
1 C F 27 0 0.00 26 109 26 94
2 C F 27 0 0.00 34 124 29 100
3 C F 39 0 0.00 24 91 23 93
4 C F 40 0 0.00 25 84 24 71
5 C M 57 0 0.00 31 90 25 85
6 C F 35 0 0.00 27 92 32 81
7 C F 48 0 0.00 28 127 21 106
8 TT F 65 555 0.35 0.00 0 30 104 25 120
9 TT F 50 592 0.14 0.25 9 27 119 37 100
10 TT F 69 666 0.21 0.52 16 24 76 30 84
11 TT F 51 740 0.21 0.31 13 29 62 17 53
12 TT F 62 813 0.19 0.42 37 61 131 34 84
13 TT F 25 259 0.17 0.54 9 14 59 18 78
14 TT F 50 370 0.29 0.31 14 30 60 25 78
15 TT F 71 481 0.35 0.57 10 36 97 31 105
16 TT F 61 555 0.54 0.15 12 55 116 27 55
17 TT M 51 555 0.40 0.43 9 22 87 20 90
18 TT F 71 555 0.35 0.56 38 51 164 22 45
19 TT M 42 703 0.31 0.13 6 47 139 21 86
20 TT F 51 740 0.55 0.03 2 60 129 41 133
21 TT M 43 740 0.21 0.19 15 55 108 18 104
22 TT F 70 740 0.26 0.46 43 53 153 3 48
23 TT F 74 740 0.23 0.48 24 42 150 12 109
24 TT F 68 1110 0.28 0.96 121 66 219 74 126
25 TCA M 76 3700 0.20 16 40 71 12 94
26 TCA M 41 3700 0.42 34 44 124 11 69
27 TCA F 40 3700 0.70 35 14 83 14 64
Adm. activity 5 administered activity; MIRD 5 total body dose calculated by MIRDOSE 3 (Oak Ridge Associated Universities, Oak Ridge,
TN); ETBD 5 equivalent total body dose calculated by micronucleus assay; Incr. MN therapy 5 increase in micronuclei after 131I therapy; Incr.
MN before 0.5 Gy 5 increase in micronuclei after irradiation with 0.5 Gy before therapy; Incr. MN before 1.0 Gy 5 increase in micronuclei after
irradiation with 1.0 Gy before therapy; Incr. MN after 0.5 Gy 5 increase in micronuclei after irradiation with 0.5 Gy after therapy; Incr. MN after
1.0 Gy 5 increase in micronuclei after irradiation with 1.0 Gy after therapy; C 5 control; TT 5 thyrotoxicosis; TCA 5 thyroid carcinoma.
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susceptible to cytogenetic damage for subsequent in vitro
irradiation at higher doses (challenge dose). The reproducibil-
ity of the data for the control population further shows that
the observed differences cannot be attributed to cell culture
or technical effects. Therefore, the observation can be
interpreted as an adaptive response phenomenon. Barquin-
ero et al. (22), using a similar experimental setup, reported
the existence of an adaptive response in vivo after occupa-
tional exposure to ionizing radiation. In their study, a 2-Gy
60Co dose was used as the challenge dose. Cytogenetic
damage was scored as dicentrics, acentrics, and chromo-
some breaks. The occupationally exposed individuals showed
a significantly lower amount of chromosomal damage after
in vitro irradiation than did the nonexposed individuals.
Determination of the mechanism behind the adaptive
response is beyond the scope of this study. This mechanism
has been studied in vitro by many investigators (10–14). The
currently accepted model of the mechanism of adaptive
response is the signaling loop model, first described by
Weichselbaum et al. (26) in 1991. The assumption has been
made that on treatment with a DNA-damaging agent, an
alarm signal is generated in the nucleus. Activation of a set
of genes follows, which leads to de novo protein synthesis.
Some of these proteins are involved in repair of the damage
inflicted by the challenge dose; hence, a lower biologic
effect of the dose is observed than that in nonadapted cells.
However, instead of an increased DNA repair rate, the
fidelity of repair seems to be changed, leading to a different
proportion of damage seen at the chromosomal level. The
lowered mutation frequency in adapted cells also points to
this possibility (27). Thus, adaptive response may involve
primarily a qualitative change in damage repair or process-
ing (28). Only a few centigrays are needed to produce an
adaptive response in human lymphocytes (29). In this study,
the mean ETBD in the patient subgroup that showed an
adaptive response was only 0.45 Gy.
The observation that only 8 of 20 patients showed an
adaptive response after receiving 131I therapy clearly shows
interindividual variability. This variability was also ob-
served in the in vivo study by Barquinero et al. (22) and in
previous in vitro studies (30–33). Both the pretherapy in
vitro irradiation and the in vivo exposure by 131I therapy led
to a somewhat higher increase in micronuclei in the patient
group that showed an adaptive response than that in the other
patient group. The in vitro dose–response curve for the
patients showing an adaptive response seemed to normalize
after 131I therapy (adaptation dose). Although the results did
not reach statistical significance, the adaptive response in
this study seems to be evident, especially in radiosensitive
individuals.
For the 8 patients who showed an adaptive response, an in
vivo exposure to ionizing radiation (challenge dose) after the
131I therapy (adaptation dose) would probably lead to less
genetic damage. The duration of the adaptive response in
FIGURE 1. Overview of increase in micronuclei after in vitro irradiation (1.0 Gy 60Co g-rays) of blood samples taken before and after
131I therapy. For controls, 2 blood samples taken 1 wk apart were irradiated. Error bars represent 95% confidence limits. Increase in
micronuclei before therapy (j), increase in micronuclei after therapy (h), and patients who show adaptive response (1) are indicated.
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vivo is currently unknown. According to Shadley et al. (34),
the duration is relatively long lasting (at least 3 cell cycles in
human lymphocytes) in vitro.
Although we know that radiation can be harmful, an
inordinate fear of the least amount of radiation exists today
in some groups (29). Instead, a fact-based scientific ap-
proach to evaluate the detrimental effects of low levels of
radiation should be adopted. The results of this study support
the point of view of an increasing number of investigators
(8–22,26–30,32,33) that some consideration should be given
to the importance of biologic defense mechanisms that could
be stimulated by low levels of radiation. However, the
results of this study do not mean that exposure to low levels
of ionizing radiation by itself is beneficial. In exposed
populations, higher levels of chromosome aberrations are
found compared with those found in nonexposed popula-
tions (35–40).
CONCLUSION
These results show that, although the iodine treatment can
act as an adaptation dose and can induce an in vivo adaptive
response, interindividual variability exists. In the evaluation
of the detrimental effects of exposure to radiation, some
consideration should be given to the importance of biologic
defense mechanisms. The results of this study do not suggest
that exposure to ionizing radiation by itself is beneficial
because the level of chromosomal damage is increased after
the iodine treatment.
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Abstract.

Applicability of the in vitro  micronucleus (MN)
assay was evaluated in 2 cancer patient
groups receiving high activities of
radiopharmaceuticals: 12 patients (22
therapies) treated with 131I-MIBG for
neuroblastoma (NB, mean 4.5 GBq, SD: 1.1)
or carcinoid tumors (CA, mean 7.7 GBq, SD:
0.5) and 15 patients (17 therapies) treated with
131I-lipiodol for hepatocellular carcinoma (HCC,
mean 1.9 GBq, SD: 0.2).
Blood samples were taken immediately before
and 1 week after administration of the
radiopharmaceutical. For 131I-MIBG patients,
the first blood sample was irradiated in vitro
with 60Co γ-rays to determine the individual
dose response curve. The equivalent total
body dose (ETBD) was derived from the
increase in MN yield after therapy. Based on
consecutive bi-planar scans taken after
therapy, the physical total body dose following
the MIRD formalism was calculated for each
therapy.
A significant correlation was found between the
ETBD and the MIRD dose (R = 0.87). The
ETBD was only 70% of the MIRD dose due to
the differences in dose rate between the in
vitro and in vivo exposure. The use of the
standard MN dose response curve for healthy
individuals in stead of the patient individual
dose response curve gave the same overall
results. The MN assay could be performed in
17 out of 22 131I-MIBG therapies due to cell
division inhibition caused by previous
chemotherapy treatments and lymphocyte
dilution caused by blood transfusions.
For HCC patients, we were able to stimulate
lymphocytes in only 12 out of 17 blood
samples. For these patients, there was no
correlation (p = 0.17) between the MIRD dose
and the ETBD based on the standard dose
response curve. This is probably due to
enhanced lymphocyte sequestration caused by
hypersplenism.
Analysis of data for multiple therapies points to
a shortened mean half-life of the lymphocytes
(T1/2 = 3.9 months).


Introduction.

In Nuclear Medicine, target-finding molecules
coupled to a radioisotope
(radiopharmaceuticals) are injected into the
patient to enable physiological imaging
(diagnosis) or therapeutic effects (radionuclide
therapy). For radionuclide therapy, high
activities (several GBq) of
radiopharmaceuticals are administered to the
patient in order to have a significant
therapeutic effect. Since 1942, the isotope
most frequently used in nuclear medicine
therapy is 131I. 131I emits both short (< 3mm)
range β-rays, used to irradiate the tumour
tissue, and long range γ-rays, used for patient
scintigraphy. Its physical half-life of 8 days
enables long term irradiation of the target
tissue.
Although the injected radiophar-maceuticals
mainly target the tissue under treatment,
inevitably the rest of the body is also irradiated
to some extent. This is partly due to the
circulation of the radiopharmaceutical in the
body before it is incorporated into the target
tissue, or is excreted, and partly by the long-
range γ-rays emitted from the
radiopharmaceutical inside the target tissue.
Since radionuclide therapies are often
repeated several times for the same patient
and can be considered as curative in the
treatment of some tumours, it is important to
determine the radiation dose to the patient as
measure of the mutagenic effect of the
therapies.
In the present study we included 27 patients
given 39 radionuclide therapies with either 131I-
MIBG (meta iodo benzyl guanidine) for
neuroblastoma and carcinoid tumours or 131I-
lipiodol for hepatocellular carcinoma.
Neuroblastoma, a slow growing tumour derived
from the sympathic nerve system is the fourth
most common tumour in children. The
treatment consists mainly of surgical dissection
of the tumour, followed by several courses of
chemotherapy. In Belgium, the 131I-MIBG is
usually given to the patient as a palliative
treatment in conjuction with or after
chemotherapy. In 1991, the cumulative
experience in children with neuroblastoma
indicated an objective response rate of 35%
(Hoefnagel CA, 1994). For metastatic carcinoid
disease, in 1991, results were available for 52
patients, revealing on the one hand an
objective response (improvement in disease
status) of only 15% but on the other hand
palliation (reduction of pain, patient resumes
“normal” life), which may be very meaningful
and long lasting, in 65% (Hoefnagel CA, 1994).
For both types of malignancy, usually a fixed
dose of 3700 to 7400 MBq of 131I-MIBG is
infused intravenously over a 2h to 4h period.

Primary hepatocellular carcinoma (HCC) is one
of the most common malignant tumours in the
world. It is responsible for an estimated 1
million deaths annually. The tumour often
presents late, which, with the underlying
cirrhosis, makes surgery difficult or impossible
in many patients (Novell and Hilson, 1994).

The survival time among patients with HCC is
extremely short and may be as low as 1-2
months. Loco regional treatment of the liver is
therefore used as a palliative or curative
treatment. Lipiodol (or poppy seed oil) naturally
contains up to 38% of iodine. Internal radiation
therapy can be achieved, when some of the
iodine present in the lipiodol is substituted by
131I. After intra-arterial injection into the hepatic
artery, it is retained by HCC for periods ranging
from several weeks to over a year, while it is
cleared from the normal liver parenchyma
within 7 days (Okuyasu et al., 1988, Ohishi et
al., 1985).

The mutagenic effect of a certain treatment or
drug can be determined by cytogenetic
biodosimetry based on the in vitro cytokinesis
blocked micronucleus assay (Ramalho et al.,
1987, Thierens et al, 1995, Thierens et al,
1999). In previous papers, we have reported
the results of studies on patient dosimetry in
nuclear medicine with the cytokinesis-blocked
micronucleus assay (Watanabe et al., 1998,
Monsieurs et al., 1999, Monsieurs et al., 2001).
In the present study, the following subjects
were investigated:
1)The effect of the malignant disease status
and previous treatments on the feasibility
of cytogenetic biodosimetry using the
micronucleus assay.
2)The comparison of the mean individual in
vitro dose response relationship of the 131I-
MIBG treated patient population to the
standard dose response relationship
determined for a control population.
3)The comparison between the equivalent total
body dose (ETBD) determined by the
micronucleus assay and the results of
physical dosimetry with the MIRD
formalism.
4)The micronucleus yield over time for patients
undergoing several sequential radionuclide
therapies.


Materials and methods.

Subject population.
This study comprises a total of 27 patients
treated with either 131I-MIBG (for
neuroblastoma and carcinoid tumours) or 131I-
lipiodol (for hepatocellular carcinoma) at the
Nuclear Medicine division of the University
Hospital of Ghent during the period 1996 -
2001. All patients gave their written informed
consent, prior to inclusion into the study.
The group treated with 131I-MIBG consists of
12 patients (8 females and 4 males) who
received a total of 22 therapies. Ten patients
with a mean age of 8 years (range 2 - 32
years) received a total of 18 therapies with a
mean activity of 4.52 GBq (SD: 1.11 GBq) for
neuroblastoma stage III or IV. The 2 remaining
patients, respectively 45 and 50 years old,
each received 2 therapies with a mean of 7.68
GBq (SD: 0.49) 131I-MIBG for carcinoid tumors
with multiple liver metastases.
A group of 15 adult patients (6 women and 9
men) with a mean age of 61 years receiving a
total of 17 131I-lipiodol therapies for
hepatocellular carcinoma were also included in
the study. These patients received a mean
activity of 1.88 GBq (SD: 0.20) of 131I-lipiodol
administered intra-arterially into the liver artery
by catheterisation. Only patient 1 received 3
consecutive therapies over a period of 8
months. The mean administered activity for
this patient was 1.82 GBq.

Blood sample collection and in vitro
irradiation.
The first heparinised 5 ml blood sample was
taken immediately before administration of the
therapeutic activity. For patients treated with
131I-MIBG, this blood sample was divided in
three fractions. One fraction served as a non-
irradiated control. The two other fractions were
irradiated in vitro at 37°C with a dose of 0.5 Gy
and 1.0 Gy 60Co γ-rays at a dose rate of 1
Gy/min. A second heparinised blood sample of
5 ml was taken 7 days post-administration.

Micronucleus assay.
Whole blood cultures were incubated at 37°C
for 70 h in a 5% CO2 atmosphere. Culture
medium consisted of RPMI 1640 with 2 mM L-
glutamine and Hepes buffer (Gibco)
supplemented with 15% fetal calf serum and
antibiotics. 20 µl of a 1% phytohaemagglutinin
solution (PHA-P; Difco) was used to stimulate
cell division. According to the method of
Fenech and Morley (1985), Cytochalasin B
(final concentration 6 µg/ml; Sigma) was added
40 h after culture initiation in order to block
cytokinesis. After an incubation period of 70 h,
the cells were harvested, treated with a
hypotonic solution of 0.075 M KCl, and fixed
with a mixture of methanol-glacial acetic acid
8:1 following the protocol described by Vral et
al. (1994). Slides were stained with
Romanowsky-Giemsa and micronuclei were
scored in 1000 binucleated cytokinesis-blocked
cells under the light microscope with a
magnification of 400×, based on the criteria
summarized by Fenech M. (1993).

Equivalent total body dose.
The equivalent total body dose (ETBD) is the
dose of ionizing radiation, which, if received

homogeneously by the whole body, would
produce the same yield of micronuclei, as
observed in the patients. The ETBD was
derived from the increase in micronucleus yield
in the blood sample of each patient, 1 week
after administration of the activity, using the
micronucleus dose response relationship of
Thierens et al. (1999) determined in the
laboratory. For the patients receiving 131I-
lipiodol therapy, this value was then corrected
for the 131I remaining in the body after the first
week by multiplying with a factor of 1.71. This
factor is based on the observed biological
retention of the 131I I these patients: 5.23 days.
For the patients receiving 131I-MIBG therapy,
the ETBD was also calculated by fitting an
individual linear-quadratic dose response curve
through the obtained data points of the in vitro
irradiated blood samples before therapy. For
the patients receiving 131I-lipiodol therapy, an
individual dose response curve could not be
obtained. The initial low amount of
lymphocytes present in the blood of these
patients caused by hypersplenism did not allow
to split-up the blood samples for in vitro
irradiation.

Total body scans.
All patients had a set of 3 (131I-MIBG) or 2 (131I-
lipiodol) 180° biplanar total body scans taken
up to 10 days (131I-MIBG) or 14 days (131I-
lipiodol) after administration of the
radiopharmaceutical. All scans were made on
an Elscint Helix double head gamma camera
fitted with high-energy parallel hole collimators.
A syringe containing a known activity of 131I in
a PMMA syringe phantom (diameter: 6 cm)
was placed at the patient’s feet. The activity in
the body was determined by comparing to the
known activity in the syringe. The activity was
then plotted versus time and a mono-
exponential function was fitted through the
dataset. The data were inserted into the
MIRDOSE3 (oak Ridge associated
Universities) software program and the total
body dose was calculated.

Statistical analysis
Statistical analysis was performed by means of
Medcalc and SPSS. Differences for the
mean were evaluated by Wilcoxon or paired
Mann-Whitney tests, where applicable.
Correlations were investigated by means of the
Spearman’s rank coefficient r. Error bars in the
figures represent the standard deviations
based on the Poisson distribution.




Results
All results have been summarized in table 1.

Figure 1.













Overview of the micronucleus yields before
and after radionuclide therapy.

The micronucleus yields for the patients before
and after therapy are represented in figure 1.
For only 17 131I-MIBG therapies out of 22,
reliable results allowing the determination of
the ETBD could be obtained with the
cytokinesis blocked micronucleus assay. The
mean increase in micronuclei after 131I-MIBG
therapy was 88 (SD: 71) for these
neuroblastoma patients while it was
significantly less (p < 0.001) with a mean
increase of 35 micronuclei (SD: 8) for carcinoid
patients. The ETBD value, based on the
standard in vitro dose response relationship of
the laboratory (Thierens et al., 1999), obtained
for the neuroblastoma patients (mean 0.90 Gy,
SD: 0.51) was significantly (p < 0.0001) higher
than for patients suffering from carcinoid
tumours (mean: 0.34 Gy, SD: 0.08). The mean
individual ETBD was determined based on the
mean micronucleus dose response curve for
this patient population using a linear-quadratic
fit through the micronucleus yields obtained
after in vitro irradiation of the first blood
sample: MNirr  = 32.9 D2 + 62.7 D (r = 0.31)
Where: MNirr  is the micronucleus yield induced
by the therapy and D is the in vitro 60Co dose.
The mean ETBD values obtained with this
curve (mean 0.93 Gy, SD: 0.47 for
neuroblastoma patients and mean 0.45 Gy,
SD: 0.09 for carcinoid patients) were not
significantly different (p > 0.20) from the values
obtained with the standard micronucleus dose
response curve.

For patients treated with 131I-lipiodol, the
cytokinesis blocked micronucleus assay was
only feasable for 12 out of 17 therapies. The
mean increase in micronucleus yield for
patients treated with 131I-lipiodol at 7 days after
therapy was 62 micronuclei (SD: 22).
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     Before therapy
     After therapy

Pt D Y G A MN bef MN 0.5 MN1 MNaft MNinc EDLQ EDL EDInd MIRD

1 N 5 M 5.55 47 136 172 356 309 2.41 3.81 2.26 2.26
2a N  10 W 5.55 78 134 140 190 112 1.09 1.38 1.12 1.23
2b N  10 W 5.55 163 179 247 226 63 0.67 0.78 0.73 0.92
2c N  10 W 5.55 116 141 232 164 58 0.62 0.72 0.68 1.13
2d N  11 W 5.55 109 172 260 209 100 1.00 1.23 1.03 1.23
2e N  11 W 5.55 115 192 213 263 148 1.37 1.82 1.37 1.02
3a N  2 W 3.70 46 70 171 81 35 0.39 0.43 0.45 0.75
3b N  2 W 3.70 68 104 164 109 41 0.46 0.51 0.51 0.81
4a N  7 M 5.55 31 38 74 87 56 0.60 0.69 0.66 1.15
4b N  8 M 3.70 46 70 171 81 35 0.39 0.43 0.45 0.93
5a N  2 W 3.70 16 62 126 127 111 1.39 1.37 1.12 1.89
5b N  2 W 5.55 62 98 129 132 70 0.73 0.86 0.79 1.84
6 N  8 W 3.70 27 69 127 32 5 - - - 0.52
7 N  32 W 3.70 186 244 346 271 85 0.87 1.05 0.92 1.59
8a N  6 M 3.70 69 - 210 50 -19 - - - 2.10
8b N  6 M 1.85 104 157 - 69 -35 - - - 0.90
9 N  7 W 5.55 78 101 - - - - - - 1.29
10 N  5 M 3.70 - - - - - - - - 2.59
M - 8 - 4.52 80 123 185 153 88 0.90 1.08 0.93 1.34
SD - 7 - 1.11 46 55 65 89 71 0.51 0.82 0.47 0.56
11a C 45 W 7.40 52 68 109 77 25 0.29 0.31 0.34 0.45
11b C  45 W 8.53 31 77 109 60 29 0.33 0.36 0.38 0.57
12a C  50 M 7.40 24 48 74 67 43 0.48 0.53 0.54 0.79
12b C  50 M 7.40 50 80 129 93 43 0.48 0.53 0.54 0.94
M - 48 - 7.68 39 68 105 74 35 0.39 0.43 0.45 0.69
SD - 3 - 0.49 12 13 20 12 8 0.08 0.10 0.09 0.19
13a H 44 F 2.04 29 - - 78 50 0.87 1.05 - 1.27
13b H  44 F 1.86 82 - - 113 31 0.57 0.65 - 1.25
13c H  44 F 1.56 62 - - 174 112 1.67 2.35 - 1.04
14 H  70 F 2.02 42 - - - - - - - 1.21
15 H  66 F 2.01 47 - - 191 144 2.03 3.02 - 0.92
16 H  75 F 1.99 43 - - 104 61 1.03 1.28 - 0.87
17 H  70 M 1.54 25 - - 81 56 0.95 1.17 - 0.54
18 H  72 F 1.79 15 - - 69 54 0.93 1.13 - 1.27
19 H  71 M 1.99 18 - - 98 80 1.28 1.68 - 1.02
20 H  58 M 1.79 20 - - 24 4 - - - -
21 H  48 M 1.54 13 - - 69 56 0.95 1.17 - 0.69
22 H  56 M 1.93 24 - - - - - - - -
23 H  56 M 2.13 93 - - 125 32 0.59 0.67 - 1.04
24 H  68 M 2.01 18 - - - - - - - 0.92
25 H  62 M 1.67 21 - - - - - - - 0.78
26 H  62 M 2.04 52 - - 125 73 1.19 1.53 - 0.65
27 H  66 F 2.13 44 - - - - - - - 1.13
M - 61 - 1.88 34 - - 96 62 1.10 1.32 - 0.97
SD - 11 - 0.20 20 - - 42 22 0.42 0.75 - 0.23
Pt:  Patient number. The number points to the patient while the letter points to the therapy number. D:
Diagnosis. (N: Neuroblastoma, C: Carcinoid tumour, H: Hepatocellular carcinoma). Y:  Patient age
(years). G:  Patient gender (M: man, W: woman). A:  Administered activity (GBq). MN bef:
Micronucleus yield before therapy. MN 0.5:  Micronucleus yield after in vitro irradiation with 0.5 Gy 60Co
γ-rays. MN 1:  Micronucleus yield after in vitro irradiation with 1 Gy 60Co γ-rays. MN aft:  Micronucleus
yield after therapy. MN inc:  Micronucleus increase after therapy. ED LQ:  Equivalent total body dose
(Gy) using the general formula determined by Thierens et al., (1999). ED L:  equivalent total body dose
(Gy) using the linear component of the general formula determined by Thierens et al., (1999). ED ind:
equivalent total body dose (Gy) using the individual dose response relationship. MIRD:  Total body
dose (Gy (N and C) or Sv (H)) according to the MIRDOSE-3.0 program. M: mean. SD: standard
deviation

For patients treated with 131I-lipiodol, a mean
ETBD value of 1.10 Gy (SD: 0.42), calculated
by means of the standard in vitro dose
response relationship, was obtained after
correction for the 131I-lipiodol remaining in the
body after the first week post-administration.

Based on bi-planar images, the physical total
body dose according to the MIRD formalism
could be determined for each patient group
and was highest for neuroblastoma patients
(mean 1.34 Gy, SD: 0.56) compared to HCC
patients treated with 131I-lipiodol (mean 0.97
Gy, SD 0.23), while it was significantly (p <
0.05) lower for carcinoid patients with a mean
of 0.69 Gy (SD: 0.19) for carcinoid patients.

Figure 2













Mean linear quadratic dose response
relationship based on the general formula
determined by Thierens at al (1999).
131I-MIBG 131I-lipiodol

When all patients included in the study are
considered, figure 2 shows only a poor
correlation between the physical MIRD dose
and the ETBD derived from the standard
micronucleus dose relationship (R = 0.37, p =
0.055).
For the patient group treated with 131I-lipidol for
HCC, the ETBD values obtained with the
micronucleus assay show no correlation with
the physical dose (r = -0.434, p = 0.170).
However, when the patients treated with 131I-
MIBG are considered separately, a significant
correlation is found (r = 0.87, p = 0.000). The
full line in figure 2 is the result of the linear
regression analysis through the 131I-MIBG data
alone. As expected, the correlations did not
change significantly when the mean individual
dose response relationship was used in this
patient group (r = 0.78, p = 0.0006). The slope
value determined by regression analysis of the
ETBD data versus the MIRD doses was 0.70.

Figure 3












Overview of the micronucleus evolution over
time following multiple therapies.

For the patients treated with multiple therapies,
the micronucleus yields before and after each
subsequent therapy were plotted versus time in
figure 3. The increase in micronucleus yield 7
days after administration of the therapeutic
activity had at least partially recovered by the
time of the subsequent therapy and rose again
after the administration of this therapy. The
mean lymphocyte half-life calculated from
these results (as derived from the reduction in
micronucleus yield between subsequent
radionuclide therapies in the same patient) was
3.9 months (range: 1.7 – 6.7 months).


Discussion

Since 131I-MIBG therapy is a second line
treatment for neuroblastoma in Belgium, all of
the included neuroblastoma patients received
already chemotherapy before the 131I-MIBG
therapy. For all neuroblastoma patients, the
initial micronucleus yield is already higher than
expected for children (Thierens et al., 1995),
which is probably due to the chemotherapy.
Earlier chemotherapy can jeopardize the
evaluability of the micronucleus assay due to
cell division inhibition. This is clearly the case
for patient 10 as we were not able to count one
thousand binucleated cells in any blood sample
either before or after the MIBG therapy. The
same occurred in the in vitro irradiated 1 Gy
and post-therapy blood samples of patient 9.
For this patient the cumulative effect of both
chemotherapy and radiation damage to the cell
were responsible for the failure of the
micronucleus assay.
Additionally, a subset of neuroblastoma
patients (patients 6 and 8) received "whole
blood" transfusions before the second blood
sample was taken. The infusion of fresh
lymphocytes dilutes the resident long-term
irradiated lymphocytes. This is illustrated by
the data of patient 8 for whom the
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micronucleus frequency was even significantly
lower after therapy than before therapy (table
1).
In spite of these problems, for the remaining
patients a significant correlation (shown in
figure 2) was found between the ETBD, based
on the standard micronucleus dose response
relationship and the MIRD dose (r = 0.87).
Within the range of micronucleus frequencies
under consideration, the ETBD values derived
from the mean in vitro dose response
relationship: MNirr  = 32,9 D2 + 62,7 D are not
significantly different (p > 0.20) from those
obtained from the standard dose response
relationship: MNirr  = (19.5 ±  0.5) D2 + (81.1 ±
0.3) D) (Thierens et al, 1999). In the present
study, the use of in vitro dose response
relationship of the considered patients in stead
of a standard curve had no major impact on
the results.
On the average, the obtained ETBD values
were 70% of the calculated MIRD values while
using the standard curve. This can be
attributed to the differences in dose rate
between the acute in vitro irradiation for the
determination of the dose response and the in
vivo irradiation at low dose rate. It has been
suggested that in this case it would be better
to use only the linear component of the
standard dose response (IAEA, 2001).
Applying this procedure to the MIBG data, the
slope of the linear regression between the
MIRD dose and the ETBD data is 0.92 which
equals unity taking into account the
uncertainty. Therefore, our results further
support the procedure supported by the IAEA.
For 131I-MIBG patients we can therefore
conclude that biological dosimetry based on
the micronucleus assay is feasible, provided it
does not closely follow chemotherapy so the
lymphocyte count is restored to normal values
and the blood sample after therapy is taken
before blood transfusions are given to the
patient.

The reason why only 12 out of 17 131I-lipiodol
therapies could be evaluated by the
micronucleus assay, is due to the low number
of lymphocytes present in their peripheral
blood and a reduction of their proliferation
capacity. Here, the problem is a consequence
of the hypersplenism occurring in many of
these patients. According to Akimaru et al.
(2001), splenic enlargement was found in 20%
of their HCC patients, resulting in
hypersplenism for many of them. The enlarged
spleen together with reduced liver function (as
a result of hepatocellular carcinoma) ensure an
impaired detoxification of the body and a
shortened half-life of all blood cells in the
patient resulting in pancytopenia (Bain BJ.,
1995). The radiation effect on these
lymphocytes caused stimulation problems in
the blood samples after treatment.

For the HCC patients, no correlation was found
between the ETBD values and the MIRD
doses. For 7 out of 11 patients the ETBD
values were higher than the MIRD dose.
Several studies point to an increased in vitro
chromosomal radiosensitivity in cancer
patients, especially in breast cancer patients
(Darroudi et al., 1995, Scott et al., 1999,
Terzoudi et al., 2000, Baria et al. 2001, Baria et
al., 2002). The initial low amount of
lymphocytes present in the blood of these
patients due to hypersplenism, will not allow to
split up the blood samples and determine the in
vitro dose response. Further research on the
biological radiosensitivity of HCC patients is
necessary. Preliminary results on dicentrics
scoring for this patient group in the laboratory
(De Ruyck et al, 2002) do not point to an
increased in vitro radiosensitivity in 131I-lipiodol
treated patients. The lymphocytes in HCC
patients clearly no longer show the normal in
vivo behaviour of lymphocytes and are
therefore not suitable for biological dosimetry
purposes.

The residual damage after multiple subsequent
131I-MIBG and 131I-lipiodol therapies was
investigated. As can be seen in figure 3, for all
patients an initial large increase in
micronucleus yield after administration of the
therapy had at least partially recovered by the
time of the subsequent therapy. A similar effect
was reported by Watanabe et al. (1998)  after
89Sr therapy for painful bone metastases and
by Fenech et al. (1990) for patients treated with
external partial body radiotherapy.

From figure 3 can be seen that after several
subsequent therapies, the micronucleus yield
before each therapy never reached the initial
level again. Instead, it rose slowly over the
course of subsequent therapies representing
the residual genetic damage of the previous
radionuclide therapies.
The short mean half-life of 3.9 months of
lymphocytes, found in the present study, is due
to an increased turnover of lymphocytes. This
result corresponds to micronucleus yields
returning to pre-treatment values within 4 to 6
months, found in children treated repeatedly for
thyroid carcinoma as reported by Streffer et al.
(1998). From the analysis of the Goiaña
accident, Ramalho et al. (1995)  concluded that
the disappearance of unstable chromosome
aberrations (such as micronuclei) is dose

dependent. The mean lymphocyte half-life in
their study was 5.3 months in people receiving
up to 1 Gy while it was significantly less (3.7
months) in people receiving more than 1 Gy, a
result very similar to the shortened lymphocyte
half-life determined in present study.


Conclusion.

The present study shows that the results of
cytogenetic biodosimetry of cancer patients
based on the in vitro  micronucleus assay have
to be treated with caution. Not only the in vitro
dose response may be different, but also
hypersplenism and other confounding factors
due to adjuvant therapy such as chemotherapy
or blood transfusions have to be taken into
account.
The analysis of the data for the multiple
therapies points to a shortened mean half-life
of the lymphocytes (T1/2 = 3.9 months).
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&p.1:Abstract. In view of the EURATOM 96/29 [1] regula-
tions, a prospective multicentre study was performed to
evaluate the present guidelines given to relatives of pa-
tients treated with iodine-131 for both thyroid carcinoma
and thyrotoxicosis, based on the real-life radiation bur-
den. This study comprised 166 measurements carried out
on a group of 94 relatives of 65 patients. All relatives
wore a thermoluminescent dosemeter (TLD) on the wrist
for 7 days. Sixty-one relatives agreed to wear another
TLD for an additional 7 days. TLD were placed on nine
patients’ bedside tables. The eight participating centres
were arbitrarily divided into three groups according to
the period of time they advised their patients to sleep
separately. Groups I, II and III respectively advised their
patients to sleep separately for 0, 7–10 and 14–21 days.
The median dose received by in-living relatives of thy-
roid carcinoma patients during the 14 days following
hospital discharge was 281 µSv (doses to infinity not
calculated); the median dose to infinity received by in-
living relatives of ambulatory treated thyrotoxicosis pa-
tients was 596 µSv, as compared with 802 µSv for in-liv-
ing relatives of hospitalised thyrotoxicosis patients. In
general the children of patients received a significantly
(P<0.1) lower mean dose than their partners. For thyroid
carcinoma patients, only two relatives out of 19 (10%)
exceeded the EURATOM 96/29 limit of 1 mSv/year. For
thyrotoxic patients, 28% of relatives exceeded the EUR-
ATOM 96/29 limit, but none of them were relatives of
patients who followed guidelines for 21 days.
The results of this study indicate that sleeping separately
for 7 days, after a period of hospitalisation of 2–3 days,
will usually be sufficient for thyroid carcinoma patients.
For thyrotoxicosis patients, up to 21 days of sleeping
separately could be necessary in order to strictly abide
by EURATOM 96/29. Therefore, the authors propose the
implementation of a non-rigid dose constraint for people
who “knowingly and willingly” help patients treated
with 131I, while still following the ALARA principle.
&kwd:Key words: Iodine-131 therapy – Thyroid carcinoma –
Thyrotoxicosis – Guidelines
Eur J Nucl Med (1998) 25:1368–1376
Introduction
Based on revised epidemiological data on the incidence
of cancer and leukaemia in populations exposed to ioni-
sing radiation, mainly deriving from the lifespan study
of Hiroshima and Nagasaki victims [2], EURATOM
96/29 [1] recommended that the limit for members of
the public for exposure to ionising radiation be reduced
from 5 mSv/year to 1 mSv/year [1]. When compared
with the natural background radiation averaged over the
world, of 2.4 mSv/year [3], the full extent of this reduc-
tion by a factor of 5 becomes clear.
It may prove difficult to ensure that the radiation bur-
den to relatives of patients treated with iodine-131 for
thyrotoxicosis or thyroid carcinoma complies with this
new dose limit [4]. In Belgium about 1500 patients are
treated with radioactive iodine every year [4].
The practical consequences of the EURATOM 96/29
regulations need to be investigated by studies measuring
the real-life radiation burden to family members of 131I-
treated patients [5]. However, because of logistic or
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practical problems, most studies published so far have
been based on dose rate measurements of 131I-treated pa-
tients upon leaving the hospital and extrapolations ac-
cording to time spent at varying distances to the patient
[5–13]. Though this technique allows estimation of dos-
es received in varying circumstances, it has the major
drawback of the use of occupancy models for the calcu-
lation of doses, which may be inaccurate [14]. There-
fore, studies measuring the dose received by in-living
relatives of the patient in real-life situations are a neces-
sary complement to dose-rate studies [5, 9, 15].
Consequently, a number of studies have measured the
radiation burden to family members using film badges,
thermoluminescent dosemeters (TLDs) or digital dose-
meters [16–25]. Most of these studies however, have
been published as abstracts and report results with re-
gard to relatives of small groups of patients (16–51 rela-
tives) except for studies by Barrington et al. [19] and
Mathieu et al. [25], which considered 92 and 74 relatives
respectively). Furthermore, each individual study has
used a separate set of guidelines. A multicentre study al-
lows comparison of the radiation burden to relatives of
groups of patients with different sets of guidelines, with
data acquisition over a short period of time.
This paper reports the results of TLD measurements
carried out in eight centres in Flanders (Belgium) over
the period from 15 February to 15 November 1997. A
total of 65 131I-treated patients were included in this
study and 94 of their relatives were monitored up to 14
days after the patient had returned home. Each partici-
pating centre advised patients of its own routine guide-
lines. The real-life radiation burden of the patient’s rela-
tives, measured under different sets of guidelines, is
compared with the EURATOM 96/29 dose limit.
Materials and methods.
Population. &p.2:The study population comprised 65 patients referred
by their endocrinologist to the nuclear medicine department of
one of the eight participating centres for 131I therapy to treat dif-
ferentiated thyroid carcinoma or thyrotoxicosis. A total of 166
measurements were carried out on a group of 94 relatives living at
home with one of these patients. In addition, TLDs were placed
on the bedside tables of nine patients to estimate the dose that
their partners would have received during the night if they had
been sleeping together.
A group of 13 patients with a mean age of 37 years (range:
17–58 years) were treated for differentiated thyroid carcinoma and
received a median activity of 4121 MBq (range: 3700–5550
MBq). In this group 19 relatives were monitored comprising nine
partners, five parents and five children with a mean age of 12
years (range: 6 months – 19 years).
A group of 52 patients with a mean age of 53 years (range:
25–89 years), suffering from thyrotoxicosis, received a median ac-
tivity of 370 MBq (range: 185–1665 MBq). Twenty-five patients
suffered from Graves’ disease, 9 from an autonomous nodule and
18 from multinodular toxic goitre. Sixteen patients were hospitali-
sed for a mean period of 3 days (range 2–5 days). All hospitalised
patients were discharged with a dose rate at 1 m from the patient
of less than 20 µmSv/h. A total of 75 relatives were monitored,
comprising 47 partners, 2 parents and 26 children with a mean age
of 18 years (range: 3–26 years). All children living at home were
included in the study even if their age exceeded the paediatric lim-
it of 16 years.
Guidelines after therapy. &p.2:In order to limit the radiation burden to
the relatives of patients treated with 131I, the patient and his family
were required to comply with radiation safety guidelines after the
patient had returned home. In order to facilitate comparison be-
tween results, the guidelines of the eight participating centres
were divided in three categories according to the duration for
which each centre advised the patient to sleep separately (Table
1). The most severe regimen for thyrotoxicosis patients was ap-
plied in group III (14 to 21 days), followed by group II (7–10
days) and group I (no separate sleeping arrangements). For thy-
roid carcinoma patients, group I followed the regimen of longer
hospitalisation (4 days) without separate sleeping arrangements
after discharge while groups II and III were hospitalised for a
shorter period (2–3 days) but advised to sleep separately for 7
days after discharge.
TLD measurements. &p.2:The dose received by the patient’s relatives
(n=94) was measured by TLDs (TLD 100). The TLDs were indi-
vidually calibrated in the cesium-137 beam of the radiation pro-
tection department. Readings were performed by a Harshaw
95 3500 reader and each reading was corrected for background
accumulation by co-reading non-irradiated controls. Under these
conditions the standard deviation on the reading was less than
3%.
All relatives were asked to wear a TLD on the wrist continu-
ously for a period of 7 days, starting from the day the patient re-
turned home. Sixty-one family members agreed to wear another
TLD on the wrist for an additional 7 days. For practical reasons
(limited co-operation from patient and relatives), the longer obser-
vation period could not be asked of all patients. Relatives were
given only one TLD per week on one wrist to enhance co-opera-
tion and especially because sequential data were preferred in this
study.
In addition, TLD dosemeters were placed on the bedside ta-
bles of nine patients in order to measure the dose their partners
would have received during the night if they had been sleeping to-
gether.
To validate guidelines, the data on doses received by the in-liv-
ing relatives were separated for discussion according to the pa-
tient’s diagnosis (thyroid carcinoma or thyrotoxicosis), the treat-
ment regimen (hospitalised or ambulatory) and the relative’s rela-
tionship to the patient (partner, child or parent).
Doses to infinity were calculated by correcting the measured
doses for the remaining activity at the end of the measuring peri-
od. For this correction, an effective half-life of 5.1 days was used
for thyrotoxicosis patients. This value was derived from the pre-
therapy uptake curve of the patients from the University Hospital
of Gent included in this study and concurs with values reported in
the literature [26–28].
Statistical analysis. &p.2:Statistical analysis was performed by Med-
calc. Because data sets were not normally distributed, differences
for the mean were investigated by means of paired or unpaired
two-tailed Wilcoxon tests where applicable.
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Results
Administered activity to the patient.
Evidently, the highest activities (median 4121 MBq,
range 3700–5550 MBq) were administered to the 13 pa-
tients suffering from thyroid carcinoma. All participating
centres administer a standard activity of 3700 MBq to
patients suffering from non-metastatic differentiated thy-
roid carcinoma, except the Middelheim Hospital of An-
twerpen (5550 MBq). In all centres, a standard activity
of 5550 MBq is given when the thyroid carcinoma has
metastasised (as shown on a pre-therapy total body scan)
and when lung or bone metastases are absent.
For patients suffering from thyrotoxicosis, all partici-
pating centres except the University Hospital of Gent
follow a standard activity protocol giving the higher ac-
tivities to those patients suffering from an autonomous
nodule or a multinodular goitre and the lower activities
to those suffering from Graves’ disease. Except for one
patient who received an activity of 888 MBq, the activity
did not surpass 740 MBq.
In the University Hospital of Gent, an aimed dose-to-
the-thyroid protocol is used, to give a dose of 70 Gy to
patients suffering from Graves’ disease, 100 Gy to pa-
tients suffering from a multinodular goitre and 150 Gy to
patients suffering from an autonomous nodule. The ac-
tivity to be administered is calculated based on the for-
mula given by Silver [29], including correction for thy-
roid mass, the maximum percentage 131I-uptake and the
effective half-life of 131 I in the thyroid. This procedure
occasionally leads to activities as high as 1110 MBq be-
Group Ia Group IIb Group IIIc
A. Thyroid carcinoma patients
Text available for patient No Yes Yes
Avoid pregnancy No information 6 months 6 months
Hospitalisation time 4 days 2–3 days 2 days
Sleep separately 0 day 7 days 7 days
No children in the house 0 days 5 days 7 days
Keep distance from children/ A few days 7 days 7 days
pregnant partnerd No information 1–2 m 2–3 m
Keep distance from adultsd 0 days 7 days 7 days
0 m 1–2 m 2–3 m
Don’t go to work 0 days 7 days 7 days
Mind personal hygiene A few days 7 days 7 days
a Middelheim Hospital Antwerpen
b University Hospital Gent, Maria Middelares Hospital Gent
c Onze Lieve Vrouw Hospital Aalst
d The upper row shows the period for which the guidelines should be followed; the lower
row shows the distance advised to patients as safe &/tbl.b:
Group Ia Group IIb Group IIIc
B. Thyrotoxicosis patients
Text available for patient Usually not Yes Yes
Avoid pregnancy 3–12 m 6 m 6 m
Hospitalisation – limit 370–740 MBq 555–740 MBq 555 MBq
Hospitalisation – time 2–5 days 2–5 days 2–5 days
Sleep separately 0–2 days 7–10 days 14–21 days
No children in the house 2–14 days 5 days 14–21 days
Keep distance from children/ 2–14 days 1,5–2 m 2–3 m
pregnant partnerd 2–7 days 7–10 days 14–21 days
Keep distance from adults 1–2 m 1,5–2 m 2–3 m
1–2 m 7–10 days 14–21 days
Don’t go to work 0–7 days 7–10 days 14–21 days
Mind personal hygiene 0–2 days 7–10 days 14–21days
a Middelheim Hospital Antwerpen, St. Lucas Hospital, Brugge, Onze Lieve Vrouw
Hospital Geraardsbergen, Maria Middelares Hospital Gent
b University Hospital Gent, St. Jan Hospital Brugge, St. Lucas Hospital Gent
c Onze Lieve Vrouw Hospital Aalst
d The upper row shows the period for which the guidelines should be followed; the lower
row shows the distance advised to patients as safe &/tbl.b:
Table 1. Guidelines given for patients treat-
ed with 131I in the participating centres, di-
vided into three groups depending on the
period of sleeping separately &/tbl.c:&tbl.b:
1371
European Journal of Nuclear Medicine Vol. 25, No. 10, October 1998
ing administered. In one patient, suffering from a multi-
nodular goitre, an exceptionally high activity of
1665 MBq was administered.
In the present study, the median administered activity
to patients suffering from thyrotoxicosis amounted to 370
MBq (range 185–1665 MBq). In this group, the highest
activities were administered to 18 patients suffering from
a multinodular toxic goitre, with a median of 566 MBq
(range: 191–1665 MBq), followed by nine patients suf-
fering from a toxic autonomous nodule, with a median
activity of 500 MBq (range: 259–1158 MBq); 25 patients
suffering from Graves’ disease received a median admin-
istered activity of only 264 MBq (range: 185– 792 MBq).
A complete overview of the median (range) activities ad-
ministered to the different patient groups classified ac-
cording to the guideline category is given in Table 2.
Dose to the relatives.
The data on the doses (median, range) received by the
patients’ relatives obtained in the present study are also
summarised in Table 2. Data are classified according
to the guideline category. Figure 1 gives an overview of
the doses received by the relatives during the first
week, while Fig. 2 shows the difference in the median
doses to the partners during the first versus the second
week.
Thyroid carcinoma patients.
Considering all patients included in the study, the mean
hospitalisation period was 3.4 days (range: 2–5 days).
Patients from group I were given no guidelines after 4
days of hospitalisation. Patients from the other groups
were hospitalised for a shorter period (2–3 days) and
were advised to sleep separately for a period of 7 days
and to limit close contact for the same period.
Figure 1A illustrates the results in respect of the mea-
sured doses during the first week of observation. None
of the family members exceeded the EURATOM 96/29
limit of 1 mSv during this week.
All groups stopped receiving guidelines during the
second week of investigation. As can be seen in Fig. 2A,
in spite of the fast wash out of the 131I from the patient’s
body, the second week still contributes significantly to
the total radiation burden to the patient’s relatives. The
median dose received by the relatives of thyroid carcino-
ma patients during the 14 days following hospital dis-
Table 2. Overview of the results of the study, according to the diagnosis, family relationships and guideline catagories in respect of sleep-
ing separately &/tbl.c:&tbl.b:
Diagnosis One week Two weeks
Group I Group II Group III All groups Group I Group II Group III All groups
TCA Activity Median 5550 3870 3700 4121 5550 3700 3700 5550
(MBq) Range 3700–4200 3700–5550 3700–5550
Partner Median 106 15 94 88 222 159 371 222
(µSv) Range 68–662 12–159 12–662 136–942 136–942
Child Median 773 0 115 0 1090 281 686
(µSv) Range 0–773 281–1090
Parent Median 79 61 516 79 159 1025 787
(µSv) Range 56–65 395–638 56–638 787–1263 159–1263
TT Activity Median 370 273 333 333 370 222 333 333
ambulatory (MBq) Range 259–555 185–862 185–518 185–862 259–555 191–862 185–518 191–862
Partner Median 796 99 264 238 842 912 646 739
(µSv) Range 238–3097 0–1041 48–837 0–3097 460–2033 0–1600 162–1566 0–2033
Child Median 88 217 127 344 375 365
(µSv) Range 0–1191 101 –281 0–1191 220–655 220–655
TT Activity Median 740 1125 740 759 740 1395 740 740
hospitalised (MBq) Range 370–888 777–1665 370–1665 370–888 1125–1665 370–1665
Partner Median 535 347 181 302 764 1128 259 629
(µSv) Range 6–1064 253–929 110–251 6–1064 6–1278 629–1626 189–328 6–1626
Child Median 203 80 105 105 516 1590 193 207
(µSv) Range 8–263 61–370 103–107 8–370 217–814 101–3079 190–196 101–3079
Parent Median 2129 2129
(µSv) Range
&/tbl.b:
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charge was 281 µSv (range: 136–1263 µSv). Doses to
infinity were not calculated as a mean effective half-life
of 2.2 days [25] makes it improbable that the dose
would rise significantly after the period under observa-
tion. Due to the low number of measurements in each
group, statistical analysis of the results could not be per-
formed.
Only 2 relatives out of 19 (10%) ended up exceeding
the EURATOM 96/29 limit of 1 mSv during the period
under investigation. These people were the mother and
the little sister of young patients.
Ambulatory treated thyrotoxicosis patients.
As indicated above, patients from group I did not sleep
separately after the administration of the activity. Pa-
tients of groups II and III were advised to sleep separate-
ly and to limit close contact with other people 7 and 14
days respectively.
An overview of the results obtained during the first
week of observation is given in Fig. 1B. Only four rela-
tives out of 50 (8%) exceeded the EURATOM 96/29 lim-
it of 1 mSv during the first week of investigation. Two
out of these four were partners of patients of group I,
who did not sleep separately from the patient. The third
was a partner of a patient of group II and the fourth, a 3-
year-old child who was kept at home after the mother’s
therapy because no other arrangements could be made.
Guidelines to patients of group II ceased to apply
during the second week of observation, whereas those to
patients of groups II and III remained unaltered (i.e.
group I could sleep with their partners while group III
could not).
In Fig. 2B, a statistically significant (P<0.1) reduc-
tion in the received dose can be observed in the relatives
Fig. 1A–C. Overview of the dose received by relatives of patients
treated with 131I during the first week of observation. A Relatives
of thyroid carcinoma patients. B Relatives of ambulatory thyro-
toxicosis patients. C Relatives of hospitalised thyrotoxicosis pa-
tients. I, II and III: Different categories of guidelines depending
on the time for which the patient is advised to sleep separately. n,
Partner; , child; , parent &/fig.c:
Fig. 2A–C. Median dose received by partners of patients treated
with 131I during the first week versus the second week of observa-
tion. A Partners of thyroid carcinoma patients. B Partners of am-
bulatory thyrotoxicosis patients. C Partners of hospitalised thyro-
toxicosis patients. Groups I–III: Different categories of guidelines
depending on the time for which the patient is advised to sleep
separately. n, Week 1; n, week 2 &/fig.c:
of patients from group I, where the guidelines did not
differ from the first week. An increase in the time spent
close to the patient due to the removal of guidelines in
group II is reflected in Fig. 2B by the significantly
(P<0.1) higher dose received by the relatives during the
second week. A slight but insignificant increase in dose
was also observed in group III in spite of the longer du-
ration of the guidelines.
Based on the data summarised in Table 2, the dose to
infinity was calculated for each individual. Taking into
account all relatives, the median dose to infinity amount-
ed to 596 µSv (range: 162–2033) for a median adminis-
tered activity of 333 MBq (range: 185–862 MBq). In
general, patients’ children tended to receive a lower dose
(median: 425 µSv; range: 0–3752 µSv) than their part-
ners (median: 777 µSv, range: 0–5961 µSv), but the dif-
ference did not reach statistical significance. Relatives of
group I patients tended to receive a higher dose to infini-
ty (median: 1456 µmSv; range: 538–5961 µmSv) than
relatives of patients of group II (median: 329 µmSv;
range: 0–2102 µmSv) and group III (median: 885 µmSv,
range: 222–2145 µmSv), but again the differences were
not statistically significant.
Overall, the EURATOM 96/29 limit was violated for
13 out of 52 relatives (25%). More relatives of group I
exceeded the EURATOM 96/29 limit (50%) than rela-
tives of the other groups (21% in group II and 38% in
group III). These results show that sleeping separately
reduces the number of people who will violate the EUR-
ATOM 96/29 limit of 1 mSv/year.
Hospitalised thyrotoxicosis patients.
Patients were hospitalised for a mean period of 3 days
(range: 2–5 days). All patients were advised to limit
close contact with their relatives. As indicated above, pa-
tients of groups II and III were also advised to sleep sep-
arately from their partners for 7–10 and 21 days.
As can be seen from Table 2, patients of group II re-
ceived a median activity of 1125 MBq (range: 777–
1665 MBq), a value significantly higher (P<0.1) than the
activity received by the other groups (median 740 MBq,
range 370–888 MBq).
An overview of the results of the TLD measurements
obtained during the first week of observation is given in
Fig. 1 C. It should be noted that the guidelines issued to
group II led to a median dose to relatives which was
slightly lower than the median dose received by the rela-
tives of group I patients, in spite of the much higher ac-
tivity administered to patients in the former group. Dur-
ing the first week, only 1 person out of 23 exceeded the
EURATOM 96/29 limit of 1 mSv/year. This person re-
ceived a dose of 1064 µSv and did not sleep separately
from the patient.
During the second week of observation, guidelines to
group II patients ceased to apply, while those to groups I
and III remained unaltered (i.e. group I could sleep with
their partners while group III could not). As can be seen
in Figure 2 C, a significant dose was received by the rel-
atives during the second week of observation. For rela-
tives of patients from groups I and III this dose was low-
er than that received during the first week. However, rel-
atives of group II patients received a higher dose during
the second week, reflecting an increase in the time spent
at close proximity to the patient. The differences were
statistically significant (P<0.1) in groups I and II.
Based on the data summarised in Table 2, the dose to
infinity was calculated for each individual. Taking into
account all relatives, the median dose to infinity amount-
ed to 802 µSv (range: 7–3620 µSv) for a median admin-
istered activity of 759 MBq (range: 555–1665 MBq).
The relatives of group I patients showed the highest dose
(median: 894 µmSv; range: 7–1495 µSv); the dose to
relatives of group II patients was slightly lower (median:
819 µSv; range 639–2108) although these patients re-
ceived a significantly (P<0.1) higher activity. Relatives
of group III patients, who followed guidelines for 3
weeks, received the lowest dose to infinity (median:
325 µSv; range: 238–412). In general the patients’ chil-
dren received a significantly (P<0.1) lower dose to infin-
ity (median: 266 µSv; range: 132–3620 µSv) than did
their partners (median: 812 µSv; range: 7–2108 µSv).
Overall the EURATOM 96/29 limit of 1 mSv/year
was violated for 9 relatives out of 26 (35%). None of
these were relatives of group III patients, who followed
guidelines for 21 days.
Bedside tables.
TLDs were placed on the patient’s bedside tables of nine
patients. The median dose measured by these TLDs was
1058 µSv, with a range of 0–2727 µSv. The wide range
in the results probably derived not only from variation in
the activity administered to the patient (median activity:
555 MBq; range: 222–3700 MBq) and the duration of
hospitalisation (range: 0–5 days), but also from differ-
ences in the exact distance of the TLD from the patient.
Discussion.
Thyroid carcinoma patients
The data presented in our study confirm the results of
other studies [7, 16, 24, 25] indicating that the doses re-
ceived by relatives of thyroid carcinoma patients are
generally lower than those doses received by relatives of
thyrotoxicosis patients. This observation is due to the
lower retention (thyroid remnant) and the faster wash-
out of the 131I activity from the body of thyroid carcino-
ma patients in spite of the higher activity administered.
The doses to the relatives of thyroid carcinoma pa-
tients measured in the present study (median 281 µSv)
are somewhat higher than those presented by Mathieu et
al. [24, 25] (median 170–240 µSv).
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the partners (median 806 µSv, range 0–5961 µSv) is
higher than the median doses of 407 µSv obtained in the
study by Barrington et al. [18] and 444 µSv obtained in
the study by Thompson et al. [21] after correcting for the
difference in administered activity. In Barrington’s study,
however, guidelines covered a considerably longer peri-
od (up to 25 days). On the other hand, somewhat higher
dose values were found in the study by Mathieu et al.
[25], who reported a median dose of 1070 µSv to the
partner after 3 weeks of measurements when separate
sleeping arrangements were adopted.
It should be noted that only 5 out of 26 included chil-
dren exceeded the EURATOM 96/29 limit. Two of these
were only 3 years old and were kept at home; the highest
dose of 3752 µSv was received by a woman of 26 years
old caring for her partially disabled mother. This corre-
sponds with the study by Barrington et al. [19], in which
only two children (aged 2 and 3 years) out of 64 re-
ceived a dose of more than 1.5 mSv.
In the present study, as well as in others [5, 19, 24,
25], the children of thyrotoxic patients received a signifi-
cantly lower dose than did the patients’ partners. The
study carried out by Barrington et al. [18], on the other
hand, concluded exactly the opposite, with a lower dose
for partners (median: 220 µSv; SD: 120 µSv) and a
higher dose for the children (median: 310 µSv; SD:
580 µSv) during a period from 3 to 6 weeks. However,
in comparison with the present study Barrington et al.
[17] included younger children (range: 0.5–17 years)
who need more care and attention from the patient. In
the present study, the mean age of the children was 18
years (range 3–26 years) since all in-living children of
the patient were included, even when their age exceeded
the paediatric limit of 16 years and also because the par-
ents were advised to let children under 7 years of age
stay at another location for about 5 days.
Bedside tables
The authors expected the TLDs placed on the bedside ta-
ble of the patient to give an underestimation of the actual
dose that would be received by the patient’s partner if
they were sleeping together. However, when comparing
the dose for bedside tables (median: 1058 µSv; range:
0–2727 µSv) to the dose for partners from group I after
2 weeks of observation (median: 782 µSv, range
6–5095 µSv), the results disagree with this assumption.
The large range of values found in the present study can
probably be explained by the inaccuracy of the distance
between the patient and the TLD. These results indicate
that in vivo measurements are more reliable than simply
placing the TLD on a bedside table or calculating the
dose to the partner.
In the present study only two relatives out of 19
(10.5%) exceeded the EURATOM 96/29 limit of 1 mSv.
Furthermore, these people represent exceptions as they
were the sister of a patient aged 17 years, who slept in
the same room as the patient, and the mother of a 26-
year-old patient who did not follow the given guidelines.
On the basis of these results it therefore seems that
(a) a longer hospitalisation period of 4 days without is-
suing guidelines to the patient and (b) or a shorter hospi-
talisation period of 2–3 days while recommending sepa-
rate sleeping and limited close contact to other people
for 7 days are equally effective in limiting the radiation
burden to the 1 mSv limit. However, a longer hospital
stay will increase the total cost of the treatment and limit
the availability of the isolation room for patients treated
with 131I. In our opinion, a hospitalisation period of 2–3
days, combined with guidelines effective for 7 days, will
not place a high burden on the patient’s family life while
reducing the dose to the relatives and limiting treatment
cost. Problems can still occur following this procedure
with young patients whose parents tend to be overcaring
after the patient returns home. When this type of behav-
iour is to be expected, the patient should be kept in the
hospital longer (e.g. 4 days instead of 2).
Thyrotoxicosis patients
In the present study, 25% of the relatives of ambulatory
treated patients and 35% of the relatives of hospitalised
patients exceeded the EURATOM 96/29 limit. These re-
sults are in good agreement with those obtained in the
study by Mathieu et al. [25] where 33% of relatives ex-
ceeded the limit of 1 mSv/year. Concerning the different
sets of guidelines, 24% (group III patients with only 14
days of guidelines), 28% (group II, 7–10 days of guide-
lines) and 38% (group I, no guidelines) of the relatives
of thyrotoxicosis patients exceeded the EURATOM
96/29 limit in the present study. However, the limit was
not violated when 21 days of guidelines were issued, as
was the case for some patients of group III. Our results
show that a period of sleeping separately and restricting
close contact for 7 days is not sufficient. Implementa-
tion of a longer period of guidelines reduces both the
median dose received by the family members and the
number of people exceeding the EURATOM 96/29 lim-
it.
The median doses to infinity received by family
members of thyrotoxicosis patients presented in this pa-
per (596 µSv for ambulatory treated patients and
802 µSv for hospitalised patients) are significantly lower
than the doses calculated by Thomson et al. [20] (medi-
an to 1010 µSv for 200 MBq), O’Doherty et al. [5], (up
to 12|400 µSv for 400 MBq) and Demir et al. [11] (up to
13|300 µSv for 370 MBq) because all of these authors
presumed that no guidelines whatsoever were issued.
When our results are compared with those of studies
in which guidelines were issued to patients, the dose to
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Guidelines
The most important guideline without any doubt is
sleeping separately. This has been proven directly in the
present study by the high doses measured at the bedside
tables, with a median value of 1058 µSv. This conclu-
sion is in agreement with studies on thyrotoxicosis pa-
tients carried out by Thomson et al. [20, 21]: the highest
dose to relatives occured during the night, with a median
of 1278 µSv (SD: 4072 µSv), while only a median dose
of 240 µSv (SD: 560 µSv) occurred during the day.
O’Doherty et al. [5] even calculated that 92% of the total
dose would occur during the night if the partner did not
sleep separately from the patient.
For most of the participating centres, the duration of
the guidelines is relatively short compared with the 7–19
nights of sleeping separately calculated as necessary by
Thomson et al. [20, 21], the 2–15 nights calculated by
Hilditch et al. [30], and the even longer period of 15–26
nights calculated by O’Doherty et al. [5]. In the present
study, only a period of sleeping separately for 21 days,
as was done for some of the relatives of group III pa-
tients, was successful in keeping the dose to the partner
below the EURATOM 96/29 limit of 1 mSv. However,
where the patient’s partner is concerned, the authors sup-
port the point of view of the Belgian Ministry of Social
Affairs, Public Health and Environment [31], stating that
voluntary “helpers” who “knowingly and willingly” sup-
port patients treated with radionuclides should not be
subject to strict dose limits but rather to non-rigid dose
constraints while following the ALARA principle.
Therefore, a period of 14 nights seems to be a reason-
able compromise between the radiation protection of the
partner and the social isolation of the patient. Where low
activities are administered (<200 MBq), 7 nights of
sleeping separately will suffice. The guideline of advis-
ing parents to let children under 7 years old stay with
family or friends seems strongly recommendable [5, 11,
18]. An overview of the guidelines validated by present
study is given in Table 3.
Although not considered in the present study, avoid-
ance of physical contact with the patient and advising
the patient to follow simple hygiene rules such as flush-
ing the toilet twice and regular washing of hands are in
keeping with the ALARA principle and will certainly
help to limit both irradiation and contamination of rela-
tives. The contamination hazard has been studied previ-
ously by many authors [5, 32–34] and poses an aspect of
radiation protection of family members of patients treat-
ed with 131I that is easier to manage than the external ir-
radiation hazard [9, 15].
Conclusions
For patients suffering from thyroid carcinoma, the re-
sults of this multicentre study suggest that the patient
should be hospitalised for 2 or 3 days with an additional
7 days of sleeping separately and avoidance of close
contact to other people.
For thyrotoxicosis patients, up to 21 days of sleeping
separately might be necessary in order to strictly adhere
to the EURATOM 96/29 limit of 1 mSv/year. Therefore,
the authors propose the implementation of a non-rigid
dose constraint for people who “knowingly and willing-
ly” help patients treated with 131I, while still following
the ALARA principle. A period of sleeping separately
and limiting close contact for 14 days is chosen as a
compromise, between 7 days, which is usually too short,
and 21 days, which may be unnecessary long, consider-
ing the social isolation of the patient and the radiation
protection of the relatives.
Advising children under the age of 7 years to spend 5
days at family or friends leads to a significant dose re-
duction.
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Table 3. Proposed revision of the guidelines for patients treated
with 131I &/tbl.c:&tbl.b:
Guidelines Thyroid Thyrotoxicosis
carcinoma
Avoid pregnancy 6 months 6 months
Hospitalisation time 2–3 days 0–3 days
Sleep separately 7 days 7–14 days
No children in the house 5 days 5 days
Keep distance to children/ 7 days 7–14 days
pregnant partner 2 m 2 m
Keep distance to adults 7 days 7–14 days
2 m 2 m
Don’t go to work 7 days 7–14 days
Mind personal hygiene 7 days 7–14 days
a The upper row shows the period for which the guidelines should
be followed; the lower row shows the distance advised to patients
as safe &/tbl.b:
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In this work, eight questions regarding patient dosimetry and radiation protection issues in
radionuclide therapy using 131I have been addressed. The results of this work will be
discussed briefly and conclusions drawn for each separate question. Also possible future
research or extended research going on in our laboratory is addressed to.

5.1. Can the patient dose after radionuclide therapy be determined before
administration of the therapeutic activity?

Although previously published studies (Fielding et al., 1991; Tristam et al, 1996) also
compare pre-and post-therapy dosimetry for patients treated with 131I-MIBG, our study is the
first in which a series of total body scintigraphies are compared before (123I-MIBG) and after
(131I-MIBG) therapy in the same circumstances, thereby combining “the best of both worlds”.

The combination of the pre-therapeutical and post-therapeutical data sets can be
represented by a bi-exponential curve through the combined data cloud. An example of one
of these bi-exponential fits is shown in the figure below.


















Fig 5.1. Bi-exponential fit through pre-therapeutic 123I-MIBG and post-therapeutic 131I-MIBG
points.
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Our results show that the 131I-MIBG therapy dose can be predicted from a single set
of 123I-MIBG dosimetric scans for all following 131I-MIBG therapies, taking into
account a correction factor of 1.20 (R = 0.85). Moreover, 123I-MIBG pre-therapy scans
do not need to be repeated before each therapy except when the biodistribution of
131I-MIBG is expected to change rapidly. This is the case especially in patients where
bone marrow invasion is present. In view of the encouraging results of this study,
dosimetric pre-therapeutic 123I-MIBG scanning is now routinely carried out before
administration of 131I-MIBG therapy in the Ghent University Hospital.

We will try to extend our study into tumor and organ dosimetry, by scanning on
another camera (the GE-IRIX system) that allows dual isotope scanning, and scatter
correction using triple energy windows around the 364 keV photo peak of 131I.
Results for 131I-MIBG therapy are not yet available since the number of patients
presenting for 131I-MIBG therapy has fallen over the last year. The same protocol is
however applied to patients undergoing 131I-lipiodol therapy.


5.2. What are the differences for the absorbed dose to organs and the effective
dose to the patient between calculations by means of the Monte Carlo code
MCNP and the MIRDOSE program?

In this study the absorbed dose to the organs and the effective dose to the patient was
determined by 2 different methods for HCC patients receiving 131I-lipiodol therapies.

In general it should be stated that MCNP results are more accurate than MIRDOSE results.
This is due to the inclusion of patient specific modelling of the liver and of the tumour within
the liver in the MCNP program. Additionally, by including the tumour into the geometry, extra
S-factors (e.g. Sliver←tumour, Stumour←liver, Slungs←tumour,...) could be calculated by the MCNP
program, which is impossible with MIRDOSE. Finally, in our MCNP calculations, the
contribution of the electron-dose deposited outside the tumour was also included.
However, due to the medium energy of the β  rays of 131I, the contribution of the additional S
values to the dose is less important, and all other organs were not modelled patient
specifically. Therefore, the mean absorbed dose for most organs was comparable between
the MCNP calculations and MIRDOSE. Overall, a good correlation (R = 0.93) was obtained
between the effective dose calculated by Monte Carlo simulation techniques (mean 2.01 Sv)
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and the effective dose calculated by MIRDOSE (mean 2.05 Sv).  Such would not be the case
however, when high-energy beta emitters (such as 188Re) were considered.
In fact, the only organ where the differences in absorbed dose were significant was the
tumour. The absorbed dose to the tumour was systematically higher calculated by MIRDOSE
than by MCNP. The difference is due to the linear interpolation that is necessary between the
tabulated discrete sphere sizes (and corresponding S-factors) tabulated in the “nodule
module” of MIRDOSE. The difference is particularly large (mean 15%) for the smaller
tumours (< 3 cm).

In our study, uptake measurements were carried out using bi-planar scans. The scans were
not corrected for scatter, and the attenuation correction was performed homogeneously for
the whole abdominal region.
Nowadays, oncological scans in the nuclear medicine department of the Ghent University
Hospital, are performed on the GE-IRIX gamma camera system. This system is capable of
dual isotope scanning using either a flood sheet filled with 57Co or  99mTc placed underneath
the patient, or the “Beacon” moving line source. The IRIX system is also capable of using
triple energy windows, allowing for correction of scatter. All these methods are currently
being investigated to correct for scatter and inhomogeneous attenuation and should improve
the determination of the correct activity inside the organs of interest.
In order to use correct volumes and anatomical localisation of the organs into completely
patient specific phantoms, fusion between SPECT and CT or MRI images can now be
performed and will hopefully lead to the determination of patient specific S-factors. However,
the use of SPECT imaging is not evident in patients treated with 131I, since the
radiopharmaceutical is highly concentrated in the tumour(s) inside the liver. It is therefore not
evident to obtain images rendering sufficient quality in order to enable the performance of
dosimetry. HCC patients are recently also treated with 188Re-lipiodol where SPECT scanning
should be easier due to the lower energy of the γ-rays

In our study, we found a significant 131I uptake in the thyroid of patients treated with 131I-
lipiodol. This was never described by the early authors (Raoul et al., 1988; Madsen et al.,
1988; Nakajo et al., 1988) and in fact, the guidelines of the European Association of Nuclear
Medicine (EANM, 2000) do not recommend any special precautions. The reason for this
iodine uptake in the thyroid remains unclear since non-ionic contrast media injected during
the arterioscopic procedure contain free inorganic iodide and the amount of stable iodide
injected should saturate the thyroid iodine uptake mechanism. Of course, other mechanisms,
such as the existing slight iodine deficiency in Belgium, may also play a role.
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We also calculated a significantly lower mean absorbed dose to the thyroid of 7.2 Gy for
patients who received thyroid blocking compared to the other patients (13.8 Gy). Since our
patient group is relatively small to compare 2 treatment schedules, a larger (68 therapies)
randomised prospective study (Bacher et al., 2002) was undertaken. The results of that study
confirm the halving of the absorbed dose to the thyroid when thyroid blocking is
administered. Since thyroid blocking is well tolerated and 131I-lipiodol treatment is usually
repeated so the thyroid will be irradiated several times, we now systematically give KI to all
these patients.

5.3 How do the results of a biological dosimetry method such as the in vitro
micronucleus assay compare to a physical dosimetry method based on bi-
planar scans?

For patients treated with 131I-MIBG and patients treated with 131I-lipiodol, the ETBD calculated
by means of the in-vitro micronucleus assay were compared to the total body doses
calculated by means of MIRDOSE based on bi-planar scans.

For patients treated with 131I-MIBG, the mean individual dose response curve is given in
figure 5.2.














Fig. 5.2: Mean individual dose response curve for patients treated with 131I-MIBG.

0
20
40
60
80
100
120
140
0 0,5 1
In vitro 60Co dose (Gy)
Increase in micronuclei per 1000 binucleated cells
Patient dosimetry and radiation protection issues for radionuclide therapy using 131I.
Discussion and conclusions. 5.  6
After exclusion of 131I-MIBG treated patients having lymphocyte division problems due to
chemotherapy and/or lymphocyte dilution caused by whole blood transfusions, a significant
correlation was found between the ETBD, based on the in-vitro micronucleus assay and the
MIRD dose (r = 0.87).

On the average, the obtained ETBD values were 70% of the calculated MIRD values. This
can be attributed to the differences in dose rate between the acute in vitro irradiation for the
determination of the dose response and the in vivo irradiation at low dose rate, which allows
a longer time for repair of DNA damage. It has been suggested that in this case it would be
better to use only the linear component of the standard dose response (IAEA, 2001).
Applying this procedure to the MIBG data, the slope of the linear regression between the
MIRD dose and the ETBD data is 0.92, which equals unity taking into account the
uncertainty. Therefore, our results further support the procedure proposed by the IAEA.

In order to take the low dose rate effect into account, experiments using low dose rate
irradiation are planned. For 188Re, the low dose rate can be mimicked by long-term irradiation
of the lymphocytes in a water bath at 37°C in a low dose rate 60Co beam. For 131I however,
the duration of irradiation would be too long using this methodology. We therefore have to
add 131I into the cell culture medium, In this way the cells can be exposed for a longer period
of time, after which, the 131I is washed from the medium. In this way, we hope to determine
individual dose response curves at low dose rate for each patient.

For the HCC patients treated with 131I-lipiodol, no correlation was found between the ETBD
values and the MIRD doses. For 7 out of 11 patients the ETBD values were higher than the
MIRD dose. The lymphocytes in HCC patients clearly no longer show the normal in vivo
behaviour of lymphocytes and are therefore not suitable for biological dosimetry purposes.

In order to avoid the problem with cellular division of the lymphocytes after mitogen
stimulation, the “premature chromosome condensation” or PCC method was tried out. The
addition of Calyculin A to the culture medium condenses the chromosomes in interphase,
allowing scoring of chromosome aberrations in interphase. This was compared to the normal
scoring of dicentrics. As it turned out, the PCC technique can be used for 131I-lipiodol
patients, but the results present no improvement on the results of dicentrics scoring (De
Ruyck et al., 2002).
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Since the ETBD doses in the HCC patients treated with 131I-lipiodol patients were higher than
the physical dosimetry results, the question of whether or not these patients could be
radiosensitive was raised. For a number of cancer patient groups, an enhanced
radiosensitivity was found (Darroudi et al., 1995; Scott et al., 1999; Terzoudi et al., 2000;
Baria et al. 2001; Baeyens et al., 2002). In order to get an answer for this question, individual
dose response curves were determined for these patients using dicentrics scoring. The
individual dose response curves included 5 dose points and compared to those of normal
healthy volunteers (De Ruyck K., unpublished results). In fact, the dose response curves of
the HCC patients were slightly, but not significantly, elevated in comparison to the healthy
volunteers, as shown in figure 5.3. It was therefore concluded that HCC patients do not show
an increased radiosensitivity compared to healthy volunteers (De Ruyck K, unpublished
results).

















Fig. 5.3.: Comparison of dose response curves of HCC patients compared to healthy
volunteers.
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5.4. What is the effect of multiple radionuclide therapies on the micronucleus
yield?

The micronucleus yield after multiple subsequent 131I-MIBG and 131I-lipiodol therapies was
investigated.
For all patients an initial large increase in micronucleus yield after administration of the
therapy had at least partially recovered by the time of the subsequent therapy. A similar
effect was reported by Watanabe et al. (1998) after 89Sr therapy for painful bone metastases
and by Fenech et al. (1990) for patients treated with external partial body radiotherapy.
The short mean half-life of 3.9 months of lymphocytes, found in the present study, is due to
an increased turnover of lymphocytes. This result can be compared to micronucleus yields
returning to pre-treatment values within 4 to 6 months, found in children treated repeatedly
for thyroid carcinoma as reported by Streffer et al. (1998). From the analysis of the Goiaña
accident, Ramalho et al. (1995) concluded that the disappearance of unstable chromosome
aberrations (such as micronuclei) is dose dependent. The mean lymphocyte half-life in their
study was 5.3 months in people receiving up to 1 Gy while it was significantly less (3.7
months) in people receiving more than 1 Gy, a result very similar to the shortened
lymphocyte half-life determined in the present study.


5.5. What is the residual damage after radionuclide therapy one year after
treatment?

In the present study the FISH method was used to explore the potential DNA damage
induced by radioiodine therapy in hyperthyroidism patients one year after treatment by
scoring the translocations involving chromosomes 2, 4 and 8.
The present study has shown that the frequency of translocations involving chromosomes 2,
4 and 8 was 5 times higher than in an age-matched control population. The stable properties
of translocations explain the high frequency of aberrations found in the present patient data.
Micronucleus data on hyperthyroidism patients treated with the same medical protocol as the
patients of this study result in estimated doses ranging from 0.16 Gy to 0.55 Gy with an
average of 0.34 Gy, 1 week after administration of the 131I. The dose estimates resulting from
chromosome painting are higher (mean 0.79 Gy ±  0.22 Gy). The difference in dose can
partly be explained by the difference in the dose received after 1 week and 1 year. Zanzonico
(1997) showed that the standard administered activity of 1036 MBq of 131I, required for a
standard 70 Gy absorbed dose to the thyroid for treatment of Graves’ disease, yielded a high
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blood absorbed dose of 1.50 Gy due to the relatively long effective half-life of 131I in the
thyroid and high serum concentrations of long-lived protein-bound activity. This estimate is
twice as high as our value but the administered activity in their study was higher: 130% of the
administered activity in our study.
The observation of a high number of translocations as well as an over-representation of
translocations involving chromosome 4 in present study suggests the need for medical
follow-up of these patients. Chromosome 4 translocations t(4,11) are regularly associated
with a specific type of acute leukaemia and probably initiate the development of this disease
(Kapelushnik et al., 1991; Palau et al., 1991). However, after over 40 years of treating
patients with 131I no epidemiological evidence on secondary carcinomas has been found
(Clarke S.1991; Hall P.  et al. 1992; Halnan K. E.1992).

The final conclusion, how far an increase in chromosomal translocation frequency reflects an
increased risk for cancer at the individual level, is not solved at the moment.

5.6. Can 131I treatment be considered as an in vivo conditioning dose leading to
an in vivo adaptive response?

The existence of an in vivo adaptive response was investigated in a population of 131I treated
hyperthyroidism patients by comparing the micronucleus yield after in vitro irradiation
(conditioning dose) of blood samples taken from these patients before and after 131I therapy
(adaptation dose). The definition of an adaptive response is that the biologic effect inflicted
by a high dose of a mutagen is less when the organism has been exposed to a chronic small
dose of a mutagen beforehand, than when the high dose is given without previous exposure.
In our study, an adaptive response exists when the number of micronuclei induced after in
vitro irradiation before 131I therapy is significantly higher than the increase in micronuclei after
the same in vitro irradiation after 131I therapy as is shown in figure 5.4.
Patient dosimetry and radiation protection issues for radionuclide therapy using 131I.
Discussion and conclusions. 5.  10














Fig. 5.4: Significant drop in the increase in micronucleus yield after in vitro irradiation after
131I therapy as compared to before therapy: adaptive response.

In the present study, an adaptive response could be visualized in 8 out of 20 individuals.
These results are the first demonstration that exposure to low doses of ionising radiation
during medical treatment (conditioning dose) makes human peripheral blood lymphocytes
less susceptible to cytogenetic damage for subsequent in vitro irradiation at higher doses
(challenge dose). They show that the iodine treatment can act as a conditioning dose and
can induce an in vivo adaptive response, but that an inter-individual variability exists. The
reproducibility of the data for the control population further shows that the observed
differences cannot be attributed to cell culture or technical effects. Therefore, the observation
can be interpreted as an adaptive response phenomenon. Recently, our group has also
reported the existence of an in vivo adaptive response for temporary nuclear workers
exposed to low dose rate irradiation for a short period of time (Thierens et al., 2002).

Investigation for the mechanism behind the adaptive response is beyond the scope of this
study. Adaptive response may primarily involve a qualitative change in damage repair or
processing (Joiner, 1994). Only a few cGy are needed to produce an adaptive response in
human lymphocytes (Wolff, 1992). Also in present study, the mean ETBD in the patient
subgroup showing an adaptive response was only 45 cGy, so selective “killing” of more
radiosensitive sub-populations of lymphocytes is highly unlikely.
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Adaptive response phenomena have been studied primarily on human lymphocyte cultures,
but also on other cell cultures such as mouse bone marrow cells, mouse spermatocytes,
mouse embryonic cells as well as mouse and human fibroblasts. It has also been described
in different cancer cell lines (UNSCEAR 1994), but the existence of an adaptive response on
thyroid cancer cell lines has not been reported yet.

The observation that only 8 out of 20 patients showed an adaptive response after receiving
131I therapy, clearly demonstrates the inter-individual variability. Both the pre-therapy in vitro
irradiation and the in vivo exposure by the 131I therapy lead to a somewhat higher increase in
micronuclei in the patient group showing an adaptive response compared to the other patient
group. The in vitro dose response curve for the patients showing an adaptive response
seems to normalize after 131I therapy (adaptation dose). Although the results did not reach
statistical significance, it therefore seems that the adaptive response in present study is seen
especially in radiosensitive individuals.

For the 8 patients showing an adaptive response, an in vivo exposure to ionising radiation
(challenge dose) following the 131I therapy (adaptation dose) would very probably lead to less
genetic damage. Therefore, in the evaluation of the detrimental effects of exposure to
radiation, some consideration should be given to the importance of biological defence
mechanisms.

5.7. Are there specific problems for biodosimetry of cancer patients?

In a healthy population, the mutagenic potential of a certain treatment or drug can be
determined by cytogenetic techniques, such as the in vitro cytokinesis-blocked micronucleus
assay (Ramalho et al., 1995; Thierens et al., 1995; Thierens et al., 1999). The success of the
micronucleus assay in genetic toxicology depends mainly on normal peripheral lymphocyte
kinetics and their intact cellular division mechanisms. As can be seen from the rather low
success rate in our study of patients treated with 131I-MIBG or 131I-lipiodol, this may not
always be the case for a cancer patient population.

Since 131I-MIBG therapy is a second line treatment for neuroblastoma in Belgium, all of the
included neuroblastoma patients received chemotherapy before the 131I-MIBG therapy.
Earlier chemotherapy can jeopardize the evaluability of the micronucleus assay due to cell
division inhibition. As a result, we were not able to count 1000 binucleated cells in some
blood samples.
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Additionally, a subset of neuroblastoma patients received "whole blood" transfusions before
the second blood sample was taken. The infusion of fresh lymphocytes dilutes the resident
long-term irradiated lymphocytes. This is illustrated in some patients by an unusually low
increase or even a significant reduction in micronucleus yield after therapy.
In spite of these problems, a significant correlation (shown in figure 2) was found between
the ETBD, based on the standard micronucleus dose response relationship and the MIRD
dose (r = 0.87). In the present study, the use of in vitro dose response relationship of the
considered patients instead of a standard curve had no major impact on the results.
For 131I-MIBG patients we can therefore conclude that biological dosimetry based on the
micronucleus assay is feasible, provided it does not follow too closely after chemotherapy so
the lymphocyte count is restored to normal values and the blood sample after therapy is
taken before blood transfusions are given to the patient.

For the patients treated with 131I-lipiodol, only 12 out of 17 131I-lipiodol therapies could be
evaluated by the micronucleus assay, due to the low number of lymphocytes present in their
peripheral blood and a reduction of their proliferation capacity. Here, the problem is a
consequence of the hypersplenism occurring in many of these patients. The radiation effect
on these lymphocytes caused stimulation problems in the blood samples after treatment.
For the HCC patients, no correlation was found between the ETBD values and the MIRD
doses. For 7 out of 11 patients the ETBD values were higher than the MIRD doses. Several
studies point to an increased in vitro chromosomal radiosensitivity in cancer patients,
especially in breast cancer patients (Darroudi et al., 1995; Scott et al., 1999; Terzoudi et al.,
2000; Baria et al. 2001; Baeyens et al., 2002). We could not study this effect in HCC patients
because the initial low amount of lymphocytes present in the blood of these patients due to
hypersplenism, did not allow splitting up the blood samples and determining the in vitro dose
response. Further research on the biological radiosensitivity of HCC patients is necessary.
Preliminary results on dicentrics scoring for this patient group in the laboratory (De Ruyck et
al., 2002) do not point to an increased in vitro radiosensitivity in 131I-lipiodol treated patients
(fig 5.4.). Also, external physiological factors such as diet, pharmaceuticals or hormone
levels can influence the number of chromosome aberrations (Robert et al, 1997; Greenrodt
et al, 2001). The lymphocytes in HCC patients clearly no longer show the normal in vivo
behaviour of lymphocytes and are therefore not suitable for biological dosimetry purposes
using the in vitro micronucleus assay.

The present study shows that the results of cytogenetic biodosimetry of cancer patients
based on the in vitro micronucleus assay have to be treated with caution. Not only the in vitro
dose response may be different, but also hypersplenism and other confounding factors due
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to adjuvant therapy such as chemotherapy or blood transfusions have to be taken into
account.

5.8. What is the radiation burden of relatives of patients treated with 131I for
thyroid diseases when implementing different sets of guidelines?

In the present work, relatives of patients receiving 131I therapy for hyperthyroidism or thyroid
carcinoma were monitored during 2 weeks after the patient returned home. A multicentre
approach was favoured to obtain results with several different regimens of routine radiation
protection guidelines.

The data presented in this study confirm the results of other studies (Harbert and Wells,
1974; Culver and Dworkin, 1992; Mathieu et al., 1997) observing that the doses received by
relatives of thyroid carcinoma patients are generally lower than the doses received by
relatives of hyperthyroidism patients. This observation is due to the lower retention (thyroid
remnant) and the faster wash out of the 131I activity from the body of thyroid carcinoma
patients in spite of the higher administered activity: only 2 out of 19 relatives of thyroid
carcinoma patients exceeded the EURATOM-29 (1996) limit of 1 mSv. It seems therefore,
that based on these results both the method of a longer hospitalisation period of 4 days
without issuing guidelines to the patient, or a shorter hospitalisation period of 2 to 3 days,
while recommending separate sleeping and limiting close contact to other people for 7 days,
are equally sufficient in limiting the radiation burden to the 1 mSv limit. However, a longer
hospital stay of the patient will increase the total cost of the treatment and limit the availability
of the isolation room for patients treated with 131I.

For hyperthyroidism patients, in the present study, 25% of the relatives of ambulatory treated
patients and 35% of the relatives of hospitalised patients exceeded the EURATOM-29 (1996)
limit. Concerning the different sets of guidelines, our results show that a period of sleeping
separately and restricting close contact for 7 days is not sufficient. Implementation of a
longer period of guidelines reduces both the median dose received by the family members
and the number of people exceeding the EURATOM-29 (1996) limit.

In the present study, as well as in other studies (O’Doherty et al., 1993; Barrington et al.,
1997; Mathieu et al., 1996; Mathieu et al., 1997), the children of hyperthyroid patients
received a significantly lower dose than the patient’s partners did. It should be noted that only
5 out of 26 of the children included in the study exceeded the EURATOM-29 (1996) limit.
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This is probably partly due to the mean age of the children in our study: 18 years (range 3 to
26 years) since all in-living children of the patient were included, even when their age
exceeded the paediatric limit of 16 years and also because the parents were advised to let
children under 7 years of age stay at another location for about 5 days.

We have also studied the opposite relationship: dose received by the parents for 131I-MIBG
therapy of the child. The results were quite different from 131I therapy. The doses were much
higher than for 131I therapy, because children are not self-sufficient and need to be helped by
the parents. The doses to the relatives were usually higher when the administered or
retained activity was higher, when the child was younger and when parents were given less
information about the guidelines to apply. It was further observed that the dose for the
patient’s mother (mean 595 µSv, range: 72-2272) was usually higher than for the father
(mean: 262 µSv, range: 44-814).

Recently the question has been raised whether or not family members should be considered
as “members of the public” or rather as “people knowingly and willingly helping” in the care of
their relatives. For the latter category, maybe less stringent dose limits could be applied.
Since long hospital stays would increase the cost for radionuclide therapies considerably and
longer periods of applying guidelines would isolate the patient even further, we adhere to the
judgement of the Belgian High Counsel of Medicine, to consider relatives of patients treated
with radionuclides not as member of the public, but instruct them with useful guidelines to
reduce their dose within the context of ALARA.

As far as the dose to the nurses in the isolation ward is concerned, their mean effective dose
amounts to 240 µSv a year (SD: 70 µSv). (Kolindou et al., 2002). When considering that
these nurses took care of 168 patients during 631 days and that these patients were treated
with various kinds of radionuclide therapies (65 with 131I for thyroid diseases, 64 with 131I-
lipiodol for HCC, and 39 with 131I-MIBG for neuroblastoma), these results show that
radionuclide therapy by means of 131I is safe for both occupationally exposed personnel as
well as members of the public. For comparison, the nurses taking care of the 14000
diagnostic procedures, receive a mean yearly dose of 2.56 mSv a year (SD: 1.46) (Kolindou
et al., 2002). This value is ten times higher than the dose received by the nurses in the
isolation ward.

The problem of 131I contamination to relatives of patients treated with 131I has not been taken
into account here. Recently however, the contamination problem has been addressed by
several authors (Lassmann et al., 1998). The mean dose to the thyroid for relatives from the
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incorporation of 131I was measured to be 0.2 mSv, with a maximum of 2 mSv for children and
0.4 mSv for adults. This corresponds to an effective dose of 0.01 mSv. As this dose is small
compared to the dose received by external radiation, it does not necessitate a longer
hospitalisation for the patients.

For patients suffering from thyroid carcinoma, the results of this multicentre study suggest to
implement hospitalisation of the patient for 2 or 3 days and an additional 7 days of sleeping
separately and avoiding close contact to other people as principal guidelines.
For hyperthyroidism patients, up to 21 days of sleeping separately could be necessary in
order to strictly abide by the EURATOM-29 (1996) limit of 1 mSv/y Therefore, the authors
propose the implication of a non-rigid dose constraint for people who “knowingly and
willingly” help patients treated with 131I, while still following the ALARA principle. A period of
sleeping separately and limiting close contact of 14 days is chosen as a compromise,
between 7 days which is usually too short and 21 days which may be unnecessary long,
considering the social isolation of the patient and the radiation protection of the relatives.
Advising children under the age of 7 to spend 5 days at family or friends leads to a significant
dose reduction
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5.9. General conclusions.

Several important conclusions regarding radionuclide therapy using 131I-labeled
radiopharmaceuticals can be drawn from the present work:

For patients treated with radionuclide therapies, both the biological dosimetry results as the
physical dosimetry results point to relatively high absorbed organ doses and high effective
doses. Since these therapies are often repeated and since some therapies can be curative,
the need for individual dosimetry in these patient groups is obvious.

For patients treated with 131I-MIBG it is feasible to calculate the dose to the patient after 131I-
MIBG therapy from a single set of 123I-MIBG pre-therapeutic scans taking into account a
factor of 1.20.

For 131I-MIBG patients there is a good correlation (r= 0.87) between the total body dose
obtained with biological and physical dosimetry methods. However, due to the difference in
between the acute in vitro irradiation of the blood samples and the long term in vivo
irradiation allowing more time for repair of genetic damage, it is better to use only the linear
component of the in vitro dose response.

For patients treated with 131I-lipiodol, Monte Carlo simulation by MCNP, taking into account
the patient’s specific anatomy is preferable to MIRDOSE calculations especially to assess
the absorbed dose to the tumour.

For patients treated with 131I for hyperthyroidism and thyroid carcinoma, the lack of evidence
for development of secondary neoplasms after 131I-therapy may be explained by the
existence of an in vivo  adaptive response. Therefore, at least some consideration should be
given to the importance of biological defense mechanisms in risk assessments after low
doses of ionising radiation.

The results of cytogenetic dosimetry of cancer patients, based on the in vitro micronucleus
assay, have to be treated with caution. For 131I-MIBG patients biological dosimetry is feasible,
provided it does not closely follow chemotherapy so the lymphocyte counts are restored to
normal values and the blood sample after therapy is taken before blood transfusions are
given to the patient. For 131I-lipiodol patients however, due to the existing hypersplenism, the
lymphocytes no longer show the normal in vivo behaviour and may therefore lead to
erroneous results in biological dosimetry.
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In order to restrict the dose to relatives of patient treated with 131I to acceptable levels, we
propose to combine restrictive guidelines (especially separate sleeping arrangements), for a
period of 14 days for hyperthyroidism patients and of 7 days for thyroid carcinoma patients,
with a short hospitalisation stay of 2 to 3 days. In this way therapies can be kept cost
effective without socially isolating the patient.
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Summary.

Introduction.
In Nuclear Medicine, for radionuclide therapy, high activities (several GBq) of 131I-labelled
radiopharmaceuticals are administered to the patient in order to have a significant
therapeutic effect. Although the injected radiopharmaceuticals mainly target the tissue under
treatment, inevitably the rest of the body is also irradiated to some extent. Since radionuclide
therapies are often repeated, can be considered as curative in the treatment of some
tumours and is also applied for treatment of benign diseases like hyperthyroidism, it is
important to determine the radiation dose to the patient as measure of the mutagenic effect
of the therapies and to determine the risk for development of fatal cancers.
A second problem caused by the radiopharmaceutical inside the patient, is the radiation
hazard they pose for their relatives. EURATOM-29 (1996) has recommended reducing the
limit for members of the public for exposure to ionising radiation to 1 mSv/y. It is therefore
necessary to determine what safety measures have to be taken to ensure that the dose to
the relatives does not exceed this dose limit.
In this work the patient dose and the dose to the relatives has been determined for different
radionuclide therapies using 131I-labeled radiopharmaceuticals: 131I for thyroid diseases, 131I-
MIBG for neuroendocrine tumours and 131I-lipiodol for treatment of HCC. Both physical and
biological dosimetry methods have been used.

Aim of the study.
In this work, an answer to the following eight questions was sought:
1. Can the whole body dose for the patient from radionuclide therapy be predicted
before administration of the therapeutic activity?
2. What are the differences for the absorbed dose to the organs and the effective dose
to the patient between calculations by means of the Monte Carlo code  MCNP  and
the MIRDOSE  program?
3. How do the results of a biological dosimetry method such as the in vitro micronucleus
assay compare to a physical dosimetry method based on bi-planar scans?
4. What is the effect of multiple radionuclide therapies on the micronucleus yield?
5. What is the residual damage after radionuclide therapy one year after treatment?
6. Can 131I treatment be considered as an in vivo conditioning dose leading to an in vivo
adaptive response?
7. Are there specific problems for biodosimetry of cancer patients?
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8. What is the radiation burden to relatives of patients treated with 131I for thyroid
diseases when implementing different sets of guidelines?

Materials and methods.
Physical dosimetry methods in nuclear medicine make use of the MIRD (Medical Internal
Radiation Dosimetry) formalism:
DT  = Σs Ãs  . S(T←S)
Where:DT  = Absorbed dose to target organ T
Ãs   = Cumulated activity in the considered source organ S
S = The organ specific S factor:
The cumulated activity values are determined by means of a set of biplanar scans (including
a syringe containing a known activity of 131I) taken at various intervals after administration of
the radiopharmaceutical. ROI’s were drawn over the relevant structures. Attenuation
correction factors were calculated based on phantom experiments. The Cumulated activity
was determined by time-integrating the activity values in each ROI to infinity. 
The absorbed dose to the organs and the effective dose to the patient were calculated with
the MIRDOSE-3  standard software program, providing standard S factors for phantoms, sex
and age matched to the patient. For HCC patients treated with 131I-lipiodol, liver and tumour
volume and position, determined by CT or MRI, were introduced in a standard Bodybuilder
phantom. Patient specific S factors were then calculated using the Monte Carlo simulation
program MCNP-4B.
For 131I-MIBG patients, a set of pre-therapeutic 123I-MIBG scans was taken only once before
administration of the first 131I-MIBG therapy. The total body dose predicted by the 123I-MIBG
scans was compared to a bi-exponential fit through the combination of the pre-therapeutic
123I-MIBG and the post therapeutic 131I-MIBG data.
The total body dose to the patient was also determined by a biological dosimetry method:
the in vitro micronucleus assay. For each patient, a first blood sample was taken before
therapy and a second one 7 days later. For patients treated with 131I and 131I-MIBG, the first
blood sample was irradiated in vitro with 60Co γ-rays to determine the individual dose
response curve.  For some 131I patients, also the second blood sample was irradiated in vitro,
and the in vitro increase in micronuclei before and after therapy was compared. In this set-
up, an adaptive response is represented by a significant decrease of the in vitro induced
micronucleus yield after therapy as compared to before therapy.
From the increase in micronucleus yield between the first and the second blood sample, the
equivalent total body dose (ETBD) was calculated using either the individual dose response
or the dose response of a control population as determined by Thierens et al (1999).  The
ETBD was compared to the total body dose calculated by means of MIRDOSE for 131I-MIBG
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and 131I-lipiodol patients. For 131I-lipiodol patients the ETBD was also compared to MCNP
results.
In order to study the residual damage after 131I therapy for thyroid diseases one year after
administration of the activity, the incidence of translocations (stable chromosome
aberrations) was scored by tricolour fluorescence in-situ hybridisation (FISH) for
chromosomes 2, 4 and 8. From the genomic translocation frequencies, derived using Lucas
formula (1999), whole body doses were calculated based on the in vitro dose response.
In order to determine the real-life radiation burden to relatives, a multicenter study was
set up. Wearing a TLD dosimeter on the wrist for 7 days monitored a total of 94 relatives of
65 patients, treated with 131I for thyroid diseases. 61 relatives agreed to wear another TLD
for an additional 7 days. The 8 participating centres were divided in 3 groups according to the
period of time they advised their patients to sleep separately. Group I, II and III respectively
advised their patients to sleep separately for 0, 7 to 10 and 14 to 21 days. The median dose
to infinity received by the relatives for the three different sets of guidelines was calculated
and compared to the EURATOM-26 dose limit.

Results and discussion.
1. There has been a lot of discussion in the literature as to whether or not the kinetics of a
tracer amount of 123I-MIBG and a therapeutic amount of 131I-MIBG are the same. However,
we found a significant correlation between pre-therapy total body dose and the total body
dose based on a bi-exponential fit through a combination of the data (R = 0.85) when all
following therapies of the patients are considered (correction factor = 1.20). Our results show
that it is acceptable to benefit from the better count statistics and the better image resolution
of 123I to calculate the total body dose pre-therapy, taking into account a factor of 1.20.
2. For 131I-lipiodol patients, the MIRDOSE results for the mean absorbed dose to the
tumour (mean 144 Gy, SD: 68) are systematically higher than the MCNP values (mean 129.5
Gy, SD: 58.2), which are more reliable. The difference is due to the linear interpolation that is
necessary between the tabulated discrete sphere sizes (and corresponding S-factors)
tabulated in the “nodule module” of MIRDOSE. The difference is particularly large (mean
15%) for the smaller tumours (< 3 cm).
For all other organs and for the calculation of the effective dose, a good correlation (R =
0.93) was obtained between MCNP and MIRDOSE results.
3. After exclusion of patients having lymphocyte division problems due to chemotherapy
and/or lymphocyte dilution caused by whole blood transfusions, a significant correlation was
found between the ETBD and the MIRD dose (r = 0.87) for patients treated with 131I-MIBG.
On the average, the obtained ETBD values were 70% of the calculated MIRD values. This
can be attributed to the differences in dose rate between the acute in vitro irradiation for the
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determination of the dose response and the in vivo irradiation at low dose rate, which allows
a longer time for repair of DNA damage.
4. For all 131I-MIBG and 131I-lipiodol patients receiving multiple therapies, an initial large
increase in micronucleus yield after administration of the radionuclide therapy had at least
partly recovered by the time of the subsequent therapy. The analysis of these data point to a
shortened mean half-life of the lymphocytes (T1/2 = 3.9 months). These results are similar to
the results calculated by Ramalho et al. (1995) concluding that the disappearance of
micronuclei is dose dependent and equals 3.7 months in people receiving more than 1 Gy.
5. The frequency of translocations for patients treated with 131I for thyroid diseases was 5
times higher than in an age-matched control population. Micronucleus data on these patients
result in estimated doses ranging from 0.16 Gy to 0.55 Gy with an average of 0.34 Gy, 1
week after administration of the 131I. The dose estimates resulting from chromosome painting
are higher (mean 0.79 Gy ±  0.22 Gy). The difference in dose can partly be explained by the
difference in the dose received after 1 week and 1 year. The observation of a high number of
translocations as well as an overrepresentation of translocation involving chromosome 4 in
present study suggests the need for medical follow-up of these patients.
6. For 8 out of 20 patients treated with 131I, the in vitro increase in micronucleus yield was
higher before than after therapy. These results are the first demonstration that exposure to
low doses of ionising radiation during medical treatment (conditioning dose) makes human
peripheral blood lymphocytes less susceptible to cytogenetic damage for subsequent in vitro
irradiation at higher doses (challenge dose). Although the results did not reach statistical
significance, it seems that the adaptive response in present study is seen especially in
radiosensitive individuals. Today, although we know that radiation can be harmful, a fact
based scientific approach to evaluate the detrimental effects of low levels of radiation should
be adopted. While making such a risk assessment, at least some consideration should be
given to the importance of biological defense mechanisms that could be stimulated by low
levels of radiation. However, the results presented here do not mean that exposure to low
levels of ionizing radiation by itself is beneficial, since higher levels of chromosome
aberrations are found in exposed populations compared to non-exposed populations.
7. The success of the micronucleus assay in genetic toxicology depends mainly on
normal peripheral lymphocyte counts and their intact cellular division mechanisms. As can be
seen from the rather low success rate in our study of patients treated with 131I-MIBG or 131I-
lipiodol, this may not always be the case for a cancer patient population.
For 131I-MIBG patients, biological dosimetry based on the micronucleus assay is feasible,
provided it does not follow too closely after chemotherapy so the lymphocyte count is
restored to normal values and the blood sample after therapy is taken before blood
transfusions are given to the patient. A significant correlation (shown in figure 2) was found
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between the ETBD and the MIRD dose (r = 0.87). The use of in vitro dose response
relationship of the considered patients instead of a standard curve had no major impact on
the results.
For the patients treated with 131I-lipiodol, the low number of lymphocytes present in their
peripheral blood and a reduction of their proliferation capacity caused stimulation problems in
the blood samples after treatment. Here, the problem is a consequence of the hypersplenism
occurring in many of these patients. No correlation was found between the ETBD values and
the MIRD doses. The lymphocytes in HCC patients clearly no longer show the normal in vivo
behaviour of lymphocytes and are therefore not suitable for biological dosimetry purposes.
8. The real-life radiation burden for relatives of patients treated with 131I for thyroid
diseases was determined. For thyroid carcinoma patients both the method of a longer
hospitalisation period of 4 days without issuing guidelines to the patient, or a shorter
hospitalisation period of 2 to 3 days, while recommending separate sleeping and limiting
close contact to other people for 7 days, are equally sufficient in limiting the radiation burden
to the 1 mSv limit. However, a longer hospital stay of the patient will increase the total cost of
the treatment and limit the availability of the isolation room for patients treated with 131I.
For hyperthyroid patients, 25 % of the relatives of ambulatory treated patients and 35 % of
the relatives of hospitalised patients exceeded the EURATOM-29 (1996) limit. However, the
limit was never violated when 21 days of guidelines were issued. Therefore, the authors
propose the implication of a non-rigid dose constraint for people who “knowingly and
willingly” help patients treated with 131I, while still following the ALARA principle. A period of
sleeping separately and limiting close contact of 14 days is chosen as a compromise,
between 7 days which is usually too short and 21 days which seems unnecessary long,
considering the social isolation of the patient.
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Inleiding.
In de nucleaire geneeskunde worden voor radionuclidentherapie hoge activiteiten
(verschillende GBq) van 131I gemerkte radiofarmaca aan de patiënt toegediend om een
therapeutisch effect te bekomen. Hoewel deze radiofarmaca voornamelijk in het doelwit
orgaan terechtkomen, wordt onvermijdelijk ook de rest van het lichaam in zekere mate
bestraald. Omdat radionuclidentherapieën vaak herhaald worden, als curatief beschouwd
kunnen worden in de behandeling van sommige tumoren en ook ingezet worden voor de
behandeling van goedaardige aandoeningen (hyperthyreoïdie), is het belangrijk de dosis
voor de patiënt te berekenen als maat voor het mutageen effect van de behandeling en voor
de berekening van het risico op ontwikkeling van fatale secundaire maligniteiten.
Een tweede probleem dat ontstaat door de toegediende radiofarmaca, is het stralingsrisico
dat de patiënten vormen voor hun familieleden. Volgens richtlijnen van EURATOM
(EURATOM-26, 1996) dient de dosis voor personen van het publiek beneden1 mSv per jaar
te blijven. Maatregelen die de dosis voor de familieleden hiertoe verlagen moeten dus
uitgewerkt worden.
In dit werk worden de dosis voor de patiënt en zijn familieleden bepaald voor verschillende
radionuclidentherapieën die gebruik maken van 131I-gemerkte radiofarmaca: 131I voor de
behandeling van schildklieraandoeningen, 131I-MIBG voor de behandeling van
neuronendocriene tumoren en 131I-lipiodol voor de behandeling van leverkanker. Er wordt
gebruik gemaakt van zowel fysische als biologische dosimetrische technieken.

Doel van de studie:
In dit werk werd een antwoord gezocht op de volgende 8 vragen:
1. Kan de patiëntdosis bij radionuclidentherapie voorspeld worden?
2. Wat zijn de verschillen voor de geabsorbeerde dosis in de organen en de effectieve
dosis tussen dosimetrische berekeningen met MCNP  en MIRDOSE?
3. Wat is de correlatie tussen biologische dosimetrie met de in vitro micronucleus test en
fysische dosimetrie gebaseerd op bi-planaire scans?
4. Wat is het effect van herhaaldelijke therapieën op het aantal  micronuclei?
5. In hoeverre zijn de stralingseffecten van 131I therapie nog aanwezig 1 jaar na de
toediening?
6. Kan 131I therapie beschouwd worden als een in vivo conditioneringsdosis die
aanleiding geeft tot een in vivo adaptieve respons?
7. Zijn er specifieke problemen bij biologische dosimetrie van kanker patiënten?
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8. Wat is de stralingsdosis opgelopen door familieleden van schildklierpatiënten
behandeld met 131I wanneer verschillende sets van leefregels gehanteerd worden?

Materiaal en methoden.
Fysische dosimetrie methoden binnen de nucleaire geneeskunde maken gebruik van het
MIRD (medical internal radiation dosimetry) formalisme:
DT  = Σs Ãs  . S(T←S)
Met:DT  = Geabsorbeerde dosis in het doelwit orgaan: T
Ãs   = Gecumuleerde activiteit in het bronorgaan: S
S(T←S)  = De orgaan specifieke S factor:
De gecumuleerde activiteit wordt bepaald aan de hand van een set bi-planaire scintigrafische
scans, genomen op verschillende tijdstippen na toediening van het radiofarmacon. ROI’s
(regions of interest) worden getrokken rond de relevante orgaan structuren. Attenuatie
correctie factors worden bepaald uit fantoom metingen. De gecumuleerde activiteit wordt
berekend door de activiteit in de ROI’s te integreren.
In dit werk wordt de geabsorbeerde dosis in elk orgaan en de effectieve dosis voor de patiënt
berekend via het programma MIRDOSE-3, waarbij gebruik wordt gemaakt van standaard S
factoren voor fantomen die qua geslacht en leeftijd overeenkomen met de patiënt. Voor de
131I-lipiodol patiënten werden de positie en het volume van de tumor en de lever, bepaald via
CT of MRI, in een standaard “Bodybuilder” fantoom ingebracht. Via Monte Carlo simulaties
met het MCNP programma konden dan patiënt specifieke S factoren berekend worden.
Voor 131I-MIBG patiënten werd één set van 123I-MIBG scans genomen voor een reeks 131I-
MIBG therapieën. De dosis van de therapie, berekend uit 123I-MIBG scans werd vergeleken
met de dosis berekend uit een bi-exponentiële fit door de combinatie van 123I-MIBG en 131I-
MIBG data.
De dosis voor de patiënt werd ook berekend via biologische dosimetrie met de in vitro
micronucleus test. Bij elke patiënt werd een bloedstaal afgenomen voor therapie en een
tweede 7 dagen na therapie. Voor 131I en 131I-MIBG patiënten werd het eerste bloedstaal in
vitro bestraald met 60Co om de individuele dosis repons relatie te bepalen. Voor sommige 131I
patiënten werd dit ook gedaan bij het tweede bloedstaal en de toename in micronuclei na in
vitro bestraling voor en na therapie werd vergeleken. Een adaptieve respons geeft in het
staal na therapie een significante verlaging in de vorming van micronuclei in vergelijking met
voor therapie.
De toename in micronuclei na radionuclidentherapie in vergelijking tot voor therapie, geeft de
equivalente lichaamsdosis (ETBD) bepaald via de individuele dosis respons relatie of de
dosis respons relatie van een controle populatie (Thierens et al., 1999). De ETBD werd
vergeleken met de dosis berekend door MIRDOSE voor de 131I-MIBG en 131I-lipiodol
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patiënten. Voor 131I-lipiodol patiënten werd de ETBD ook vergeleken met de dosis berekend
via MCNP.
Om de stralingseffecten nog overblijvend 1 jaar na de radionuclidentherapie te bepalen, werd
de incidentie van stabiele chromosoom aberraties (translocaties) gemeten door driekleuren
fluorescentie in-situ hybridisatie (FISH) op chromosoom 2, 4 en 8. Uit de frequenties van de
translocaties die op deze manier verkregen werden kon de lichaamsdosis bepaald worden
via de formule van Lucas (1999) na  het bepalen van de in vitro dosis respons relatie.
Om de reële stralingsbelasting van familieleden van 131I patiënten te bepalen werd een
multicenter studie opgezet. De 8 deelnemende centra werden opgesplitst in 3 groepen
afhankelijk van de tijd die zij adviseerden aan de familieleden om apart van de patiënt te
slapen. Groep I, II en III adviseerden respectievelijk 2, 7 tot 10 en 14 tot 21 dagen. In totaal
werd de stralingsbelasting van 94 familieleden van 65 patiënten gemeten via
thermoluminescente dosimeters (TLD’s) die gedurende 7 dagen aan de pols gedragen
werden. 61 familieleden stemden toe om een tweede TLD te dragen voor de volgende 7
dagen. De geïntegreerde dosis voor de familieleden in de drie groepen werd vergeleken.

Resultaten en discussie.
1. In de literatuur bestaat onenigheid over het al dan niet overeenkomen van de kinetiek
van een 123I-MIBG speuractiviteit en een 131I-MIBG therapeutische activiteit. In ons werk werd
echter een goede correlatie (r = 0.85) gevonden tussen de dosis voorspeld op basis van de
pretherapeutische 123I-MIBG scans en de dosis berekend via een bi-exponentiële fit door de
combinatie van 123I-MIBG en 131I-MIBG data, zelfs wanneer alle volgende therapieën in
beschouwing werden genomen (correctie factor = 1.20). Onze resultaten tonen aan dat het
aanvaardbaar is gebruik te maken van de betere beeldresolutie en telstatistiek van 123I om de
dosis bij 131I-MIBG therapie te voorspellen, wanneer met een factor van 1.20 wordt rekening
gehouden.
2. Bij 131I-lipiodol patiënten werd de geabsorbeerde dosis in de tumor systematisch
overschat door MIRDOSE (gemiddeld 144 Gy, SD: 68) in vergelijking met het meer
betrouwbare MCNP programma (gemiddeld 130 Gy, SD: 58). Het verschil is te wijten aan de
lineaire interpolatie die in MIRDOSE nodig is tussen de getabuleerde diameters (en
corresponderende S-factoren) in de “nodule module” voor de tumorbron. Het verschil is
vooral belangrijk (15%) voor kleinere tumoren (< 3 cm). Voor de geabsorbeerde dosis van
andere organen en voor de effectieve dosis werd een goede correlatie (r = 0.93) bekomen
tussen MCNP en MIRDOSE.
3. Een goede correlatie werd vastgesteld (r = 0.87) tussen de ETBD berekend met de
micronucleus testen en de MIRD dosis van 131I-MIBG patiënten, na uitsluiting van patiënten
waarbij problemen met de lymfocytaire celdeling werden vastgesteld, veroorzaakt door
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vroegere chemotherapie en/of waarbij de bestraalde lymfocyten gemengd werden met
onbestraalde door toediening van bloedtransfusie. Gemiddeld was de ETBD slechts 70%
van de MIRD dosis. Dit verschil is te wijten aan de verschillen in dosistempo tussen de acute
in vitro bestraling voor het bepalen van de dosis respons relatie en de in vivo bestraling met
laag dosistempo, die meer tijd laat voor DNA herstel.
4. Voor al de 131I-MIBG en 131I-lipiodol patiënten die herhaaldelijke therapieën kregen
toegediend, was de initiële stijging in micronuclei na therapie gedeeltelijk genormaliseerd bij
aanvang van de volgende therapie. Deze data wijzen op een verkort halfleven van de
lymfocyten (3.9 maanden). Dit is in overeenstemming met de resultaten van Ramalho et al.
(1995): de snelheid waarmee de micronuclei verdwijnen is dosis afhankelijk en voor dosissen
groter dan 1 Gy gelijk aan 3.7 maanden.
5. De translocatie frequentie bij 131I patiënten was 5 keer hoger dan in een controle
populatie. Micronucleus data geven een dosis van gemiddeld 0.34 Gy, 1 week na toediening
van het 131I. De dosis schatting via FISH is hoger: 0.79 ±  0.22 Gy. Het verschil in dosis kan
gedeeltelijk verklaard worden door het verschil in dosis tussen 1 week en 1 jaar. De hoge
translocatie frequentie en de overmatig voorkomen van chromosoom 4 translocaties nopen
tot zorgvuldige medische opvolging van deze patiënten.
6. Bij 8 van de 20 onderzochte patiënten die behandeld werden met 131I voor
schildklieraandoeningen, werd bij in vitro bestraling van de bloedstalen na therapie een
beduidend lagere toename in micronuclei gevonden dan voor therapie. Deze resultaten
tonen aan dat blootstelling aan een lage stralingsdosis voor een medische behandeling
(conditioning dose) humane perifere lymfocyten minder gevoelig maakt aan de
cytogenetische schade veroorzaakt door daaropvolgende in vitro bestraling met een hoge
dosis (challenge dose). Hoewel de resultaten niet statistisch significant waren, lijkt het erop
dat de adaptieve respons vooral bij stralingsgevoelige individuen kon worden vastgesteld.
Ons inziens dient men rekening te houden met dit fenomeen bij de evaluatie van de risico’s
verbonden aan blootstelling aan straling.
7. Het welslagen van de micronucleus test in genetische toxicologie hangt grotendeels
af van het intact blijven van de celdelingmechanismen. Zoals blijkt uit de nogal beperkte
slaagkans ervan bij onze patiënten, is dit niet altijd het geval voor kanker patiënten.
Voor 131I-MIBG patiënten, is biologische dosimetry via de micronucleus test mogelijk,
wanneer de radionuclidentherapie niet direct volgt op de chemotherapie. Bovendien moet het
bloedstaal na therapie genomen worden voordat men bloedtransfusies toedient. Wij vonden
een significante correlatie tussen de ETBD en de MIRD dosis (r = 0.87). Het gebruik van een
individueel bepaalde dosis respons relatie in plaats van de standaard dosis respons relatie
voor gezonde vrijwilligers had geen invloed op deze resultaten.
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Voor patiënten behandeld met 131I-lipiodol werden problemen met de stimulatie tot celdeling
vastgesteld in bloedstalen genomen na therapie. Deze worden veroorzaakt door het lage
aantal lymfocyten dat deze patiënten nog bezitten en een vermindering van hun proliferatie
capaciteit. Deze problemen zijn het gevolg van het hypersplenisme dat bij een aantal van
deze patiënten voorkomt. Er werd geen correlatie gevonden tussen de ETBD en de MIRD
dosis. Deze lymfocyten vertonen duidelijk niet langer het normale in vivo gedrag en zijn
daarom niet geschikt voor biologische dosimetrie met de in vitro micronucleus test.
8. Voor schildklier carcinoom patiënten blijken de methoden van een lange
hospitalisatieduur (4d) en een korte hospitalisatieduur (2d), waarbij gedurende 1 week
leefregels aan de patiënten worden opgelegd, beide even effectief in het reduceren van de
dosis voor de familieleden tot 1 mSv. Een langere hospitalisatieduur laat de kostprijs voor de
therapie echter gevoelig stijgen en beperkt de beschikbaarheid van isolatiekamers.
Voor familieleden van hyperthyreoïdie patiënten bleek de dosis voor 25% van de
familieleden van ambulante patiënten en 35% van de familieleden van gehospitaliseerde
patiënten hoger dan de dosislimiet van 1 mSv, behalve wanneer de gedurende 21 dagen
leefregels werden opgelegd. Wij stellen dan ook voor om voor familieleden van 131I patiënten,
een soepelere dosisbeperking op te leggen terwijl het ALARA principe toch nog gevolgd
wordt. Een periode van leefregels gedurende 14 dagen wordt voorgesteld als compromis
tussen 7 dagen, die duidelijk te kort zijn en 21 dagen die de patiënt sociaal isoleren.
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(Recommendations for regulation concerning 131I therapy for thyroid disease
based on practical data from the UH Gent).

2003:
* January 1997 – May 2003: PhD. in Medical Sciences:
Thesis: Department for Anatomy, Embryology, Histology and Medical Physics..
Promotor: Prof. H. Thierens. Co-promotor: Prof. R.A. Dierckx, MD
Title: Patient dosimetry and radiation protection issues for radionuclide therapy
using 131I.


Jobs:

2000-2001:
* from 1st february 2000 untill 30th september 2001: Chemist at the Division of Nuclear
Medicine, University Hospital of Ghent, Ghent, Belgium.

From 2001:
* Since 1st  October 2001: Health Physicist at the Department of Health Physics at the
University of Ghent, Ghent, Belgium.


General Information.

Languages:
Dutch: mother tongue
English, French, German: fluently
Spanish, Turkish: notions

Programming:
Fortran 77

Software:
Microsoft Windows, Mackintosh, Hermes, MIRDOSE 3, Matlab, SPSS

Hobby’s:
Scubadiving (2* CMAS, member of “Sepia” club, Ghent, Belgium).
 Dog training (member of “Kwispel” club, Beervelde, Belgium)
Travelling, Swimming, Hiking, Off road, Reading, Cinema...
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Publications.

International Publications.

1995:
1. P. Vandamme, J. Hommez, M. Vancanneyt, M. Monsieurs, B. Hoste, B. Cookson, CH.
Wirsing von König, K. Kersters, P. Blackall. “Bordetella hinzii” sp. nov. Isolated from
poultry and humans. Int. J. Syst. Microbiol. 1995, 37- 45.

1997:
2. C. Van De Wiele, K. Osmanagaoglu, M. Monsieurs, K. Van Laere, JM. Kaufman, RA
Dierckx. 201-Tl scintigraphy does not allow visualisation of the thyroid in euthyroid and
hyperthyroid patients treated with amidarone. Nucl. Med. Comm. 1997, 18: 513 – 516.

1998:
3. M. Monsieurs, H. Thierens, RA. Dierckx, K. Casier, E. De Baere, L. De Ridder, C. De
Sadeleer, H. De Winter, M. Lippens, S. Van Imschoot, D. Wulfrank, M. Simons. Real-life
radiation burden to relatives of patients treated with iodine-131: a study in eight centres
in Flanders (Belgium). Eur. J. Nucl. Med.  1998, 25: 1368 – 1376.

1999:
4. M. Monsieurs, H. Thierens, C. Van De Wiele, A. Vral, I. Meirlaen, H. De Winter, C. De
Sadeleer, L. De Ridder, JM. Kaufman, RA. Dierckx. Estimation of risk based on biological
dosimetry for patients treated with radioiodine. Nucl. Med. Comm. 1999, 20; 911-917.

2000:
5. M. Monsieurs, H. Thierens, A. Vral, C. Van De Wiele, L. De Ridder, RA. Dierckx.
Adaptive response in patients treated with 131I. J. Nucl. Med. 2000, 41; 17-22.

6. K. Van Laere, M. Koole, T. Kauppinen, M. Monsieurs,  L. Bauwens, RA. Dierckx, Non
uniform transmission in brain SPECT using 201Tl, 153Gd and 99mTc static line sources:
antropomorphic dosimetry studies and influence on brain quantification. J. Nucl. Med.
2000 in press.

7. H. Thierens, M. Monsieurs, B. Brans, T. Van Den Driessche, I. Christiaens, RA Dierckx.
Dosimetry form organ to cellular dimensions. Comp. Med. Imag. 2000; 25(2):187-193.

2001:
8. M. Monsieurs, H. Thierens, A. Vral, B. Brans, L. De Ridder and RA. Dierckx. Patient
dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumors. Nucl. Med.
Comm. 2001; 22:367-374.

9. V. Lambert, H. Thierens, M. Monsieurs, C. Roncancio, C. Laurent. Translocation
frequencies in patients treated one year earlier with radioactive iodine for thyrotoxicosis.
Intl. J. Radiat. Biol. 2001, 77(6): 679-685.

2002:
10. B. Brans, M. Monsieurs, G. Laureys, JM. Kaufman, H. Thierens, RA Dierckx: Thyroidial
uptake and radiation dose after repetitive I-131-MIBG treatments: influence of
potassiumiodide for thyroid blocking. Medical and Pediatric Oncology, 2002, 38: 41-46.
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11. K. Bacher, B. Brans, M. Monsieurs, F. De Winter, RA Dierckx H. Thierens. Thyroidal
uptake and radiation dose after 131I-lipiodol treatment: is thyroid blocking by
potassiumiodide necessary? Eur. J. Nucl. Med., 2002; 29(10):1311-1316...

12.M. Monsieurs, B. Brans, K. Bacher, S. Van De Putte, RA Dierckx, H. Thierens. Patient
dosimetry for neuroendocrine tumours based on 123I-MIBG pre-therapy scans and 131I-
MIBG post therapy scans. Eur. J. Nucl. Med., 2002, 29(12): 1581-1587.

13.M Monsieurs, K. Bacher, B. Brans, A. Vral, L. De Ridder, RA Dierckx, H. Thierens.
Patient dosimetry after 131I-lipiodol therapy. Eur. J. Nucl. Med., 2003, 30(4): 554-561.

14.M. Monsieurs, A. Vral, B. Brans, L. De Ridder, RA Dierckx, H. Thierens. Application of
the micronucleus assay in patients treated with radionuclide therapies: results and
limitations. Mutagenesis, in revision.

National Publications.

1999:
1. M. Monsieurs, H. Thierens, A. Vral, C. Van De Wiele, L. De Ridder, RA Dierckx.
Cytogenetische studies bij patiënten behandeld met 131I-NaI voor
schildklieraandoeningen of met 131I-MIBG voor neuroblastoma. (Cytogenetic studies
on patients treated with 131I for thyroid disease or with 131I-MIBG for neuroblastoma)
Tijdschr. Nucl. Geneesk. 1999; 21 (2): 53-58.
2002:
2. B. Brans, M. Monsieurs, K. Bacher, F. De Vos, H. Thierens, G. Slegers, R.A.
Dierckx. Toepassingen van de radionuclidentherapie: radiofarmaca,
werkingsmechanismen en stralingsbescherming. Tijdschrift voor geneeskunde, 2002;
58 (17):1090-1097.

3. B. Lambert, B. Brans, M. Monsieurs, G. Laureys, R. Rubens, S. Van Belle, R.A.
Dierckx. Toepassingen van 131I-MIBG therapie bij neuroendocriene tumoren.
Tijdschrift voor geneeskunde 2002; 58(17): 1098-1106.

4. K. Bacher, M. Monsieurs, B. Lambert, R. Dierckx, H. Thierens. Towards individual
patient dosimetry in metabolic radiotherapy. Ann. Belg. Ver. Stralingsbescherming,
2002, 27(4): 183-189.


Book chapters.

1999:
1. H. Thierens, M. Monsieurs, T. Vandendriessche, I. Christiaens, RA Dierckx.
Dosimetry form organ to cellular dimensions. Proceedings of the international
congres on New Technologies in Nuclear Medicine. Mol (Belgium) 5-6 may 1999.
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International Communications.

1994:
1. P. Segers, M. Vancanneyt, L. Hauben, M. Monsieurs, E. Falsen, JF. Bernardet, P.
Vandamme, K. Kersters. Polyphasic taxonomy of Flavobacterium  and Weeksella
species. 7th International Congress of bacteriology and Applied Microbiology
Division. Prague (Chechoslovakya), June, 1994.

1996:
2. M. Monsieurs, JP. Van Haelst, C. Van De Wiele, B. Brans, M. Simons,H. Thierens,
RA. Dierckx. Radioiodine uptake curve allows estimation of the obligatory
hospitalisation time for iodine-131 treated hyperthyroid patients. International
Symposium on Radioiodine. Mayo Clinic, Rochester (Minnesota), 24 – 27 August,
1996.

3. M. Monsieurs, C. Van De Wiele, B. Brans, M. Simons, H. Thierens, RA. Dierckx.
Iodine-131 therapy in hyperthyroid patients and thyroid carcinoma patients: Validation
of routine guidelines. International Symposium on Radioiodine. Mayo Clinic,
Rochester (Minnesota), 24 – 27 August, 1996.

4. M. Monsieurs, C. Van De Wiele, B. Brans, M. Simons, H. Thierens, RA Dierckx.
Impact of ICRP-60 on the routine guidelines given after iodine-131 therapy:
preliminary results. European Association of Nuclear Medicine Congress.
Copenhagen (Denmark), 14 – 18 September, 1996.

5. M. Monsieurs, JP. Van Haelst, C. Van De Wiele, B. Brans, M. Simons, RA. Dierckx,
H. Thierens. Prédiction de la durée d’hospitalisation de patients hyperthyréoidièns
trâités à l’iode-131 partant de la courbe de captation d’une dose traceuse. 35eme
Colloque de Médicine Nucléaire de la langue française. Lille (France), 16 –18 octobre
1996. Médicine nucléaire: Imagerie fonctionelle en métabolique 1996; 20:499.

1998:
6. M. Monsieurs, H. Thierens, RA. Dierckx, A. Vral, C. Van De Wiele, G. Laureys, H.
De Winter, JM. Kaufman, L. De Ridder. Cytogenetic study of equivalent total body
dose to patients treated with 131I and 131I-MIBG for thyroid carcinoma and
neuroblastoma. International Congress of Nuclear Oncology, Antalya (Turkey), 28th
April- 2nd May, 1998.

7. B. Brans, G. Laureys, C. D’Hooge, M. Monsieurs, RA. Dierckx. Stage IV
Neuroblastoma: When is bone scintigraphy really usefull? International Congress of
Nuclear Oncology, Antalya (Turkey), 28th April- 2nd May, 1998.

8. M. Monsieurs, H. Thierens, RA. Dierckx, K. Casier, E. De Baere, L. De Ridder, C. De
Sadeleer, H. De Winter, M. Lippens, S. Van Imschoot, D. Wulfrank, M. Simons. Real-
life radiation burden to relatives of patients treated with I-131 for benign and
malignant thyroid disease: a multicenter study in 8 centres in Flanders (Belgium).
Society of Nuclear Medicine Meeting, Toronto (Canada), 7 – 13 June, 1998. J. Nucl.
Med. 1998; 39: 189P.

9. M. Monsieurs, H. Thierens, L. De Ridder, C. Van De Wiele, A. Vral, RA. Dierckx. In-
vivo adaptive response in patients treated with 131I for malignant and benign thyroid
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disease. Joint World Federation of Nuclear Medicine and European Association of
Nuclear Medicine and Biology Congress Berlin (Germany), 30th August – 4th
September, 1998. Eur. J. Nucl. Med. 1998; 25: 1137.

10. S. Vandenberghe, M. De Keukeleire, M. Koole, M. Monsieurs, P. Lahorte, RA.
Dierckx. Risk analysis in a department of Nuclear medicine. 8th  Biennial and 2nd
African Congress, South- African Society of Nuclear Medicine, Cape Town (South
Africa), 7 – 9 October, 1998. Proceeding Eight biennal and 2nd African cngress, P78.

1999:
11. K. Van Laere, L. Bouwens, M. Monsieurs, RA. Dierckx. Society of Nuclear Medicine
Meeting, Los Angeles (USA), 6 – 10 June 1999. J. Nucl. Med. 1999; vol 40: 283 P.

12. M. Monsieurs, H. Thierens, A. Vral, B. Brans, L. De Ridder, RA Dierckx. Biological
dosimetry after single and multiple subsequent 131-I-MIBG therapies using the
cytokinesis-blocked micronucleus assay. Symposium on “Frontiers in Nuclear
Medicine Technology”, Mol (Belgium), 6-7 May 1999. Tijdschr. Nucl. Geneesk. 1999,
21(3): 101.

13. M. Monsieurs, H. Thierens, A. Vral, B. Brans, L. De Ridder, RA Dierckx.
Radiotoxicity after 131-I-MIBG therapy using the micronucleus assay. European
Society of Nuclear Medicine Congress. Barcelona (Spain), 9 -13 October 1999. Eur.
J. Nucl. Med. 1999; 26: 1211

14. M. Monsieurs, H. Thierens, A. Vral, B. Brans, L. De Ridder, RA Dierckx. Biological
dosimetry after subsequent 1312-I-MIBG therapies using the cytokinesis- blocked
micronucleus assay. European Society of Nuclear Medicine Congress. Barcelona
(Spain), 9 -13 October 1999. Eur. J. nucl. Med. 1999; 26: 1214.

15. B. Brans, J. Versijpt, F. De Winter, O. De Winter, M. Monsieurs, RA Dierckx. Lithium
as an adjunct in the treatment of Graves’ thyrotoxicosis with small-pool syndrome:
effect on outcome. European Society of Nuclear Medicine Congress. Barcelona
(Spain), 9-13 October 1999. Eur. J. Nucl; med. 1999; 26: 1214.

16. S. Vandenberghe, Y. D’Asseler, M. Koole, M. Monsieurs, R. Vandewalle, I.
Lemahieu, RA Dierckx. Physical evaluation on 511 keV imaging with gamma camera
and PET. IEEE on Medical Imaging and Nuclear Science. Seattle (USA), October
1999. IEEE proceedings MIC 1999 short paper.

2000:
17. F. De Winter, H. De Winter, P. Van Crombrugge, B. Brans, M. Monsieurs, RA
Dierckx. Methimazole pretreatment lowers the calculated I-131 dose in
hyperthyroidism. SASNM Millenium congress and autumn school 2000.
Bloemfontein, 10 –14 april 2000. Proceedings congress 2000: p38.

18. M. Monsieurs, H. Thierens, A. Vral, B. Brans, L. De Ridder, RA Dierckx.
Radiotoxicity after 131I-MIBG therapy for neuroblastoma and carcinoid tumors. Society
of Nuclear Medicine Annual Meeting, St. Louis, (USA), 3-7 june 2000. J. Nucl. Med.
2000, 41 (5): 272P.
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19. M. Monsieurs, J. Kallisvaart, D. Van Dijk, B. Brans, RA Dierckx, H. Thierens. Real-
life radiation burden to family members and nursing staff caring for 131I-MIBG treated
patients. Society of Nuclear Medicine Annual Meeting, St. Louis, (USA), 3-7 june
2000. J. Nucl. Med. 2000, 41 (5): 272 P.

20. M.  Monsieurs, H. Thierens, B. Brans, S. van De Putte, G. Laureys, RA. Dierckx.
Patient dosimetry based on a combination of 123I-MIBG and 131I-MIBG biplanar scans
for 131I-MIBG therapy: correlation with thrombocytopenia. European Society of
Nuclear Medicine Congress. Paris (France), 2-7 September 2000. Eur. J. Nucl. Med.
2000 27/8.

21. B. Brans, M.Monsieurs, G. Laureys, F. De Winter, H. Thierens, RA Dierckx.
Thyroidal uptake of 131I after blocking with potassiumiodide in patients treated with
131I-MIBG therapy. European Society of Nuclear Medicine Congress. Paris (France),
2-7 September 2000. Eur. J. Nucl. Med. 2000: 27/8.

22. P. De Bondt, J. Kint, M. Monsieurs, J. Kuyvenhoven, P. Gemmel, G. Slegers, RA
Dierckx. ISO certification in nuclear medicine. European Society of Nuclear Medicine
Congress. Paris (France), 2-7 September 2000. Eur. J. Nucl. Med. 2000: 27/8.

23. K. Bacher, H. Thierens, M. Monsieurs, B. Brans, F. De Winter, L. Defreyne, RA
Dierckx. Evaluation of radiation exposure during administration of 131I-lipiodol
therapy. European Society of Nuclear Medicine Congress. Paris (France), 2-7
September 2000. Eur. J. Nucl. Med. 2000: 27/8.

2001:
24. K. Bacher, H. Thierens, S. Van De Putte, M. Monsieurs, B. Brans, RA Dierckx.
188Re-lipiodol: prediction of the patient dose based on 131I-lipiodol bi-planar scanning
and Monte-carlo simulation. European Society of Nuclear Medicine Congress. Napels
(Italy), 25-29 August 2001.

25. K. Bacher, B. Brans, R. Troisi, M. Monsieurs, L. Defreyne, P. Vanlangenhove, I.
Colle, B. De Hemptinne, H. Thierens, RA Dierckx. 131I-lipiodol therapy : influence of
potassiumiodide on thyroidal uptake and dose. European Society of Nuclear
Medicine Congress. Napels (Italy), 25-29 August 2001.

26. M. Monsieurs, A. Vral, B. Brans, L. De Ridder, RA Dierckx, H. Thierens. Application
of the micronucleus assay in patients treated with radionuclide therapies : results and
limitations. European Environmental Mutagen Society annual congress, Ghent
(Belgium), September 2001.

2002:
27. A. Kolindou, E. Entok, M. Monsieurs, RA. Dierckx. Dose to nurses taking care of
patients in an isolation wrad after 131-I radionuclide therapy. Turk. J. Nucl. Med.
2002, 11(1): pp38.

28. M. Monsieurs, K. Bacher, A Vral, L. De Ridder, RA Dierckx, H Thierens. Patient
dosimetry after 131I-lipiodol therapy. European Society of Nuclear Medicine Congress.
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29. M. Monsieurs, B. Brans, K. Bacher, S. Van De Putte, RA Dierckx, H. Thierens.
Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumors based on 123I-
MIBG pre-therapy scans and 131I-MIBG post therapy scans.  European Society of
Nuclear Medicine Congress. Vienna (Austria), August 31 – September 4, 2002,
Accepted for oral  presentation.
2003:
30. M. Monsieurs, F. De Vos, J. caussin, F. Jamar, RA Dierckx, H. Thierens.
Radionuclide therapy in Belgium: a 6 year inventory. European Society of Nuclear
Medicine Congress, Amsterdam (Netherlands) 23-27 August 2003. submitted.


National Communications.

1998:
1. M. Monsieurs, I. Meirlaen, A. Vral, C. Van De Wiele, K. Casier, G. Laureys, H. De
Winter, L. De Ridder, RA. Dierckx, H. Thierens. Micronucleus Induction in peripheral
blood lymphocytes of patients treated with 131I and 131I-MIBG for thyroid carcinoma and
neuroblastoma: preliminary results of a multicenter study. Belgisch Genootschap voor
Nucleaire Geneeskunde, Bruxelles (Belgium),14th February, 1998.

2000:
2. P. De Bondt, J. Kint, M. Monsieurs, J. Kuyvenhoven, P. Gemmel, G. Slegers, RA.
Dierckx. ISO certification in nuclear medicine. Belgisch Genootschap voor Nucleaire
Geneeskunde, Bruxelles (Belgium), 7th October 2000.

2001:
3. K. Bacher, H. Thierens, M. Monsieurs, B. Brans, L. Defreyne, P. Vanlangenhove, RA
Dierckx. Evaluation of radiation exposure during the administration of 131I-lipiodol.
Belgisch Genootschap voor Nucleaire Geneeskunde, Knokke (Belgium), 18-20 May
2001.

4. K. Bacher, B. Brans, R. Troisi, M. Monsieurs, L. Defreyne, P. Vanlangenhove, I. Colle,
B. de Hemptinne, H. Thierens, RA Dierckx. 131I-lipiodol therapy: influence of
potassiumiodide on thyroidal uptake and dose. Belgisch Genootschap voor Nucleaire
Geneeskunde, Knokke (Belgium), 18-20 May 2001.

5. K. Bacher, H. Thierens, S. Van De Putte, M. Monsieurs, B. Brans, RA Dierckx. 188Re-
lipiodol: prediction of the patient dose based on 131I-lipiodol bi-planar scanning and
Monte-Carlo simulation. Belgisch Genootschap voor Nucleaire Geneeskunde, Knokke
(Belgium), 18-20 May 2001.

6. M. Monsieurs,  F. De Vos, F. Jacobs, G. Slegers, RA Dierckx. Designing a state of the
art hotlab in a nuclear medicine division. Belgisch Genootschap voor Nucleaire
Geneeskunde, Knokke (Belgium), 18-20 May 2001.

7. J. Kint, M. Monsieurs, F. Jacobs, F. De Vos, C. Van De Wiele, D. Welvaert, RA
Dierckx. Problems and solutions while implementing an ISO-9002 certification for a
nuclear medicine division. Belgisch Genootschap voor Nucleaire Geneeskunde, Knokke
(Belgium), 18-20 May 2001.
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8. F. Jacobs, M. Monsieurs, F. De Vos, E. Nolf, RA Dierckx. Setting up a prevention plan
for a nuclear medicine facility. Belgisch Genootschap voor Nucleaire Geneeskunde,
Knokke (Belgium), 18-20 May 2001.

9. I. Dekeyser, F. De Vos, M. Monsieurs, G. Slegers, RA Dierckx. Quality control of
radiopharmaceuticals. Belgisch Genootschap voor Nucleaire Geneeskunde, Knokke
(Belgium), 18-20 May 2001.



Thesises.

1994:
1. “Taxonomische studie van enkele klinische flavobacteria en “Bordetella hinzii”.
Scriptie voorgelegd tot het behalen van de graad van licenciaat in de Biotechnologie”.
Promotor: K. Kersters.

1996
2. “Aanbevelingen tot regelgeving i.v.m. 131-I therapie voor schildklieraandoeningen op
basis van praktijkgegevens uit het UZ Gent.
Scriptie ingediend tot het behalen van de graad van gediplomeerde in de
gespecialiseerde studie van de biomedische en klinische ingenieurstechnieken, optie
stralingsfysica”.
Promotor: H. Thierens.


Peer reviewed grants.

1996:
1. Adac Advanced Clinical Research Grant.
Company:  Adac.
Subject: “Optimisation of 131I-therapy to patient and environment” (Optimalisatie van de
131I therapie naar patiënt en omgeving). Multicenter study (1/2/1997-1/2/1998).

1998:
2.  Bijzonder Onderzoeksfonds (BOF).
University:  Ghent University.
Subject: “131-I-MIBG treatment for neuroblastoma: a study of tumor uptake and patient
dosimetry”.(MIBG-iodium-131 therapie voor neuroblastoma: studie van tumoropname en
patiëntdosimetrie). (1/2/1998 –1/2/2000).



Awards.

1997:
1. Mallinckrodt Benelux Award 1997.
Company:  Tyco-Mallickrodt.
Subject:  Project: “Cytogenetic studies of patients undergoing 131I therapy for malignant
and benign thyroid disease and 131I-MIBG therapy for neuroblastoma”.
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2000:
2. Alavi-Mandell prize 2000.
Journal: The Journal of Nuclear Medicine.
Subject: Article: “Adaptive response in patients treated with 131I”. JNM 2000, 41; 17-22.

2001:
3. Mutagenesis Poster Award 2001.
Journal: Mutagenesis.
Subject: Poster:  “Application of the micronucleus assay in patients treated with
radionuclide therapies : results and limitations”.  EEMS 2001, 1-5 September 2001 Ghent.


Memberships.

Commissions.

International:
EANM: Taskgroup on Dosimetry (vice chairman).
SIOP taskgroup on Neuroblastoma.

National:
BGNG: (Belgisch Genootschap voor Nucleaire Geneeskunde): Taskgroup Radiation
Protection.


Associations.

International:
EANM (European Association of Nuclear Medicine).

National:
BGNG (Belgisch Genootschap voor Nucleaire Geneeskunde).
BVZF (Belgische Vereniging voor Ziekenhuis Fysici).
BVS (Belgische Vereniging voor Stralingshygiëne).
BNS (Belgian Nuclear Society).
